1	BACKGROUND	B
2	:	B
3	Ischemic	B
4	heart	B
5	disease	B
6	is	B
7	the	B
8	primary	B
9	cause	B
10	of	B
11	morbidity	B
12	and	B
13	mortality	B
14	among	B
15	diabetics	B
16	,	B
17	especially	B
18	those	B
19	who	B
20	became	B
21	ill	B
22	at	B
23	a	B
24	young	B
25	age	B
26	.	B

1	More	B
2	importantly	B
3	,	B
4	this	B
5	fusion	B
6	converted	B
7	a	B
8	less	B
9	effective	B
10	vaccine	B
11	into	B
12	one	B
13	with	B
14	significant	B
15	potency	B
16	against	B
17	established	B
18	E7	B
19	-	B
20	expressing	B
21	metastatic	B
22	tumors	B
23	.	B

1	Reverse	B
2	transcription	B
3	-	B
4	PCR	B
5	analysis	B
6	of	B
7	mRNA	B
8	from	B
9	patients	B
10	shows	B
11	that	B
12	each	B
13	of	B
14	these	B
15	five	B
16	mutations	B
17	results	B
18	in	B
19	aberrant	B
20	splicing	B
21	.	B

1	Using	B
2	the	B
3	postural	B
4	and	B
5	force	B
6	data	B
7	as	B
8	input	B
9	to	B
10	a	B
11	3	B
12	-	B
13	D	B
14	biomechanical	B
15	model	B
16	,	B
17	the	B
18	lumbosacral	B
19	spinal	B
20	compression	B
21	was	B
22	calculated	B
23	.	B

1	Sequence	B
2	analysis	B
3	revealed	B
4	significant	B
5	differences	B
6	between	B
7	the	B
8	5	B
9	'	B
10	region	B
11	of	B
12	the	B
13	beta	B
14	subunit	B
15	gene	B
16	and	B
17	the	B
18	corresponding	B
19	regions	B
20	of	B
21	the	B
22	homologous	B
23	GlyR	B
24	alpha	B
25	subunit	B
26	genes	B
27	;	B
28	it	B
29	also	B
30	identified	B
31	a	B
32	novel	B
33	exon	B
34	(	B
35	exon	B
36	0	B
37	)	B
38	that	B
39	encodes	B
40	most	B
41	of	B
42	the	B
43	5	B
44	'-	B
45	untranslated	B
46	portion	B
47	of	B
48	the	B
49	GlyR	B
50	beta	B
51	mRNA	B
52	.	B

1	Therefore	B
2	,	B
3	we	B
4	suggested	B
5	that	B
6	both	B
7	proteins	B
8	might	B
9	belong	B
10	to	B
11	the	B
12	PLTP	B
13	family	B
14	.	B

1	Influence	B
2	of	B
3	compression	B
4	therapy	B
5	on	B
6	symptoms	B
7	following	B
8	soft	B
9	tissue	B
10	injury	B
11	from	B
12	maximal	B
13	eccentric	B
14	exercise	B
15	.	B

1	STAT5A	B
2	mutations	B
3	in	B
4	the	B
5	Src	B
6	homology	B
7	2	B
8	(	B
9	SH2	B
10	)	B
11	and	B
12	SH3	B
13	domains	B
14	did	B
15	not	B
16	alter	B
17	the	B
18	BTK	B
19	-	B
20	mediated	B
21	tyrosine	B
22	phosphorylation	B
23	.	B

1	In	B
2	the	B
3	present	B
4	work	B
5	,	B
6	the	B
7	complete	B
8	genome	B
9	sequences	B
10	of	B
11	Pyrococcus	B
12	horikoshii	B
13	and	B
14	Pyrococcus	B
15	abyssi	B
16	,	B
17	two	B
18	species	B
19	in	B
20	a	B
21	genus	B
22	of	B
23	hyperthermophilic	B
24	archaeon	B
25	(	B
26	archaebacterium	B
27	),	B
28	were	B
29	compared	B
30	to	B
31	detect	B
32	large	B
33	genome	B
34	polymorphisms	B
35	linked	B
36	with	B
37	restriction	B
38	-	B
39	modification	B
40	gene	B
41	homologs	B
42	.	B

1	In	B
2	addition	B
3	,	B
4	these	B
5	patients	B
6	show	B
7	both	B
8	quantitative	B
9	and	B
10	qualitative	B
11	differences	B
12	in	B
13	their	B
14	infectious	B
15	microbiological	B
16	spectrum	B
17	,	B
18	mainly	B
19	in	B
20	clean	B
21	-	B
22	contaminated	B
23	,	B
24	contaminated	B
25	and	B
26	dirty	B
27	surgical	B
28	procedures	B
29	.	B

1	Here	B
2	we	B
3	show	B
4	that	B
5	PKC	B
6	and	B
7	p44	B
8	/	B
9	p42MAPK	B
10	signalings	B
11	are	B
12	required	B
13	for	B
14	the	B
15	HBx	B
16	-	B
17	induced	B
18	Sp1	B
19	-	B
20	mediated	B
21	IGF	B
22	-	B
23	II	B
24	P4	B
25	transcriptional	B
26	activity	B
27	since	B
28	(	B
29	i	B
30	)	B
31	PKC	B
32	activation	B
33	by	B
34	PMA	B
35	or	B
36	PKC	B
37	expression	B
38	vector	B
39	increases	B
40	Sp1	B
41	phosphorylation	B
42	and	B
43	P4	B
44	activity	B
45	in	B
46	HBx	B
47	-	B
48	transfected	B
49	HepG2	B
50	cells	B
51	;	B
52	(	B
53	ii	B
54	)	B
55	PKC	B
56	inhibition	B
57	by	B
58	PKC	B
59	inhibitor	B
60	Go6976	B
61	reduces	B
62	Sp1	B
63	phosphorylation	B
64	,	B
65	P4	B
66	activity	B
67	,	B
68	and	B
69	IGF	B
70	-	B
71	II	B
72	mRNA	B
73	in	B
74	HBx	B
75	-	B
76	transfected	B
77	HepG2	B
78	cells	B
79	;	B
80	and	B
81	(	B
82	iii	B
83	)	B
84	the	B
85	inhibition	B
86	of	B
87	MEK	B
88	activation	B
89	by	B
90	U0126	B
91	reduces	B
92	Sp1	B
93	phosphorylation	B
94	,	B
95	P4	B
96	activity	B
97	and	B
98	IGF	B
99	-	B
100	II	B
101	mRNA	B
102	in	B
103	HBx	B
104	-	B
105	transfected	B
106	HepG2	B
107	cells	B
108	.	B

1	We	B
2	show	B
3	that	B
4	p73	B
5	can	B
6	transcriptionally	B
7	inhibit	B
8	a	B
9	number	B
10	of	B
11	cellular	B
12	and	B
13	viral	B
14	promoters	B
15	.	B

1	Similarly	B
2	,	B
3	curcumin	B
4	(	B
5	diferuloylmethane	B
6	),	B
7	an	B
8	anti	B
9	-	B
10	inflammatory	B
11	agent	B
12	,	B
13	suppressed	B
14	OSM	B
15	-	B
16	stimulated	B
17	STAT1	B
18	phosphorylation	B
19	,	B
20	DNA	B
21	-	B
22	binding	B
23	activity	B
24	of	B
25	STAT1	B
26	,	B
27	and	B
28	c	B
29	-	B
30	Jun	B
31	N	B
32	-	B
33	terminal	B
34	kinase	B
35	activation	B
36	without	B
37	affecting	B
38	JAK1	B
39	,	B
40	JAK2	B
41	,	B
42	JAK3	B
43	,	B
44	ERK1	B
45	/	B
46	2	B
47	,	B
48	and	B
49	p38	B
50	phosphorylation	B
51	.	B

1	The	B
2	effects	B
3	of	B
4	the	B
5	transfected	B
6	receptors	B
7	were	B
8	associated	B
9	with	B
10	antagonism	B
11	of	B
12	activator	B
13	protein	B
14	1	B
15	(	B
16	AP	B
17	-	B
18	1	B
19	)	B
20	activity	B
21	.	B

1	Furthermore	B
2	,	B
3	the	B
4	soluble	B
5	forms	B
6	of	B
7	ATF6	B
8	and	B
9	the	B
10	G13	B
11	gene	B
12	product	B
13	are	B
14	unable	B
15	to	B
16	bind	B
17	to	B
18	several	B
19	point	B
20	mutants	B
21	of	B
22	the	B
23	cis	B
24	-	B
25	acting	B
26	ER	B
27	stress	B
28	response	B
29	element	B
30	in	B
31	vitro	B
32	that	B
33	hardly	B
34	respond	B
35	to	B
36	ER	B
37	stress	B
38	in	B
39	vivo	B
40	.	B

1	PURPOSE	B
2	:	B
3	The	B
4	objective	B
5	of	B
6	this	B
7	study	B
8	was	B
9	to	B
10	assess	B
11	first	B
12	embryo	B
13	cleavage	B
14	(	B
15	FEC	B
16	)	B
17	25	B
18	-	B
19	27	B
20	h	B
21	after	B
22	intracytoplasmic	B
23	sperm	B
24	injection	B
25	(	B
26	ICSI	B
27	)	B
28	as	B
29	a	B
30	parameter	B
31	for	B
32	the	B
33	embryo	B
34	selection	B
35	process	B
36	.	B

1	RESULTS	B
2	:	B
3	A	B
4	significant	B
5	correlation	B
6	(	B
7	p	B
8	<	B
9	0	B
10	.	B
11	001	B
12	)	B
13	was	B
14	observed	B
15	for	B
16	mean	B
17	wall	B
18	thickness	B
19	and	B
20	vessel	B
21	wall	B
22	area	B
23	between	B
24	MRI	B
25	and	B
26	histopathology	B
27	(	B
28	r	B
29	=	B
30	0	B
31	.	B
32	87	B
33	and	B
34	r	B
35	=	B
36	0	B
37	.	B
38	85	B
39	,	B
40	respectively	B
41	).	B

1	Molecular	B
2	cloning	B
3	,	B
4	genomic	B
5	mapping	B
6	,	B
7	and	B
8	expression	B
9	of	B
10	two	B
11	secretor	B
12	blood	B
13	group	B
14	alpha	B
15	(	B
16	1	B
17	,	B
18	2	B
19	)	B
20	fucosyltransferase	B
21	genes	B
22	differentially	B
23	regulated	B
24	in	B
25	mouse	B
26	uterine	B
27	epithelium	B
28	and	B
29	gastrointestinal	B
30	tract	B
31	.	B

1	We	B
2	show	B
3	that	B
4	several	B
5	heme	B
6	-	B
7	responsive	B
8	mechanisms	B
9	combine	B
10	to	B
11	regulate	B
12	DAN	B
13	/	B
14	TIR	B
15	gene	B
16	expression	B
17	.	B

1	No	B
2	'	B
3	TATA	B
4	'	B
5	motif	B
6	was	B
7	identified	B
8	near	B
9	either	B
10	the	B
11	GABPalpha	B
12	or	B
13	ATPsynCF6	B
14	transcription	B
15	start	B
16	sites	B
17	.	B

1	These	B
2	results	B
3	indicate	B
4	the	B
5	presence	B
6	of	B
7	TATA	B
8	-	B
9	unified	B
10	transcription	B
11	systems	B
12	in	B
13	contemporary	B
14	eukaryotes	B
15	and	B
16	provide	B
17	insight	B
18	into	B
19	the	B
20	residual	B
21	need	B
22	for	B
23	TBP	B
24	by	B
25	all	B
26	three	B
27	Pols	B
28	in	B
29	other	B
30	eukaryotes	B
31	despite	B
32	a	B
33	lack	B
34	of	B
35	TATA	B
36	elements	B
37	in	B
38	their	B
39	promoters	B
40	.	B

1	Different	B
2	thermoluminescent	B
3	detectors	B
4	(	B
5	TLD	B
6	)	B
7	have	B
8	been	B
9	used	B
10	to	B
11	measure	B
12	the	B
13	contribution	B
14	of	B
15	the	B
16	low	B
17	linear	B
18	energy	B
19	transfer	B
20	component	B
21	(	B
22	LET	B
23	<	B
24	10	B
25	keV	B
26	/	B
27	micrometer	B
28	)	B
29	and	B
30	plastic	B
31	nuclear	B
32	track	B
33	detectors	B
34	(	B
35	PNTD	B
36	)	B
37	for	B
38	the	B
39	high	B
40	linear	B
41	energy	B
42	tranfer	B
43	(	B
44	LET	B
45	)	B
46	component	B
47	.	B

1	However	B
2	,	B
3	the	B
4	beta5L	B
5	splice	B
6	variant	B
7	was	B
8	found	B
9	only	B
10	in	B
11	the	B
12	retina	B
13	.	B

1	This	B
2	analysis	B
3	supports	B
4	the	B
5	use	B
6	of	B
7	fluticasone	B
8	propionate	B
9	88	B
10	microg	B
11	twice	B
12	daily	B
13	as	B
14	first	B
15	-	B
16	line	B
17	treatment	B
18	in	B
19	patients	B
20	with	B
21	persistent	B
22	asthma	B
23	previously	B
24	treated	B
25	with	B
26	short	B
27	-	B
28	acting	B
29	beta2	B
30	-	B
31	agonist	B
32	alone	B
33	.	B

1	The	B
2	mice	B
3	are	B
4	phenotypically	B
5	normal	B
6	and	B
7	do	B
8	not	B
9	develop	B
10	spontaneous	B
11	tumors	B
12	at	B
13	an	B
14	early	B
15	age	B
16	,	B
17	in	B
18	contrast	B
19	to	B
20	knock	B
21	-	B
22	out	B
23	(	B
24	p53	B
25	(-/-))	B
26	strains	B
27	with	B
28	a	B
29	defective	B
30	p53	B
31	gene	B
32	.	B

1	Furthermore	B
2	,	B
3	stable	B
4	expression	B
5	of	B
6	a	B
7	constitutively	B
8	active	B
9	form	B
10	of	B
11	chicken	B
12	Notch1	B
13	or	B
14	Notch2	B
15	in	B
16	a	B
17	B	B
18	cell	B
19	line	B
20	results	B
21	in	B
22	a	B
23	down	B
24	-	B
25	regulation	B
26	of	B
27	surface	B
28	IgM	B
29	expression	B
30	,	B
31	which	B
32	is	B
33	accompanied	B
34	by	B
35	the	B
36	reduction	B
37	of	B
38	IgH	B
39	gene	B
40	transcripts	B
41	.	B

1	On	B
2	Cox	B
3	proportional	B
4	hazards	B
5	regression	B
6	adenocarcinoma	B
7	(	B
8	P	B
9	=	B
10	0	B
11	.	B
12	006	B
13	),	B
14	the	B
15	development	B
16	of	B
17	BPF	B
18	(	B
19	P	B
20	=	B
21	0	B
22	.	B
23	003	B
24	),	B
25	older	B
26	age	B
27	(	B
28	P	B
29	=	B
30	0	B
31	.	B
32	03	B
33	)	B
34	and	B
35	higher	B
36	pathological	B
37	stage	B
38	(	B
39	P	B
40	=	B
41	0	B
42	.	B
43	02	B
44	)	B
45	were	B
46	independent	B
47	adverse	B
48	predictors	B
49	of	B
50	survival	B
51	.	B

1	We	B
2	found	B
3	that	B
4	RhoA	B
5	can	B
6	initiate	B
7	a	B
8	linear	B
9	kinase	B
10	cascade	B
11	leading	B
12	to	B
13	the	B
14	activation	B
15	of	B
16	ERK6	B
17	(	B
18	p38	B
19	gamma	B
20	),	B
21	a	B
22	recently	B
23	identified	B
24	member	B
25	of	B
26	the	B
27	p38	B
28	family	B
29	of	B
30	MAPKs	B
31	.	B

1	Twenty	B
2	-	B
3	six	B
4	(	B
5	55	B
6	%)	B
7	(	B
8	95	B
9	%	B
10	CI	B
11	,	B
12	41	B
13	-	B
14	69	B
15	%)	B
16	patients	B
17	experienced	B
18	>	B
19	or	B
20	=	B
21	grade	B
22	3	B
23	acute	B
24	toxicity	B
25	(	B
26	RTOG	B
27	).	B

1	We	B
2	hypothesize	B
3	that	B
4	proprioception	B
5	may	B
6	be	B
7	used	B
8	to	B
9	calibrate	B
10	the	B
11	efference	B
12	copy	B
13	during	B
14	development	B
15	and	B
16	in	B
17	response	B
18	to	B
19	perturbations	B
20	by	B
21	signaling	B
22	potential	B
23	mismatches	B
24	between	B
25	eye	B
26	movement	B
27	information	B
28	derived	B
29	from	B
30	the	B
31	efferent	B
32	command	B
33	and	B
34	the	B
35	actual	B
36	motion	B
37	of	B
38	the	B
39	eye	B
40	transduced	B
41	by	B
42	the	B
43	proprioceptive	B
44	organs	B
45	.	B

1	Thus	B
2	,	B
3	BALB	B
4	/	B
5	c	B
6	mice	B
7	appear	B
8	to	B
9	be	B
10	the	B
11	most	B
12	appropriate	B
13	strain	B
14	of	B
15	mice	B
16	to	B
17	perform	B
18	studies	B
19	on	B
20	the	B
21	possible	B
22	connection	B
23	between	B
24	infection	B
25	with	B
26	T	B
27	.	B
28	canis	B
29	and	B
30	allergic	B
31	asthma	B
32	.	B

1	They	B
2	correspond	B
3	to	B
4	nucleotides	B
5	equivalent	B
6	to	B
7	base	B
8	-	B
9	pair	B
10	C1	B
11	-	B
12	G72	B
13	and	B
14	discriminator	B
15	base	B
16	A73	B
17	in	B
18	the	B
19	amino	B
20	acid	B
21	-	B
22	acceptor	B
23	branch	B
24	of	B
25	the	B
26	molecule	B
27	.	B

1	Our	B
2	results	B
3	suggest	B
4	that	B
5	the	B
6	central	B
7	role	B
8	of	B
9	the	B
10	Notch	B
11	-	B
12	CBF1	B
13	/	B
14	RBP	B
15	-	B
16	Jkappa	B
17	signaling	B
18	pathway	B
19	in	B
20	cell	B
21	fate	B
22	decisions	B
23	renders	B
24	it	B
25	susceptible	B
26	to	B
27	pathways	B
28	of	B
29	viral	B
30	replication	B
31	and	B
32	oncogenic	B
33	conversion	B
34	.	B

1	High	B
2	-	B
3	affinity	B
4	binding	B
5	of	B
6	NF	B
7	-	B
8	1	B
9	to	B
10	PSE	B
11	-	B
12	B	B
13	,	B
14	but	B
15	not	B
16	to	B
17	PSE	B
18	-	B
19	A	B
20	,	B
21	was	B
22	confirmed	B
23	by	B
24	competition	B
25	of	B
26	DNA	B
27	-	B
28	protein	B
29	interactions	B
30	by	B
31	using	B
32	NF	B
33	-	B
34	1	B
35	DNA	B
36	elements	B
37	and	B
38	antibodies	B
39	.	B

1	The	B
2	first	B
3	case	B
4	of	B
5	HCV	B
6	seroconversion	B
7	in	B
8	Portugal	B
9	after	B
10	the	B
11	introduction	B
12	of	B
13	HCV	B
14	NAT	B
15	screening	B
16	.	B

1	Substitutions	B
2	in	B
3	the	B
4	YFV	B
5	Ag	B
6	-	B
7	binding	B
8	region	B
9	(	B
10	ABR	B
11	)	B
12	occur	B
13	at	B
14	four	B
15	of	B
16	the	B
17	eight	B
18	highly	B
19	conserved	B
20	residues	B
21	that	B
22	are	B
23	essential	B
24	for	B
25	binding	B
26	of	B
27	peptide	B
28	-	B
29	Ag	B
30	in	B
31	the	B
32	class	B
33	Ia	B
34	molecules	B
35	.	B

1	The	B
2	Novacor	B
3	Left	B
4	Ventricular	B
5	Assist	B
6	System	B
7	(	B
8	LVAS	B
9	)	B
10	(	B
11	Novacor	B
12	Corp	B
13	,	B
14	Oakland	B
15	,	B
16	CA	B
17	)	B
18	was	B
19	initially	B
20	console	B
21	-	B
22	based	B
23	and	B
24	has	B
25	been	B
26	available	B
27	since	B
28	1993	B
29	in	B
30	a	B
31	wearable	B
32	configuration	B
33	.	B

1	Ileal	B
2	digestibilities	B
3	of	B
4	DM	B
5	,	B
6	OM	B
7	,	B
8	CP	B
9	,	B
10	total	B
11	dietary	B
12	fiber	B
13	(	B
14	TDF	B
15	),	B
16	fat	B
17	and	B
18	gross	B
19	energy	B
20	(	B
21	GE	B
22	)	B
23	were	B
24	lower	B
25	(	B
26	P	B
27	<	B
28	0	B
29	.	B
30	05	B
31	)	B
32	for	B
33	dogs	B
34	fed	B
35	diets	B
36	containing	B
37	supplemental	B
38	fiber	B
39	compared	B
40	with	B
41	dogs	B
42	fed	B
43	the	B
44	control	B
45	diet	B
46	.	B

1	In	B
2	addition	B
3	,	B
4	the	B
5	consensus	B
6	amino	B
7	acid	B
8	motif	B
9	for	B
10	serine	B
11	threonine	B
12	receptor	B
13	kinases	B
14	was	B
15	also	B
16	present	B
17	.	B

1	Here	B
2	,	B
3	we	B
4	show	B
5	that	B
6	the	B
7	phorbol	B
8	ester	B
9	PMA	B
10	decreases	B
11	both	B
12	basal	B
13	and	B
14	dexamethasone	B
15	/	B
16	cAMP	B
17	-	B
18	induced	B
19	expression	B
20	of	B
21	a	B
22	luciferase	B
23	gene	B
24	under	B
25	the	B
26	control	B
27	of	B
28	the	B
29	G6Pase	B
30	promoter	B
31	in	B
32	transiently	B
33	transfected	B
34	H4IIE	B
35	hepatoma	B
36	cells	B
37	.	B

1	The	B
2	difference	B
3	between	B
4	the	B
5	patients	B
6	and	B
7	the	B
8	controls	B
9	was	B
10	statistically	B
11	significant	B
12	(	B
13	p	B
14	=	B
15	0	B
16	.	B
17	03	B
18	).	B

1	Altogether	B
2	,	B
3	we	B
4	confirm	B
5	that	B
6	all	B
7	genes	B
8	of	B
9	the	B
10	Rad52	B
11	recombinational	B
12	repair	B
13	pathway	B
14	are	B
15	required	B
16	for	B
17	the	B
18	survival	B
19	of	B
20	rad27	B
21	Delta	B
22	strains	B
23	at	B
24	both	B
25	permissive	B
26	(	B
27	23	B
28	degrees	B
29	C	B
30	)	B
31	and	B
32	semipermissive	B
33	(	B
34	30	B
35	degrees	B
36	C	B
37	)	B
38	temperatures	B
39	for	B
40	growth	B
41	.	B

1	Neuron	B
2	-	B
3	specific	B
4	Bcl	B
5	-	B
6	2	B
7	homology	B
8	3	B
9	domain	B
10	-	B
11	only	B
12	splice	B
13	variant	B
14	of	B
15	Bak	B
16	is	B
17	anti	B
18	-	B
19	apoptotic	B
20	in	B
21	neurons	B
22	,	B
23	but	B
24	pro	B
25	-	B
26	apoptotic	B
27	in	B
28	non	B
29	-	B
30	neuronal	B
31	cells	B
32	.	B

1	The	B
2	mechanism	B
3	of	B
4	the	B
5	induction	B
6	of	B
7	3beta	B
8	-	B
9	HSD	B
10	type	B
11	1	B
12	gene	B
13	expression	B
14	was	B
15	further	B
16	characterized	B
17	in	B
18	ZR	B
19	-	B
20	75	B
21	-	B
22	1	B
23	human	B
24	breast	B
25	cancer	B
26	cells	B
27	.	B

1	Contagious	B
2	bovine	B
3	pleuropneumonia	B
4	is	B
5	a	B
6	major	B
7	threat	B
8	for	B
9	cattle	B
10	in	B
11	Africa	B
12	.	B

1	Treatment	B
2	includes	B
3	both	B
4	medical	B
5	and	B
6	surgical	B
7	options	B
8	,	B
9	with	B
10	medical	B
11	therapy	B
12	further	B
13	subclassified	B
14	into	B
15	pharmacologic	B
16	and	B
17	pneumatic	B
18	dilation	B
19	.	B

1	Since	B
2	the	B
3	latter	B
4	is	B
5	very	B
6	small	B
7	for	B
8	physiological	B
9	flows	B
10	,	B
11	the	B
12	result	B
13	is	B
14	that	B
15	alpha	B
16	<	B
17	1	B
18	even	B
19	at	B
20	relatively	B
21	high	B
22	values	B
23	of	B
24	the	B
25	Reynolds	B
26	number	B
27	(	B
28	i	B
29	.	B
30	e	B
31	.,	B
32	for	B
33	non	B
34	-	B
35	negligible	B
36	inertia	B
37	)	B
38	and	B
39	we	B
40	validate	B
41	our	B
42	perturbation	B
43	theory	B
44	results	B
45	by	B
46	comparison	B
47	with	B
48	a	B
49	numerical	B
50	integration	B
51	of	B
52	the	B
53	full	B
54	model	B
55	.	B

1	This	B
2	plus	B
3	the	B
4	reduced	B
5	phosphorylation	B
6	of	B
7	p27	B
8	by	B
9	MAPK	B
10	enhanced	B
11	the	B
12	stability	B
13	of	B
14	p27	B
15	that	B
16	associated	B
17	with	B
18	nuclear	B
19	Cdk2	B
20	at	B
21	high	B
22	stoichiometry	B
23	and	B
24	inhibited	B
25	its	B
26	kinase	B
27	activity	B
28	.	B

1	Similar	B
2	data	B
3	were	B
4	also	B
5	obtained	B
6	when	B
7	either	B
8	dominant	B
9	negative	B
10	EGFR	B
11	-	B
12	CD533	B
13	or	B
14	dominant	B
15	negative	B
16	Ras	B
17	N17	B
18	were	B
19	used	B
20	to	B
21	block	B
22	MAPK	B
23	activation	B
24	.	B

1	The	B
2	assay	B
3	herein	B
4	described	B
5	allows	B
6	the	B
7	comparison	B
8	of	B
9	relative	B
10	FGFR	B
11	expression	B
12	levels	B
13	,	B
14	both	B
15	within	B
16	a	B
17	single	B
18	RNA	B
19	pool	B
20	and	B
21	among	B
22	multiple	B
23	RNA	B
24	pool	B
25	samples	B
26	.	B

1	This	B
2	was	B
3	most	B
4	pronounced	B
5	during	B
6	the	B
7	initial	B
8	phase	B
9	of	B
10	Erk	B
11	activation	B
12	.	B

1	DESIGN	B
2	:	B
3	Prospective	B
4	cohort	B
5	study	B
6	with	B
7	a	B
8	20	B
9	y	B
10	follow	B
11	-	B
12	up	B
13	period	B
14	,	B
15	the	B
16	First	B
17	National	B
18	Health	B
19	and	B
20	Examination	B
21	Survey	B
22	(	B
23	NHANES	B
24	1	B
25	)	B
26	Epidemiologic	B
27	Follow	B
28	-	B
29	up	B
30	Study	B
31	(	B
32	NHEFS	B
33	).	B

1	To	B
2	assess	B
3	the	B
4	maximum	B
5	oxygen	B
6	uptake	B
7	(	B
8	V	B
9	'	B
10	O2	B
11	max	B
12	)	B
13	of	B
14	Hong	B
15	Kong	B
16	Chinese	B
17	children	B
18	and	B
19	to	B
20	explore	B
21	its	B
22	association	B
23	with	B
24	respiratory	B
25	illnesses	B
26	,	B
27	we	B
28	conducted	B
29	the	B
30	Multistage	B
31	Fitness	B
32	Test	B
33	(	B
34	MFT	B
35	),	B
36	a	B
37	20	B
38	-	B
39	m	B
40	shuttle	B
41	run	B
42	test	B
43	,	B
44	in	B
45	1	B
46	,	B
47	427	B
48	schoolchildren	B
49	aged	B
50	between	B
51	8	B
52	-	B
53	12	B
54	years	B
55	.	B

1	After	B
2	all	B
3	doses	B
4	of	B
5	d	B
6	-	B
7	amphetamine	B
8	,	B
9	responding	B
10	occurred	B
11	largely	B
12	on	B
13	the	B
14	saline	B
15	key	B
16	under	B
17	both	B
18	schedules	B
19	.	B

1	A	B
2	novel	B
3	myeloid	B
4	-	B
5	restricted	B
6	zebrafish	B
7	CCAAT	B
8	/	B
9	enhancer	B
10	-	B
11	binding	B
12	protein	B
13	with	B
14	a	B
15	potent	B
16	transcriptional	B
17	activation	B
18	domain	B
19	.	B

1	METHODS	B
2	:	B
3	Humphrey	B
4	Field	B
5	Analyzer	B
6	model	B
7	630	B
8	(	B
9	HFA	B
10	I	B
11	,	B
12	program	B
13	30	B
14	-	B
15	2	B
16	with	B
17	a	B
18	rectangular	B
19	6	B
20	degrees	B
21	x	B
22	6	B
23	degrees	B
24	grid	B
25	)	B
26	was	B
27	used	B
28	as	B
29	the	B
30	conventional	B
31	perimetric	B
32	method	B
33	.	B

1	These	B
2	data	B
3	reveal	B
4	a	B
5	complex	B
6	network	B
7	of	B
8	interactions	B
9	between	B
10	GTPases	B
11	in	B
12	the	B
13	ARF	B
14	family	B
15	and	B
16	their	B
17	effectors	B
18	and	B
19	reveal	B
20	a	B
21	potential	B
22	for	B
23	cross	B
24	-	B
25	talk	B
26	not	B
27	demonstrated	B
28	previously	B
29	.	B

1	Net	B
2	lift	B
3	and	B
4	combined	B
5	drag	B
6	from	B
7	all	B
8	8	B
9	bearings	B
10	of	B
11	the	B
12	4	B
13	-	B
14	bladed	B
15	impeller	B
16	are	B
17	compared	B
18	with	B
19	predictions	B
20	based	B
21	on	B
22	2	B
23	-	B
24	D	B
25	theory	B
26	.	B

1	In	B
2	the	B
3	course	B
4	of	B
5	screening	B
6	for	B
7	transcription	B
8	factors	B
9	which	B
10	interact	B
11	with	B
12	the	B
13	human	B
14	myeloperoxidase	B
15	(	B
16	MPO	B
17	)	B
18	promoter	B
19	we	B
20	,	B
21	for	B
22	the	B
23	first	B
24	time	B
25	,	B
26	identified	B
27	and	B
28	cloned	B
29	the	B
30	cDNA	B
31	and	B
32	genomic	B
33	DNA	B
34	for	B
35	human	B
36	HBP1	B
37	(	B
38	HMG	B
39	-	B
40	Box	B
41	containing	B
42	protein	B
43	1	B
44	),	B
45	a	B
46	member	B
47	of	B
48	the	B
49	high	B
50	mobility	B
51	group	B
52	of	B
53	non	B
54	-	B
55	histone	B
56	chromosomal	B
57	proteins	B
58	.	B

1	Therefore	B
2	,	B
3	vitamin	B
4	D3	B
5	analogues	B
6	have	B
7	a	B
8	substantial	B
9	antipsoriatic	B
10	effect	B
11	.	B

1	Methylation	B
2	at	B
3	both	B
4	cytosine	B
5	residues	B
6	in	B
7	the	B
8	E2F	B
9	element	B
10	((	B
11	m	B
12	)	B
13	CG	B
14	(	B
15	m	B
16	)	B
17	CG	B
18	)	B
19	generated	B
20	a	B
21	new	B
22	methylcytosine	B
23	-	B
24	specific	B
25	DNA	B
26	-	B
27	protein	B
28	complex	B
29	.	B

1	Hepatitis	B
2	A	B
3	infected	B
4	food	B
5	handler	B
6	at	B
7	an	B
8	Edmonton	B
9	,	B
10	Alberta	B
11	retail	B
12	food	B
13	facility	B
14	:	B
15	public	B
16	health	B
17	protection	B
18	strategies	B
19	.	B

1	The	B
2	co	B
3	-	B
4	existence	B
5	of	B
6	TE	B
7	domains	B
8	within	B
9	modular	B
10	PKSs	B
11	along	B
12	with	B
13	physically	B
14	separated	B
15	,	B
16	monofunctional	B
17	TEs	B
18	(	B
19	TE	B
20	IIs	B
21	)	B
22	has	B
23	been	B
24	reported	B
25	for	B
26	a	B
27	number	B
28	of	B
29	modular	B
30	polyketide	B
31	and	B
32	non	B
33	-	B
34	ribosomal	B
35	peptide	B
36	synthases	B
37	(	B
38	NRPS	B
39	).	B

1	Two	B
2	independent	B
3	transgenic	B
4	lines	B
5	were	B
6	produced	B
7	,	B
8	and	B
9	both	B
10	showed	B
11	expression	B
12	of	B
13	the	B
14	Gus	B
15	gene	B
16	specifically	B
17	in	B
18	the	B
19	endosperm	B
20	during	B
21	mid	B
22	-	B
23	development	B
24	(	B
25	first	B
26	detected	B
27	10	B
28	-	B
29	12	B
30	d	B
31	after	B
32	anthesis	B
33	).	B

1	Treadmill	B
2	training	B
3	at	B
4	least	B
5	for	B
6	2	B
7	weeks	B
8	can	B
9	reduce	B
10	the	B
11	infarction	B
12	size	B
13	and	B
14	edema	B
15	caused	B
16	by	B
17	MCA	B
18	occlusion	B
19	(	B
20	P	B
21	<	B
22	0	B
23	.	B
24	01	B
25	).	B

1	Mechanism	B
2	in	B
3	the	B
4	sequential	B
5	control	B
6	of	B
7	cell	B
8	morphology	B
9	and	B
10	S	B
11	phase	B
12	entry	B
13	by	B
14	epidermal	B
15	growth	B
16	factor	B
17	involves	B
18	distinct	B
19	MEK	B
20	/	B
21	ERK	B
22	activations	B
23	.	B

1	We	B
2	randomly	B
3	assigned	B
4	1	B
5	,	B
6	219	B
7	subjects	B
8	to	B
9	receive	B
10	either	B
11	the	B
12	standard	B
13	three	B
14	-	B
15	times	B
16	-	B
17	weekly	B
18	(	B
19	TIW	B
20	)	B
21	interferon	B
22	alfa	B
23	-	B
24	2b	B
25	dose	B
26	(	B
27	3	B
28	MIU	B
29	)	B
30	or	B
31	the	B
32	once	B
33	-	B
34	weekly	B
35	(	B
36	QW	B
37	)	B
38	peginterferon	B
39	alfa	B
40	-	B
41	2b	B
42	(	B
43	0	B
44	.	B
45	5	B
46	,	B
47	1	B
48	.	B
49	0	B
50	,	B
51	or	B
52	1	B
53	.	B
54	5	B
55	microg	B
56	/	B
57	kg	B
58	).	B

1	These	B
2	data	B
3	suggest	B
4	that	B
5	proper	B
6	direct	B
7	binding	B
8	of	B
9	Nhp2p	B
10	to	B
11	H	B
12	/	B
13	ACA	B
14	snoRNAs	B
15	is	B
16	required	B
17	for	B
18	the	B
19	assembly	B
20	of	B
21	H	B
22	/	B
23	ACA	B
24	snoRNPs	B
25	and	B
26	hence	B
27	for	B
28	the	B
29	stability	B
30	of	B
31	some	B
32	of	B
33	their	B
34	components	B
35	.	B

1	The	B
2	decrements	B
3	in	B
4	cerebrovascular	B
5	resistance	B
6	induced	B
7	by	B
8	hexamethonium	B
9	,	B
10	in	B
11	mm	B
12	Hg	B
13	ml	B
14	(-	B
15	1	B
16	).	B
17	min	B
18	(-	B
19	1	B
20	),	B
21	were	B
22	:	B
23	under	B
24	control	B
25	.	B

1	Here	B
2	we	B
3	provide	B
4	the	B
5	first	B
6	evidence	B
7	for	B
8	the	B
9	involvement	B
10	of	B
11	GCN1	B
12	-	B
13	GCN2	B
14	interaction	B
15	in	B
16	activation	B
17	of	B
18	GCN2	B
19	per	B
20	se	B
21	.	B

1	As	B
2	a	B
3	reflection	B
4	of	B
5	uncertainties	B
6	in	B
7	the	B
8	estimates	B
9	for	B
10	individual	B
11	sources	B
12	,	B
13	the	B
14	90th	B
15	percentiles	B
16	of	B
17	PCDD	B
18	/	B
19	F	B
20	releases	B
21	for	B
22	1999	B
23	ranged	B
24	up	B
25	to	B
26	4	B
27	.	B
28	1	B
29	g	B
30	I	B
31	-	B
32	TEQ	B
33	/	B
34	y	B
35	.	B

1	To	B
2	test	B
3	the	B
4	hypothesis	B
5	that	B
6	these	B
7	elements	B
8	are	B
9	required	B
10	for	B
11	promoter	B
12	activity	B
13	,	B
14	we	B
15	compared	B
16	the	B
17	reporter	B
18	expression	B
19	activity	B
20	of	B
21	segments	B
22	containing	B
23	mutations	B
24	of	B
25	these	B
26	elements	B
27	with	B
28	activity	B
29	of	B
30	the	B
31	parent	B
32	Hlx	B
33	promoter	B
34	sequence	B
35	.	B

1	Using	B
2	RACE	B
3	techniques	B
4	we	B
5	have	B
6	cloned	B
7	and	B
8	sequenced	B
9	one	B
10	of	B
11	the	B
12	hamster	B
13	liver	B
14	3	B
15	-	B
16	hydroxy	B
17	-	B
18	hexobarbital	B
19	dehydrogenases	B
20	which	B
21	catalyze	B
22	not	B
23	only	B
24	cyclic	B
25	alcohols	B
26	but	B
27	also	B
28	17beta	B
29	-	B
30	hydroxy	B
31	-	B
32	steroids	B
33	and	B
34	3alpha	B
35	-	B
36	hydroxysteroids	B
37	.	B

1	Concerted	B
2	transcriptional	B
3	activation	B
4	of	B
5	the	B
6	low	B
7	density	B
8	lipoprotein	B
9	receptor	B
10	gene	B
11	by	B
12	insulin	B
13	and	B
14	luteinizing	B
15	hormone	B
16	in	B
17	cultured	B
18	porcine	B
19	granulosa	B
20	-	B
21	luteal	B
22	cells	B
23	:	B
24	possible	B
25	convergence	B
26	of	B
27	protein	B
28	kinase	B
29	a	B
30	,	B
31	phosphatidylinositol	B
32	3	B
33	-	B
34	kinase	B
35	,	B
36	and	B
37	mitogen	B
38	-	B
39	activated	B
40	protein	B
41	kinase	B
42	signaling	B
43	pathways	B
44	.	B

1	Human	B
2	T	B
3	-	B
4	cell	B
5	leukemia	B
6	virus	B
7	type	B
8	I	B
9	(	B
10	HTLV	B
11	-	B
12	I	B
13	)	B
14	Tax	B
15	is	B
16	a	B
17	potent	B
18	transcriptional	B
19	regulator	B
20	that	B
21	can	B
22	activate	B
23	or	B
24	repress	B
25	specific	B
26	cellular	B
27	genes	B
28	and	B
29	that	B
30	has	B
31	been	B
32	proposed	B
33	to	B
34	contribute	B
35	to	B
36	leukemogenesis	B
37	in	B
38	adult	B
39	T	B
40	-	B
41	cell	B
42	leukemia	B
43	.	B

1	Also	B
2	,	B
3	small	B
4	,	B
5	sense	B
6	and	B
7	antisense	B
8	approximately	B
9	22	B
10	nt	B
11	RNAs	B
12	,	B
13	derived	B
14	from	B
15	the	B
16	satRNA	B
17	,	B
18	were	B
19	associated	B
20	with	B
21	the	B
22	replicating	B
23	satellite	B
24	.	B

1	Deletional	B
2	analyses	B
3	of	B
4	VDR	B
5	indicated	B
6	that	B
7	GRIP1	B
8	and	B
9	RAC3	B
10	required	B
11	an	B
12	intact	B
13	VDR	B
14	activation	B
15	function	B
16	(	B
17	AF	B
18	-	B
19	2	B
20	)	B
21	domain	B
22	for	B
23	efficient	B
24	interaction	B
25	as	B
26	well	B
27	as	B
28	additional	B
29	but	B
30	distinct	B
31	regions	B
32	of	B
33	the	B
34	VDR	B
35	.	B

1	RESULTS	B
2	:	B
3	During	B
4	the	B
5	stabilization	B
6	period	B
7	,	B
8	PaCO2	B
9	(	B
10	mean	B
11	+/-	B
12	SD	B
13	)	B
14	was	B
15	33	B
16	+/-	B
17	5	B
18	mm	B
19	Hg	B
20	,	B
21	and	B
22	arrhythmias	B
23	were	B
24	not	B
25	detected	B
26	.	B

1	TT	B
2	cells	B
3	,	B
4	a	B
5	human	B
6	MTC	B
7	cell	B
8	line	B
9	expressing	B
10	MEN	B
11	2A	B
12	type	B
13	RET	B
14	,	B
15	display	B
16	transcriptionally	B
17	active	B
18	RelA	B
19	(	B
20	p65	B
21	)	B
22	in	B
23	the	B
24	nucleus	B
25	.	B

1	The	B
2	human	B
3	protein	B
4	sequence	B
5	exhibits	B
6	a	B
7	putative	B
8	DNA	B
9	-	B
10	binding	B
11	domain	B
12	similar	B
13	to	B
14	that	B
15	seen	B
16	in	B
17	rat	B
18	HBP1	B
19	and	B
20	shows	B
21	homology	B
22	with	B
23	the	B
24	activation	B
25	and	B
26	repressor	B
27	domains	B
28	previously	B
29	demonstrated	B
30	in	B
31	the	B
32	rat	B
33	protein	B
34	.	B

1	In	B
2	contrast	B
3	the	B
4	human	B
5	and	B
6	mouse	B
7	BCNT	B
8	proteins	B
9	contain	B
10	one	B
11	repeat	B
12	unit	B
13	and	B
14	lack	B
15	the	B
16	RTE	B
17	-	B
18	1	B
19	-	B
20	derived	B
21	portion	B
22	.	B

1	Direct	B
2	superoxide	B
3	scavenging	B
4	activity	B
5	of	B
6	nonsteroidal	B
7	anti	B
8	-	B
9	inflammatory	B
10	drugs	B
11	:	B
12	determination	B
13	by	B
14	electron	B
15	spin	B
16	resonance	B
17	using	B
18	the	B
19	spin	B
20	trap	B
21	method	B
22	.	B

1	A	B
2	single	B
3	nucleotide	B
4	polymorphism	B
5	(	B
6	SNP	B
7	)	B
8	in	B
9	exon	B
10	2	B
11	,	B
12	which	B
13	is	B
14	tightly	B
15	liked	B
16	to	B
17	another	B
18	SNP	B
19	(	B
20	GTG83	B
21	/	B
22	ATG83	B
23	),	B
24	creates	B
25	an	B
26	additional	B
27	alternative	B
28	in	B
29	-	B
30	frame	B
31	AUG	B
32	in	B
33	B	B
34	-	B
35	type	B
36	MTH1	B
37	mRNAs	B
38	yielding	B
39	the	B
40	fourth	B
41	MTH1	B
42	polypeptide	B
43	,	B
44	p26	B
45	that	B
46	possesses	B
47	an	B
48	additional	B
49	mitochondrial	B
50	targeting	B
51	signal	B
52	.	B

1	Six	B
2	of	B
3	the	B
4	gstC	B
5	'	B
6	mutants	B
7	,	B
8	primarily	B
9	in	B
10	the	B
11	C	B
12	-	B
13	terminal	B
14	half	B
15	of	B
16	C	B
17	',	B
18	exhibited	B
19	a	B
20	defect	B
21	in	B
22	the	B
23	ability	B
24	to	B
25	bind	B
26	L	B
27	protein	B
28	.	B

1	We	B
2	developed	B
3	a	B
4	system	B
5	for	B
6	domain	B
7	shuffling	B
8	to	B
9	establish	B
10	the	B
11	function	B
12	of	B
13	C1	B
14	domains	B
15	from	B
16	human	B
17	Raf	B
18	kinase	B
19	and	B
20	rat	B
21	PKC	B
22	eta	B
23	in	B
24	yeast	B
25	.	B

1	Expression	B
2	of	B
3	herpes	B
4	simplex	B
5	virus	B
6	type	B
7	2	B
8	US3	B
9	affects	B
10	the	B
11	Cdc42	B
12	/	B
13	Rac	B
14	pathway	B
15	and	B
16	attenuates	B
17	c	B
18	-	B
19	Jun	B
20	N	B
21	-	B
22	terminal	B
23	kinase	B
24	activation	B
25	.	B

1	Inhibition	B
2	of	B
3	constitutive	B
4	NF	B
5	-	B
6	kappaB	B
7	activity	B
8	results	B
9	in	B
10	cell	B
11	death	B
12	of	B
13	TT	B
14	cells	B
15	and	B
16	blocks	B
17	focus	B
18	formation	B
19	induced	B
20	by	B
21	oncogenic	B
22	forms	B
23	of	B
24	RET	B
25	in	B
26	NIH	B
27	3T3	B
28	cells	B
29	.	B

1	Corneal	B
2	scrapping	B
3	and	B
4	deep	B
5	stromal	B
6	biopsy	B
7	were	B
8	obtained	B
9	and	B
10	stained	B
11	for	B
12	microscopic	B
13	evaluation	B
14	with	B
15	periodic	B
16	acid	B
17	-	B
18	Schiff	B
19	,	B
20	Giemsa	B
21	,	B
22	and	B
23	Gomori	B
24	'	B
25	s	B
26	methenamine	B
27	silver	B
28	stains	B
29	.	B

1	ICAM	B
2	-	B
3	1	B
4	has	B
5	been	B
6	suggested	B
7	a	B
8	predictor	B
9	of	B
10	the	B
11	onset	B
12	of	B
13	GO	B
14	.	B

1	Once	B
2	ICP	B
3	reaches	B
4	critical	B
5	values	B
6	(>	B
7	30	B
8	mm	B
9	Hg	B
10	)	B
11	herniation	B
12	occurs	B
13	,	B
14	usually	B
15	within	B
16	2	B
17	to	B
18	5	B
19	days	B
20	.	B

1	The	B
2	present	B
3	data	B
4	also	B
5	demonstrate	B
6	that	B
7	ectopic	B
8	expression	B
9	of	B
10	blr1	B
11	increased	B
12	JNK	B
13	/	B
14	SAPK	B
15	activity	B
16	,	B
17	but	B
18	JNK	B
19	/	B
20	SAPK	B
21	activation	B
22	was	B
23	not	B
24	needed	B
25	for	B
26	accelerated	B
27	RA	B
28	-	B
29	induced	B
30	differentiation	B
31	and	B
32	growth	B
33	arrest	B
34	.	B

1	Here	B
2	,	B
3	we	B
4	identify	B
5	Rsc3	B
6	and	B
7	Rsc30	B
8	as	B
9	novel	B
10	components	B
11	of	B
12	the	B
13	essential	B
14	yeast	B
15	remodeler	B
16	RSC	B
17	complex	B
18	.	B

1	The	B
2	pharmacokinetic	B
3	profiles	B
4	of	B
5	digoxin	B
6	and	B
7	warfarin	B
8	were	B
9	not	B
10	altered	B
11	by	B
12	the	B
13	simultaneous	B
14	and	B
15	continued	B
16	administration	B
17	of	B
18	sevelamer	B
19	.	B

1	Forskolin	B
2	treatment	B
3	(	B
4	10	B
5	microM	B
6	)	B
7	of	B
8	the	B
9	transfected	B
10	cells	B
11	for	B
12	3	B
13	--	B
14	6	B
15	h	B
16	maximally	B
17	induced	B
18	luciferase	B
19	threefold	B
20	.	B

1	E2F1	B
2	-	B
3	mediated	B
4	transcriptional	B
5	inhibition	B
6	of	B
7	the	B
8	plasminogen	B
9	activator	B
10	inhibitor	B
11	type	B
12	1	B
13	gene	B
14	.	B

1	In	B
2	this	B
3	report	B
4	this	B
5	technique	B
6	was	B
7	applied	B
8	to	B
9	human	B
10	breast	B
11	carcinoma	B
12	MDA	B
13	-	B
14	MB231	B
15	cells	B
16	overexpressing	B
17	human	B
18	MPG	B
19	in	B
20	order	B
21	to	B
22	assess	B
23	whether	B
24	up	B
25	-	B
26	regulation	B
27	of	B
28	the	B
29	initial	B
30	step	B
31	in	B
32	BER	B
33	alters	B
34	the	B
35	activity	B
36	of	B
37	selected	B
38	other	B
39	BER	B
40	(	B
41	hOGG1	B
42	and	B
43	APE	B
44	/	B
45	ref	B
46	-	B
47	1	B
48	)	B
49	or	B
50	direct	B
51	reversal	B
52	(	B
53	MGMT	B
54	)	B
55	repair	B
56	activities	B
57	.	B

1	Chlamydia	B
2	and	B
3	cervical	B
4	cancer	B
5	:	B
6	a	B
7	real	B
8	association	B
9	?	B

1	In	B
2	children	B
3	unable	B
4	to	B
5	perform	B
6	forced	B
7	expiratory	B
8	maneuvers	B
9	(	B
10	n	B
11	=	B
12	25	B
13	),	B
14	FOT	B
15	,	B
16	contrary	B
17	to	B
18	the	B
19	interrupter	B
20	technique	B
21	,	B
22	clearly	B
23	identified	B
24	a	B
25	subgroup	B
26	of	B
27	young	B
28	children	B
29	with	B
30	high	B
31	resistance	B
32	values	B
33	at	B
34	baseline	B
35	,	B
36	which	B
37	returned	B
38	to	B
39	normal	B
40	after	B
41	bronchodilation	B
42	.	B

1	Together	B
2	,	B
3	these	B
4	results	B
5	identify	B
6	HPK1	B
7	as	B
8	a	B
9	new	B
10	component	B
11	of	B
12	TCR	B
13	signaling	B
14	.	B

1	Pro	B
2	-	B
3	inflammatory	B
4	cytokine	B
5	,	B
6	tumor	B
7	necrosis	B
8	factor	B
9	-	B
10	alpha	B
11	(	B
12	TNF	B
13	-	B
14	alpha	B
15	),	B
16	produced	B
17	from	B
18	adipose	B
19	tissues	B
20	in	B
21	obese	B
22	subjects	B
23	,	B
24	is	B
25	known	B
26	to	B
27	play	B
28	a	B
29	predominant	B
30	role	B
31	in	B
32	inducing	B
33	insulin	B
34	resistance	B
35	.	B

1	The	B
2	Schistosoma	B
3	mansoni	B
4	homologue	B
5	(	B
6	SmSmad2	B
7	)	B
8	was	B
9	overexpressed	B
10	in	B
11	bacteria	B
12	as	B
13	a	B
14	Sj26	B
15	-	B
16	GST	B
17	fusion	B
18	protein	B
19	and	B
20	used	B
21	to	B
22	raise	B
23	specific	B
24	antibodies	B
25	.	B

1	To	B
2	study	B
3	the	B
4	in	B
5	vivo	B
6	role	B
7	of	B
8	p16	B
9	.	B
10	7	B
11	,	B
12	a	B
13	phi29	B
14	mutant	B
15	containing	B
16	a	B
17	suppressible	B
18	mutation	B
19	in	B
20	gene	B
21	16	B
22	.	B
23	7	B
24	was	B
25	constructed	B
26	.	B

1	The	B
2	differences	B
3	in	B
4	the	B
5	CPIgG	B
6	,	B
7	CRP	B
8	,	B
9	and	B
10	fibrinogen	B
11	levels	B
12	in	B
13	patients	B
14	who	B
15	were	B
16	diagnosed	B
17	with	B
18	ACS	B
19	versus	B
20	those	B
21	who	B
22	were	B
23	not	B
24	(	B
25	non	B
26	-	B
27	ACS	B
28	)	B
29	were	B
30	evaluated	B
31	.	B

1	There	B
2	are	B
3	many	B
4	different	B
5	proposals	B
6	for	B
7	the	B
8	statistical	B
9	analysis	B
10	of	B
11	data	B
12	to	B
13	determine	B
14	early	B
15	onset	B
16	of	B
17	action	B
18	.	B

1	Coexpression	B
2	of	B
3	the	B
4	p120	B
5	(	B
6	ctn	B
7	)	B
8	protein	B
9	with	B
10	an	B
11	N	B
12	-	B
13	terminal	B
14	deletion	B
15	,	B
16	which	B
17	eliminates	B
18	some	B
19	potential	B
20	tyrosine	B
21	phosphorylation	B
22	sites	B
23	,	B
24	or	B
25	the	B
26	protein	B
27	with	B
28	a	B
29	single	B
30	amino	B
31	acid	B
32	substitution	B
33	(	B
34	tyrosine	B
35	at	B
36	217	B
37	to	B
38	phenylalanine	B
39	)	B
40	resulted	B
41	in	B
42	an	B
43	increase	B
44	in	B
45	the	B
46	aggregation	B
47	of	B
48	v	B
49	-	B
50	Src	B
51	-	B
52	transformed	B
53	EL	B
54	and	B
55	EalphaCL	B
56	cells	B
57	.	B

1	We	B
2	find	B
3	that	B
4	our	B
5	response	B
6	function	B
7	is	B
8	well	B
9	approximated	B
10	by	B
11	the	B
12	GSER	B
13	only	B
14	within	B
15	a	B
16	particular	B
17	frequency	B
18	range	B
19	determined	B
20	by	B
21	the	B
22	material	B
23	parameters	B
24	of	B
25	both	B
26	the	B
27	bead	B
28	and	B
29	the	B
30	network	B
31	.	B

1	The	B
2	novel	B
3	approach	B
4	to	B
5	insulin	B
6	administration	B
7	known	B
8	as	B
9	chronic	B
10	intermittent	B
11	intravenous	B
12	insulin	B
13	therapy	B
14	(	B
15	CIIIT	B
16	)	B
17	delivers	B
18	insulin	B
19	in	B
20	a	B
21	pulsatile	B
22	fashion	B
23	and	B
24	achieves	B
25	physiological	B
26	insulin	B
27	concentration	B
28	in	B
29	the	B
30	portal	B
31	vein	B
32	.	B

1	This	B
2	article	B
3	comparatively	B
4	evaluates	B
5	five	B
6	Generic	B
7	Systems	B
8	that	B
9	describe	B
10	the	B
11	basic	B
12	alternatives	B
13	to	B
14	composting	B
15	facility	B
16	design	B
17	and	B
18	control	B
19	.	B

1	With	B
2	a	B
3	GC	B
4	content	B
5	of	B
6	45	B
7	%	B
8	the	B
9	one	B
10	segment	B
11	would	B
12	correspond	B
13	to	B
14	"	B
15	isochore	B
16	H1	B
17	"	B
18	and	B
19	the	B
20	other	B
21	segment	B
22	(	B
23	39	B
24	%	B
25	GC	B
26	in	B
27	human	B
28	,	B
29	40	B
30	%	B
31	GC	B
32	in	B
33	mouse	B
34	)	B
35	to	B
36	"	B
37	isochore	B
38	L1	B
39	/	B
40	L2	B
41	".	B

1	A	B
2	review	B
3	of	B
4	the	B
5	literature	B
6	identified	B
7	8	B
8	comprehensive	B
9	clinical	B
10	studies	B
11	,	B
12	all	B
13	of	B
14	which	B
15	failed	B
16	to	B
17	document	B
18	any	B
19	relationship	B
20	between	B
21	NF1	B
22	and	B
23	intracranial	B
24	aneurysms	B
25	.	B

1	Serial	B
2	US	B
3	images	B
4	were	B
5	obtained	B
6	before	B
7	and	B
8	20	B
9	,	B
10	30	B
11	,	B
12	40	B
13	,	B
14	50	B
15	,	B
16	60	B
17	,	B
18	90	B
19	,	B
20	120	B
21	,	B
22	150	B
23	,	B
24	180	B
25	,	B
26	240	B
27	,	B
28	and	B
29	300	B
30	s	B
31	after	B
32	intravenous	B
33	injection	B
34	of	B
35	2	B
36	g	B
37	of	B
38	contrast	B
39	agent	B
40	using	B
41	conventional	B
42	and	B
43	harmonic	B
44	PD	B
45	US	B
46	.	B

1	Eight	B
2	CAD	B
3	patients	B
4	who	B
5	were	B
6	matched	B
7	to	B
8	the	B
9	treated	B
10	patients	B
11	for	B
12	age	B
13	(+/-	B
14	3	B
15	years	B
16	),	B
17	baseline	B
18	low	B
19	density	B
20	lipoprotein	B
21	(+/-	B
22	5	B
23	mg	B
24	/	B
25	dL	B
26	),	B
27	and	B
28	triglycerides	B
29	(+/-	B
30	50	B
31	mg	B
32	/	B
33	dL	B
34	)	B
35	but	B
36	who	B
37	had	B
38	never	B
39	been	B
40	treated	B
41	with	B
42	lipid	B
43	-	B
44	lowering	B
45	drugs	B
46	were	B
47	selected	B
48	as	B
49	controls	B
50	.	B

1	Here	B
2	we	B
3	present	B
4	evidence	B
5	that	B
6	the	B
7	distal	B
8	half	B
9	(	B
10	Stem	B
11	2	B
12	)	B
13	of	B
14	the	B
15	conserved	B
16	base	B
17	-	B
18	paired	B
19	stem	B
20	structure	B
21	found	B
22	in	B
23	all	B
24	hY	B
25	RNAs	B
26	also	B
27	plays	B
28	a	B
29	critical	B
30	role	B
31	in	B
32	the	B
33	export	B
34	process	B
35	.	B

1	The	B
2	contrasting	B
3	effects	B
4	of	B
5	dopaminergic	B
6	stimulation	B
7	on	B
8	the	B
9	motor	B
10	performance	B
11	and	B
12	on	B
13	some	B
14	aspects	B
15	of	B
16	cognitive	B
17	processing	B
18	suggest	B
19	the	B
20	existence	B
21	of	B
22	complex	B
23	interactions	B
24	within	B
25	pre	B
26	-	B
27	and	B
28	postsynaptic	B
29	brain	B
30	dopamine	B
31	receptors	B
32	,	B
33	and	B
34	an	B
35	intervention	B
36	of	B
37	segregated	B
38	basal	B
39	ganglia	B
40	-	B
41	prefrontal	B
42	cortex	B
43	loops	B
44	in	B
45	motor	B
46	and	B
47	cognitive	B
48	behaviour	B
49	.	B

1	The	B
2	size	B
3	of	B
4	the	B
5	infarct	B
6	was	B
7	determined	B
8	using	B
9	the	B
10	creatine	B
11	kinase	B
12	integral	B
13	method	B
14	.	B

1	These	B
2	corrections	B
3	do	B
4	not	B
5	involve	B
6	sequences	B
7	predicted	B
8	to	B
9	function	B
10	as	B
11	transcription	B
12	factor	B
13	binding	B
14	sites	B
15	.	B

1	A	B
2	comprehensive	B
3	neuropsychological	B
4	battery	B
5	was	B
6	administered	B
7	to	B
8	48	B
9	veterans	B
10	with	B
11	Gulf	B
12	War	B
13	Illness	B
14	(	B
15	GWI	B
16	)	B
17	characterized	B
18	by	B
19	severe	B
20	fatigue	B
21	(	B
22	GV	B
23	-	B
24	F	B
25	)	B
26	and	B
27	39	B
28	healthy	B
29	veterans	B
30	(	B
31	GV	B
32	-	B
33	H	B
34	).	B

1	Quantitative	B
2	PCR	B
3	studies	B
4	indicated	B
5	that	B
6	synthesis	B
7	and	B
8	transport	B
9	of	B
10	vector	B
11	DNA	B
12	into	B
13	the	B
14	nucleus	B
15	were	B
16	similar	B
17	for	B
18	macrophages	B
19	infected	B
20	with	B
21	the	B
22	clone	B
23	239	B
24	and	B
25	316	B
26	pseudotypes	B
27	,	B
28	suggesting	B
29	that	B
30	the	B
31	restriction	B
32	for	B
33	SIVmac239	B
34	infection	B
35	is	B
36	after	B
37	reverse	B
38	transcription	B
39	and	B
40	nuclear	B
41	import	B
42	of	B
43	viral	B
44	DNA	B
45	.	B

1	EXAFS	B
2	measurements	B
3	around	B
4	the	B
5	Ge	B
6	-	B
7	K	B
8	edge	B
9	have	B
10	been	B
11	carried	B
12	out	B
13	for	B
14	liquid	B
15	Ge	B
16	-	B
17	Si	B
18	alloys	B
19	for	B
20	the	B
21	first	B
22	time	B
23	to	B
24	investigate	B
25	the	B
26	local	B
27	structure	B
28	around	B
29	a	B
30	Ge	B
31	atom	B
32	.	B

1	Hp	B
2	positive	B
3	relatives	B
4	of	B
5	gastric	B
6	cancer	B
7	had	B
8	a	B
9	markedly	B
10	higher	B
11	prevalence	B
12	of	B
13	atrophy	B
14	than	B
15	those	B
16	with	B
17	Hp	B
18	negativity	B
19	without	B
20	cancer	B
21	relatives	B
22	(	B
23	29	B
24	vs	B
25	.	B

1	Thus	B
2	,	B
3	replication	B
4	fork	B
5	movement	B
6	near	B
7	HML	B
8	pauses	B
9	at	B
10	a	B
11	silent	B
12	origin	B
13	which	B
14	is	B
15	competent	B
16	for	B
17	replication	B
18	initiation	B
19	but	B
20	kept	B
21	silent	B
22	through	B
23	Orc2p	B
24	,	B
25	a	B
26	component	B
27	of	B
28	the	B
29	replication	B
30	initiator	B
31	.	B

1	Cardiac	B
2	markers	B
3	troponin	B
4	T	B
5	,	B
6	CK	B
7	-	B
8	MB	B
9	mass	B
10	and	B
11	myoglobin	B
12	were	B
13	helpful	B
14	in	B
15	the	B
16	differential	B
17	diagnosis	B
18	of	B
19	chest	B
20	pain	B
21	,	B
22	even	B
23	when	B
24	the	B
25	ECG	B
26	was	B
27	unremarkable	B
28	or	B
29	nonspecific	B
30	.	B

1	RESULTS	B
2	:	B
3	A	B
4	novel	B
5	gene	B
6	was	B
7	cloned	B
8	.	B

1	Both	B
2	pancreatic	B
3	and	B
4	intestinal	B
5	cell	B
6	lines	B
7	were	B
8	found	B
9	to	B
10	express	B
11	a	B
12	number	B
13	of	B
14	POU	B
15	(	B
16	OCT	B
17	binding	B
18	)	B
19	homeodomain	B
20	proteins	B
21	examined	B
22	by	B
23	electrophoretic	B
24	mobility	B
25	shift	B
26	assay	B
27	.	B

1	In	B
2	conclusion	B
3	,	B
4	USPIO	B
5	-	B
6	enhanced	B
7	MRI	B
8	data	B
9	were	B
10	capable	B
11	to	B
12	characterize	B
13	tumor	B
14	microvessel	B
15	properties	B
16	in	B
17	this	B
18	breast	B
19	cancer	B
20	model	B
21	:	B
22	microvascular	B
23	permeability	B
24	(	B
25	determined	B
26	using	B
27	USPIO	B
28	)	B
29	correlated	B
30	significantly	B
31	with	B
32	tumor	B
33	grade	B
34	.	B

1	Radiolabeled	B
2	biantennary	B
3	N	B
4	-	B
5	glycans	B
6	synthesized	B
7	by	B
8	Pro	B
9	(-)	B
10	5Lec20	B
11	were	B
12	proportionately	B
13	less	B
14	ricin	B
15	-	B
16	bound	B
17	than	B
18	similar	B
19	species	B
20	from	B
21	parental	B
22	CHO	B
23	cells	B
24	,	B
25	and	B
26	Lec20	B
27	cell	B
28	extracts	B
29	had	B
30	a	B
31	markedly	B
32	reduced	B
33	ability	B
34	to	B
35	transfer	B
36	Gal	B
37	to	B
38	GlcNAc	B
39	-	B
40	terminating	B
41	acceptors	B
42	.	B

1	CONCLUSION	B
2	:	B
3	The	B
4	training	B
5	of	B
6	novices	B
7	using	B
8	MIST	B
9	-	B
10	VR	B
11	yields	B
12	quantifiable	B
13	changes	B
14	in	B
15	skill	B
16	that	B
17	are	B
18	transferable	B
19	to	B
20	a	B
21	simple	B
22	real	B
23	task	B
24	and	B
25	are	B
26	similar	B
27	to	B
28	the	B
29	results	B
30	achieved	B
31	with	B
32	conventional	B
33	training	B
34	.	B

1	To	B
2	investigate	B
3	the	B
4	convergent	B
5	role	B
6	of	B
7	the	B
8	insulin	B
9	/	B
10	IGF	B
11	-	B
12	I	B
13	effector	B
14	pathway	B
15	mediating	B
16	bihormonal	B
17	stimulation	B
18	of	B
19	LDL	B
20	receptor	B
21	promoter	B
22	expression	B
23	,	B
24	transfected	B
25	granulosa	B
26	-	B
27	luteal	B
28	cells	B
29	were	B
30	pretreated	B
31	for	B
32	30	B
33	min	B
34	with	B
35	two	B
36	specific	B
37	inhibitors	B
38	of	B
39	phophatidylinositol	B
40	3	B
41	-	B
42	kinase	B
43	,	B
44	wortmannin	B
45	(	B
46	100	B
47	nM	B
48	)	B
49	and	B
50	LY	B
51	294002	B
52	(	B
53	10	B
54	microM	B
55	),	B
56	or	B
57	of	B
58	mitogen	B
59	-	B
60	activated	B
61	protein	B
62	kinase	B
63	kinase	B
64	,	B
65	PD	B
66	98059	B
67	(	B
68	50	B
69	microM	B
70	),	B
71	U0126	B
72	(	B
73	10	B
74	microM	B
75	),	B
76	or	B
77	the	B
78	latter	B
79	'	B
80	s	B
81	inactive	B
82	derivative	B
83	,	B
84	U0124	B
85	(	B
86	10	B
87	microM	B
88	).	B

1	Instead	B
2	,	B
3	affective	B
4	flattening	B
5	was	B
6	associated	B
7	with	B
8	both	B
9	dopamine	B
10	receptor	B
11	sensitivity	B
12	and	B
13	psychomotor	B
14	slowing	B
15	.	B

1	Other	B
2	therapies	B
3	are	B
4	also	B
5	available	B
6	,	B
7	including	B
8	hypertonic	B
9	saline	B
10	solution	B
11	,	B
12	THAM	B
13	(	B
14	Tris	B
15	-	B
16	hydroxy	B
17	-	B
18	methyl	B
19	-	B
20	aminomethane	B
21	)	B
22	buffer	B
23	,	B
24	and	B
25	high	B
26	-	B
27	dose	B
28	barbiturates	B
29	.	B

1	CONCLUSION	B
2	:	B
3	There	B
4	are	B
5	no	B
6	differences	B
7	in	B
8	the	B
9	measurement	B
10	data	B
11	derived	B
12	from	B
13	this	B
14	method	B
15	and	B
16	actual	B
17	measurement	B
18	data	B
19	from	B
20	an	B
21	object	B
22	created	B
23	by	B
24	the	B
25	computer	B
26	-	B
27	aided	B
28	dental	B
29	design	B
30	program	B
31	.	B

1	NF	B
2	-	B
3	kappaB	B
4	pathway	B
5	activation	B
6	occurs	B
7	during	B
8	transformation	B
9	induced	B
10	by	B
11	a	B
12	number	B
13	of	B
14	classical	B
15	oncogenes	B
16	,	B
17	including	B
18	Bcr	B
19	/	B
20	Abl	B
21	,	B
22	Ras	B
23	and	B
24	Rac	B
25	,	B
26	and	B
27	is	B
28	necessary	B
29	for	B
30	full	B
31	transforming	B
32	potential	B
33	.	B

1	Our	B
2	results	B
3	indicate	B
4	that	B
5	Gab1	B
6	is	B
7	involved	B
8	in	B
9	the	B
10	control	B
11	of	B
12	egr	B
13	-	B
14	1	B
15	expression	B
16	regulated	B
17	by	B
18	insulin	B
19	.	B

1	The	B
2	human	B
3	cytomegalovirus	B
4	(	B
5	HCMV	B
6	)	B
7	major	B
8	immediate	B
9	-	B
10	early	B
11	protein	B
12	IE2	B
13	is	B
14	a	B
15	nuclear	B
16	phosphoprotein	B
17	that	B
18	is	B
19	believed	B
20	to	B
21	be	B
22	a	B
23	key	B
24	regulator	B
25	in	B
26	both	B
27	lytic	B
28	and	B
29	latent	B
30	infections	B
31	.	B

1	Unexpectedly	B
2	,	B
3	Arg1	B
4	-	B
5	expressing	B
6	COS1	B
7	cells	B
8	showed	B
9	no	B
10	significant	B
11	proteinase	B
12	activity	B
13	to	B
14	various	B
15	synthesized	B
16	substrates	B
17	under	B
18	neutral	B
19	or	B
20	acidic	B
21	conditions	B
22	in	B
23	this	B
24	study	B
25	.	B

1	METHODS	B
2	:	B
3	126	B
4	patients	B
5	with	B
6	histologically	B
7	confirmed	B
8	MFH	B
9	were	B
10	analyzed	B
11	.	B

1	Regression	B
2	analyses	B
3	showed	B
4	that	B
5	SOREMP	B
6	dream	B
7	occurrences	B
8	were	B
9	significantly	B
10	related	B
11	to	B
12	the	B
13	amount	B
14	of	B
15	REM	B
16	sleep	B
17	,	B
18	while	B
19	NREMP	B
20	dream	B
21	occurrences	B
22	were	B
23	related	B
24	to	B
25	arousals	B
26	from	B
27	NREM	B
28	sleep	B
29	.	B

1	[	B
2	Diabetologia	B
3	(	B
4	2001	B
5	)	B
6	44	B
7	[	B
8	Suppl	B
9	3	B
10	]:	B
11	B37	B
12	-	B
13	B44	B
14	]	B

1	RESULTS	B
2	:	B
3	In	B
4	vivo	B
5	,	B
6	there	B
7	was	B
8	a	B
9	wide	B
10	distribution	B
11	with	B
12	the	B
13	coefficient	B
14	of	B
15	variation	B
16	(	B
17	SD	B
18	/	B
19	mean	B
20	x	B
21	100	B
22	%)	B
23	for	B
24	different	B
25	valve	B
26	sizes	B
27	ranging	B
28	from	B
29	21	B
30	%	B
31	to	B
32	39	B
33	%	B
34	in	B
35	the	B
36	St	B
37	Jude	B
38	Medical	B
39	valve	B
40	and	B
41	from	B
42	25	B
43	%	B
44	to	B
45	33	B
46	%	B
47	in	B
48	the	B
49	Omnicarbon	B
50	valve	B
51	.	B

1	A	B
2	microsporidian	B
3	,	B
4	Nosema	B
5	algerae	B
6	Vavra	B
7	and	B
8	undeen	B
9	,	B
10	was	B
11	found	B
12	parasitizing	B
13	larvae	B
14	and	B
15	adults	B
16	of	B
17	a	B
18	laboratory	B
19	colony	B
20	of	B
21	Culex	B
22	pipiens	B
23	L	B
24	.	B
25	originated	B
26	from	B
27	Gharbia	B
28	Governorate	B
29	.	B

1	Nearly	B
2	all	B
3	isolates	B
4	of	B
5	S	B
6	.	B
7	intermedius	B
8	and	B
9	most	B
10	isolates	B
11	of	B
12	S	B
13	.	B
14	constellatus	B
15	,	B
16	but	B
17	only	B
18	19	B
19	%	B
20	of	B
21	those	B
22	of	B
23	S	B
24	.	B
25	anginosus	B
26	,	B
27	were	B
28	associated	B
29	with	B
30	abscess	B
31	.	B

1	One	B
2	of	B
3	the	B
4	conserved	B
5	RNA	B
6	subdomains	B
7	,	B
8	designated	B
9	P3	B
10	,	B
11	has	B
12	previously	B
13	been	B
14	shown	B
15	to	B
16	be	B
17	required	B
18	for	B
19	nucleolar	B
20	localization	B
21	.	B

1	A	B
2	total	B
3	of	B
4	25	B
5	patients	B
6	with	B
7	malignant	B
8	brain	B
9	tumours	B
10	were	B
11	investigated	B
12	.	B

1	Interventions	B
2	aimed	B
3	at	B
4	these	B
5	specific	B
6	mediators	B
7	and	B
8	processes	B
9	may	B
10	be	B
11	successful	B
12	in	B
13	reducing	B
14	the	B
15	very	B
16	significant	B
17	human	B
18	and	B
19	economic	B
20	costs	B
21	of	B
22	vascular	B
23	access	B
24	dysfunction	B
25	.	B

1	We	B
2	used	B
3	stored	B
4	plasma	B
5	samples	B
6	from	B
7	409	B
8	patients	B
9	in	B
10	the	B
11	National	B
12	Institute	B
13	of	B
14	Neurological	B
15	Diseases	B
16	and	B
17	Stroke	B
18	(	B
19	NINDS	B
20	)	B
21	tissue	B
22	plasminogen	B
23	activator	B
24	(	B
25	t	B
26	-	B
27	PA	B
28	)	B
29	Stroke	B
30	Trial	B
31	to	B
32	examine	B
33	the	B
34	relationship	B
35	between	B
36	an	B
37	apolipoprotein	B
38	(	B
39	Apo	B
40	)	B
41	E2	B
42	or	B
43	an	B
44	Apo	B
45	E4	B
46	phenotype	B
47	and	B
48	a	B
49	favorable	B
50	outcome	B
51	3	B
52	months	B
53	after	B
54	stroke	B
55	,	B
56	the	B
57	risk	B
58	of	B
59	intracerebral	B
60	hemorrhage	B
61	,	B
62	and	B
63	the	B
64	response	B
65	to	B
66	intravenous	B
67	t	B
68	-	B
69	PA	B
70	therapy	B
71	.	B

1	These	B
2	results	B
3	were	B
4	robust	B
5	to	B
6	changes	B
7	in	B
8	the	B
9	baseline	B
10	assumptions	B
11	of	B
12	the	B
13	model	B
14	.	B

1	Cis	B
2	-	B
3	acting	B
4	CCAAT	B
5	elements	B
6	are	B
7	frequently	B
8	found	B
9	in	B
10	eukaryotic	B
11	promoter	B
12	regions	B
13	.	B

1	The	B
2	binary	B
3	and	B
4	tertiary	B
5	combinations	B
6	of	B
7	plant	B
8	-	B
9	derived	B
10	molluscicides	B
11	Azadirachta	B
12	indica	B
13	and	B
14	Cedrus	B
15	deodara	B
16	oil	B
17	with	B
18	synergists	B
19	MGK	B
20	-	B
21	264	B
22	,	B
23	piperonyl	B
24	butoxide	B
25	(	B
26	PB	B
27	)	B
28	and	B
29	fruit	B
30	powder	B
31	of	B
32	Embelia	B
33	ribes	B
34	were	B
35	used	B
36	against	B
37	the	B
38	Lymnaea	B
39	acuminata	B
40	.	B

1	This	B
2	article	B
3	reports	B
4	the	B
5	design	B
6	and	B
7	development	B
8	of	B
9	an	B
10	ECG	B
11	simulator	B
12	intended	B
13	for	B
14	use	B
15	in	B
16	the	B
17	testing	B
18	,	B
19	calibration	B
20	and	B
21	maintenance	B
22	of	B
23	electrocardiographic	B
24	equipment	B
25	.	B

1	Exchanging	B
2	the	B
3	human	B
4	propeptide	B
5	in	B
6	this	B
7	chimera	B
8	with	B
9	either	B
10	the	B
11	murine	B
12	MIC	B
13	-	B
14	1	B
15	or	B
16	TGF	B
17	-	B
18	beta1	B
19	propeptide	B
20	resulted	B
21	in	B
22	secretion	B
23	of	B
24	the	B
25	unprocessed	B
26	,	B
27	monomeric	B
28	chimera	B
29	,	B
30	suggesting	B
31	a	B
32	specific	B
33	interaction	B
34	between	B
35	the	B
36	human	B
37	MIC	B
38	-	B
39	1	B
40	propeptide	B
41	and	B
42	mature	B
43	peptide	B
44	.	B

1	RESULTS	B
2	:	B
3	The	B
4	analyzed	B
5	fragment	B
6	has	B
7	significant	B
8	activity	B
9	in	B
10	EpCAM	B
11	positive	B
12	cells	B
13	,	B
14	and	B
15	it	B
16	is	B
17	regulated	B
18	negatively	B
19	by	B
20	tumor	B
21	necrosis	B
22	factor	B
23	alpha	B
24	(	B
25	TNFalpha	B
26	).	B

1	The	B
2	mutant	B
3	receptors	B
4	,	B
5	as	B
6	well	B
7	as	B
8	sBMPR	B
9	-	B
10	IA	B
11	,	B
12	were	B
13	expressed	B
14	as	B
15	fusion	B
16	proteins	B
17	with	B
18	thioredoxin	B
19	in	B
20	Escherichia	B
21	coli	B
22	,	B
23	and	B
24	purified	B
25	using	B
26	reverse	B
27	phase	B
28	high	B
29	performance	B
30	liquid	B
31	chromatography	B
32	(	B
33	RP	B
34	-	B
35	HPLC	B
36	)	B
37	after	B
38	digestion	B
39	with	B
40	enterokinase	B
41	.	B

1	The	B
2	dual	B
3	specificity	B
4	kinases	B
5	mitogen	B
6	-	B
7	activated	B
8	protein	B
9	kinase	B
10	(	B
11	MAPK	B
12	)	B
13	kinase	B
14	(	B
15	MKK	B
16	)	B
17	7	B
18	and	B
19	MKK4	B
20	are	B
21	the	B
22	only	B
23	molecules	B
24	known	B
25	to	B
26	directly	B
27	activate	B
28	the	B
29	stress	B
30	kinases	B
31	stress	B
32	-	B
33	activated	B
34	protein	B
35	kinases	B
36	(	B
37	SAPKs	B
38	)/	B
39	c	B
40	-	B
41	Jun	B
42	N	B
43	-	B
44	terminal	B
45	kinases	B
46	(	B
47	JNKs	B
48	)	B
49	in	B
50	response	B
51	to	B
52	environmental	B
53	or	B
54	mitogenic	B
55	stimuli	B
56	.	B

1	This	B
2	unique	B
3	work	B
4	needs	B
5	to	B
6	be	B
7	edited	B
8	critically	B
9	and	B
10	afterwards	B
11	translated	B
12	into	B
13	Urdu	B
14	and	B
15	other	B
16	languages	B
17	for	B
18	the	B
19	benefit	B
20	of	B
21	the	B
22	present	B
23	day	B
24	students	B
25	and	B
26	scholars	B
27	.	B

1	RANTES	B
2	(	B
3	regulated	B
4	upon	B
5	activation	B
6	,	B
7	normally	B
8	T	B
9	-	B
10	cell	B
11	expressed	B
12	and	B
13	presumably	B
14	secreted	B
15	)	B
16	is	B
17	a	B
18	CC	B
19	chemokine	B
20	which	B
21	recruits	B
22	and	B
23	activates	B
24	monocytes	B
25	,	B
26	lymphocytes	B
27	,	B
28	and	B
29	eosinophils	B
30	,	B
31	all	B
32	cell	B
33	types	B
34	present	B
35	in	B
36	the	B
37	lung	B
38	inflammatory	B
39	infiltrate	B
40	induced	B
41	by	B
42	RSV	B
43	infection	B
44	.	B

1	Gabapentin	B
2	for	B
3	opiod	B
4	-	B
5	related	B
6	myoclonus	B
7	in	B
8	cancer	B
9	patients	B
10	.	B

1	Recently	B
2	,	B
3	it	B
4	was	B
5	shown	B
6	that	B
7	purified	B
8	RAG1	B
9	/	B
10	2	B
11	proteins	B
12	can	B
13	cleave	B
14	DNA	B
15	hairpins	B
16	in	B
17	vitro	B
18	,	B
19	but	B
20	the	B
21	same	B
22	activity	B
23	was	B
24	also	B
25	described	B
26	for	B
27	a	B
28	protein	B
29	complex	B
30	of	B
31	the	B
32	DNA	B
33	repair	B
34	proteins	B
35	Nbs1	B
36	/	B
37	Mre11	B
38	/	B
39	Rad50	B
40	.	B

1	APC	B
2	-	B
3	resistance	B
4	was	B
5	determined	B
6	with	B
7	a	B
8	functional	B
9	method	B
10	with	B
11	high	B
12	sensitivity	B
13	and	B
14	specificity	B
15	for	B
16	the	B
17	factor	B
18	V	B
19	Leiden	B
20	mutation	B
21	.	B

1	A	B
2	picture	B
3	is	B
4	emerging	B
5	showing	B
6	a	B
7	gradient	B
8	of	B
9	function	B
10	among	B
11	p53	B
12	,	B
13	p73	B
14	,	B
15	p63	B
16	ranging	B
17	from	B
18	tumor	B
19	suppression	B
20	to	B
21	development	B
22	.	B

1	High	B
2	plasma	B
3	AVP	B
4	levels	B
5	observed	B
6	in	B
7	the	B
8	two	B
9	cases	B
10	suggest	B
11	that	B
12	SSRIs	B
13	stimulate	B
14	AVP	B
15	secretion	B
16	,	B
17	thereby	B
18	causing	B
19	SIADH	B
20	.	B

1	Mutation	B
2	of	B
3	the	B
4	octamer	B
5	element	B
6	also	B
7	significantly	B
8	reduced	B
9	the	B
10	ability	B
11	of	B
12	HDAC1	B
13	to	B
14	confer	B
15	repression	B
16	of	B
17	inducible	B
18	HLA	B
19	-	B
20	DRA	B
21	promoter	B
22	activation	B
23	.	B

1	Requirements	B
2	for	B
3	the	B
4	nuclear	B
5	-	B
6	cytoplasmic	B
7	translocation	B
8	of	B
9	infected	B
10	-	B
11	cell	B
12	protein	B
13	0	B
14	of	B
15	herpes	B
16	simplex	B
17	virus	B
18	1	B
19	.	B

1	The	B
2	system	B
3	,	B
4	designed	B
5	to	B
6	exploit	B
7	the	B
8	relatively	B
9	constant	B
10	small	B
11	intestine	B
12	transit	B
13	time	B
14	,	B
15	consists	B
16	of	B
17	a	B
18	drug	B
19	-	B
20	containing	B
21	core	B
22	coated	B
23	with	B
24	a	B
25	polymeric	B
26	matrix	B
27	formed	B
28	by	B
29	a	B
30	channeling	B
31	agent	B
32	(	B
33	NaCl	B
34	,	B
35	mannitol	B
36	,	B
37	and	B
38	Emdex	B
39	)	B
40	and	B
41	an	B
42	inert	B
43	polymer	B
44	(	B
45	Eudragit	B
46	RS100	B
47	).	B

1	The	B
2	activity	B
3	of	B
4	Rac1	B
5	leads	B
6	to	B
7	STAT3	B
8	translocation	B
9	to	B
10	the	B
11	nucleus	B
12	coincident	B
13	with	B
14	STAT3	B
15	-	B
16	dependent	B
17	gene	B
18	expression	B
19	.	B

1	Treatment	B
2	of	B
3	ischemic	B
4	heart	B
5	disease	B
6	in	B
7	the	B
8	elderly	B

1	To	B
2	avoid	B
3	misinterpretations	B
4	,	B
5	special	B
6	reference	B
7	values	B
8	should	B
9	be	B
10	applied	B
11	for	B
12	preadolescents	B
13	,	B
14	at	B
15	least	B
16	with	B
17	regard	B
18	to	B
19	FVC	B
20	and	B
21	FEV1	B
22	.	B

1	STUDY	B
2	OBJECTIVE	B
3	:	B
4	This	B
5	study	B
6	assessed	B
7	several	B
8	methodological	B
9	aspects	B
10	related	B
11	to	B
12	the	B
13	quality	B
14	of	B
15	published	B
16	controlled	B
17	clinical	B
18	trials	B
19	(	B
20	CCTs	B
21	)	B
22	in	B
23	relation	B
24	to	B
25	the	B
26	participation	B
27	of	B
28	an	B
29	epidemiologist	B
30	/	B
31	biostatistician	B
32	(	B
33	E	B
34	/	B
35	B	B
36	).	B

1	To	B
2	the	B
3	best	B
4	of	B
5	our	B
6	knowledge	B
7	,	B
8	SNTCS	B
9	is	B
10	highly	B
11	malignant	B
12	.	B

1	Northern	B
2	blot	B
3	analysis	B
4	with	B
5	one	B
6	of	B
7	the	B
8	PARNAs	B
9	revealed	B
10	a	B
11	highly	B
12	abundant	B
13	signal	B
14	of	B
15	approximately	B
16	2	B
17	.	B
18	0	B
19	kilobases	B
20	(	B
21	kb	B
22	)	B
23	present	B
24	in	B
25	all	B
26	cell	B
27	lines	B
28	tested	B
29	.	B

1	The	B
2	effect	B
3	of	B
4	crude	B
5	oil	B
6	spillage	B
7	on	B
8	growth	B
9	,	B
10	productivity	B
11	and	B
12	nutrient	B
13	uptake	B
14	of	B
15	maize	B
16	(	B
17	Zea	B
18	mays	B
19	L	B
20	.)	B
21	was	B
22	assessed	B
23	in	B
24	a	B
25	pot	B
26	experiment	B
27	using	B
28	an	B
29	Evwreni	B
30	manifold	B
31	sample	B
32	of	B
33	a	B
34	petroleum	B
35	development	B
36	company	B
37	,	B
38	which	B
39	had	B
40	a	B
41	specific	B
42	gravity	B
43	of	B
44	0	B
45	.	B
46	8778	B
47	.	B

1	10	B
2	.	B
3	0	B
4	+/-	B
5	2	B
6	.	B
7	0	B
8	pmol	B
9	/	B
10	24	B
11	h	B
12	,	B
13	P	B
14	<	B
15	0	B
16	.	B
17	01	B
18	)	B
19	and	B
20	remained	B
21	elevated	B
22	.	B

1	Pitx2	B
2	rescues	B
3	the	B
4	GABAergic	B
5	differentiation	B
6	defect	B
7	and	B
8	partially	B
9	rescues	B
10	the	B
11	axon	B
12	guidance	B
13	and	B
14	behavioral	B
15	phenotypes	B
16	of	B
17	unc	B
18	-	B
19	30	B
20	mutants	B
21	,	B
22	indicating	B
23	a	B
24	high	B
25	degree	B
26	of	B
27	functional	B
28	conservation	B
29	between	B
30	these	B
31	evolutionarily	B
32	related	B
33	genes	B
34	.	B

1	Phosphatidylinositol	B
2	3	B
3	-	B
4	kinase	B
5	potentiates	B
6	,	B
7	but	B
8	does	B
9	not	B
10	trigger	B
11	,	B
12	T	B
13	cell	B
14	proliferation	B
15	mediated	B
16	by	B
17	the	B
18	IL	B
19	-	B
20	2	B
21	receptor	B
22	.	B

1	In	B
2	addition	B
3	,	B
4	stonin	B
5	2	B
6	binds	B
7	to	B
8	the	B
9	C2B	B
10	domains	B
11	of	B
12	synaptotagmins	B
13	I	B
14	and	B
15	II	B
16	.	B

1	Sequence	B
2	comparison	B
3	and	B
4	binding	B
5	studies	B
6	of	B
7	the	B
8	18	B
9	-	B
10	bp	B
11	MOK2	B
12	-	B
13	binding	B
14	sites	B
15	present	B
16	in	B
17	intron	B
18	2	B
19	of	B
20	human	B
21	,	B
22	bovine	B
23	,	B
24	and	B
25	mouse	B
26	IRBP	B
27	genes	B
28	show	B
29	that	B
30	the	B
31	3	B
32	'-	B
33	half	B
34	sequence	B
35	is	B
36	the	B
37	essential	B
38	core	B
39	element	B
40	for	B
41	MOK2	B
42	binding	B
43	.	B

1	Measurements	B
2	were	B
3	obtained	B
4	:	B
5	(	B
6	i	B
7	)	B
8	just	B
9	after	B
10	the	B
11	traumatic	B
12	exposure	B
13	(	B
14	D0	B
15	);	B
16	(	B
17	ii	B
18	)	B
19	3	B
20	days	B
21	after	B
22	this	B
23	first	B
24	measurement	B
25	(	B
26	D3	B
27	);	B
28	and	B
29	(	B
30	iii	B
31	)	B
32	30	B
33	days	B
34	after	B
35	(	B
36	D30	B
37	).	B

1	Long	B
2	-	B
3	term	B
4	results	B
5	with	B
6	MACOP	B
7	-	B
8	B	B
9	and	B
10	radiation	B
11	therapy	B
12	for	B
13	aggressive	B
14	lymphomas	B
15	]	B
16	BACKGROUND	B
17	:	B
18	Long	B
19	-	B
20	term	B
21	results	B
22	are	B
23	needed	B
24	to	B
25	evaluate	B
26	chemotherapy	B
27	regimens	B
28	and	B
29	prognostic	B
30	factors	B
31	in	B
32	non	B
33	-	B
34	Hodgkin	B
35	'	B
36	s	B
37	lymphomas	B
38	(	B
39	NHL	B
40	).	B

1	From	B
2	the	B
3	above	B
4	results	B
5	,	B
6	we	B
7	might	B
8	infer	B
9	that	B
10	the	B
11	seizure	B
12	type	B
13	of	B
14	TLE	B
15	and	B
16	a	B
17	high	B
18	frequency	B
19	of	B
20	seizure	B
21	are	B
22	two	B
23	major	B
24	independent	B
25	precipitate	B
26	factors	B
27	for	B
28	abnormal	B
29	latencies	B
30	of	B
31	P300	B
32	in	B
33	the	B
34	epileptic	B
35	patients	B
36	.	B

1	Rapamycin	B
2	(	B
3	FRAP	B
4	/	B
5	mTOR	B
6	inhibitor	B
7	)	B
8	blocked	B
9	4E	B
10	-	B
11	BP1	B
12	phosphorylation	B
13	causing	B
14	a	B
15	predominance	B
16	of	B
17	the	B
18	alpha	B
19	(	B
20	hypophosphorylated	B
21	)	B
22	band	B
23	.	B

1	We	B
2	investigate	B
3	the	B
4	reaction	B
5	kinetics	B
6	of	B
7	small	B
8	spherical	B
9	particles	B
10	with	B
11	inertia	B
12	,	B
13	obeying	B
14	coalescence	B
15	type	B
16	of	B
17	reaction	B
18	,	B
19	B	B
20	+	B
21	B	B
22	-->	B
23	B	B
24	,	B
25	and	B
26	being	B
27	advected	B
28	by	B
29	hydrodynamical	B
30	flows	B
31	with	B
32	time	B
33	-	B
34	periodic	B
35	forcing	B
36	.	B

1	Corticosteroid	B
2	-	B
3	mediated	B
4	transcriptional	B
5	inhibition	B
6	was	B
7	greater	B
8	for	B
9	MR	B
10	/	B
11	GR	B
12	in	B
13	combination	B
14	than	B
15	for	B
16	MR	B
17	or	B
18	GR	B
19	alone	B
20	.	B

1	These	B
2	data	B
3	define	B
4	a	B
5	conserved	B
6	pathway	B
7	wherein	B
8	sequential	B
9	histone	B
10	modifications	B
11	establish	B
12	a	B
13	"	B
14	histone	B
15	code	B
16	"	B
17	essential	B
18	for	B
19	the	B
20	epigenetic	B
21	inheritance	B
22	of	B
23	heterochromatin	B
24	assembly	B
25	.	B

1	The	B
2	bovine	B
3	PGHS	B
4	-	B
5	2	B
6	cDNA	B
7	was	B
8	cloned	B
9	by	B
10	a	B
11	combination	B
12	of	B
13	reverse	B
14	transcription	B
15	-	B
16	polymerase	B
17	chain	B
18	reaction	B
19	and	B
20	cDNA	B
21	library	B
22	screening	B
23	.	B

1	Telomerase	B
2	is	B
3	a	B
4	ribonucleoprotein	B
5	complex	B
6	that	B
7	synthesizes	B
8	telomeric	B
9	DNA	B
10	onto	B
11	chromosomes	B
12	using	B
13	its	B
14	RNA	B
15	component	B
16	as	B
17	template	B
18	.	B

1	The	B
2	iterative	B
3	method	B
4	proposed	B
5	by	B
6	Bengtsson	B
7	[	B
8	Appl	B
9	.	B

1	Several	B
2	distinct	B
3	apoptotic	B
4	stimuli	B
5	induce	B
6	the	B
7	expression	B
8	and	B
9	caspase	B
10	-	B
11	dependent	B
12	cleavage	B
13	of	B
14	hTAF	B
15	(	B
16	II	B
17	)	B
18	80	B
19	delta	B
20	.	B
21	hTAF	B
22	(	B
23	II	B
24	)	B
25	80	B
26	delta	B
27	,	B
28	unlike	B
29	hTAF	B
30	(	B
31	II	B
32	)	B
33	80	B
34	,	B
35	forms	B
36	a	B
37	TFIID	B
38	-	B
39	like	B
40	complex	B
41	lacking	B
42	hTAF	B
43	(	B
44	II	B
45	)	B
46	31	B
47	.	B

1	With	B
2	NEU	B
3	overexpression	B
4	,	B
5	nodal	B
6	control	B
7	decreased	B
8	from	B
9	72	B
10	%	B
11	to	B
12	34	B
13	%	B
14	(	B
15	p	B
16	=	B
17	.	B
18	008	B
19	).	B

1	The	B
2	mouse	B
3	platelet	B
4	-	B
5	derived	B
6	growth	B
7	factor	B
8	(	B
9	PDGF	B
10	)	B
11	beta	B
12	-	B
13	receptor	B
14	promoter	B
15	contains	B
16	a	B
17	CCAAT	B
18	motif	B
19	,	B
20	and	B
21	NF	B
22	-	B
23	Y	B
24	plays	B
25	an	B
26	essential	B
27	role	B
28	in	B
29	its	B
30	transcription	B
31	.	B

1	Biol	B
2	.	B

1	The	B
2	loop	B
3	domain	B
4	of	B
5	heat	B
6	shock	B
7	transcription	B
8	factor	B
9	1	B
10	dictates	B
11	DNA	B
12	-	B
13	binding	B
14	specificity	B
15	and	B
16	responses	B
17	to	B
18	heat	B
19	stress	B
20	.	B

1	This	B
2	activation	B
3	was	B
4	then	B
5	blocked	B
6	by	B
7	CGS	B
8	12066A	B
9	.	B

1	Among	B
2	the	B
3	transcription	B
4	factors	B
5	known	B
6	to	B
7	interact	B
8	with	B
9	Groucho	B
10	-	B
11	related	B
12	protein	B
13	,	B
14	only	B
15	RUNX1	B
16	was	B
17	appreciably	B
18	downregulated	B
19	by	B
20	E2A	B
21	-	B
22	HLF	B
23	.	B

1	A	B
2	new	B
3	intron	B
4	of	B
5	476	B
6	base	B
7	pairs	B
8	was	B
9	found	B
10	in	B
11	the	B
12	middle	B
13	of	B
14	the	B
15	5	B
16	'-	B
17	untranslated	B
18	leader	B
19	sequence	B
20	and	B
21	was	B
22	shown	B
23	to	B
24	robustly	B
25	enhance	B
26	the	B
27	promoter	B
28	activity	B
29	.	B

1	Our	B
2	findings	B
3	further	B
4	our	B
5	understanding	B
6	of	B
7	how	B
8	ZBP	B
9	-	B
10	89	B
11	modulates	B
12	cell	B
13	proliferation	B
14	and	B
15	reveals	B
16	a	B
17	novel	B
18	mechanism	B
19	by	B
20	which	B
21	the	B
22	p53	B
23	protein	B
24	is	B
25	stabilized	B
26	.	B

1	In	B
2	the	B
3	free	B
4	-	B
5	swimming	B
6	rotatory	B
7	test	B
8	mice	B
9	spend	B
10	most	B
11	of	B
12	the	B
13	time	B
14	swimming	B
15	close	B
16	to	B
17	the	B
18	wall	B
19	of	B
20	the	B
21	container	B
22	attempting	B
23	to	B
24	escape	B
25	from	B
26	an	B
27	aversive	B
28	test	B
29	situation	B
30	.	B

1	As	B
2	well	B
3	,	B
4	mixtures	B
5	of	B
6	(	B
7	LA	B
8	)(	B
9	12	B
10	)	B
11	with	B
12	the	B
13	longer	B
14	chain	B
15	PEs	B
16	exhibit	B
17	unusual	B
18	biomodal	B
19	enthalpy	B
20	variations	B
21	,	B
22	suggesting	B
23	peptide	B
24	immiscibility	B
25	in	B
26	thicker	B
27	gel	B
28	state	B
29	bilayers	B
30	.	B

1	At	B
2	the	B
3	time	B
4	of	B
5	the	B
6	blind	B
7	therapeutic	B
8	doses	B
9	,	B
10	Tg	B
11	-	B
12	off	B
13	values	B
14	ranged	B
15	from	B
16	8	B
17	to	B
18	608	B
19	microg	B
20	/	B
21	l	B
22	.	B

1	Nephrotoxicity	B
2	after	B
3	orthotopic	B
4	liver	B
5	transplantation	B
6	in	B
7	cyclosporin	B
8	A	B
9	and	B
10	FK	B
11	506	B
12	-	B
13	treated	B
14	patients	B
15	.	B

1	In	B
2	contrast	B
3	to	B
4	MPc3	B
5	,	B
6	data	B
7	indicate	B
8	that	B
9	the	B
10	Pc	B
11	protein	B
12	M33	B
13	does	B
14	not	B
15	interact	B
16	with	B
17	AF9	B
18	.	B

1	Hydrocoele	B
2	is	B
3	common	B
4	in	B
5	men	B
6	in	B
7	Wuchereria	B
8	bancrofti	B
9	-	B
10	endemic	B
11	areas	B
12	,	B
13	the	B
14	treatment	B
15	for	B
16	which	B
17	is	B
18	currently	B
19	surgical	B
20	intervention	B
21	.	B

1	Of	B
2	the	B
3	patients	B
4	in	B
5	each	B
6	regimen	B
7	who	B
8	reached	B
9	study	B
10	end	B
11	points	B
12	,	B
13	17	B
14	of	B
15	29	B
16	(	B
17	59	B
18	%)	B
19	were	B
20	in	B
21	regimen	B
22	A	B
23	,	B
24	11	B
25	of	B
26	20	B
27	(	B
28	55	B
29	%)	B
30	were	B
31	in	B
32	regimen	B
33	B	B
34	,	B
35	and	B
36	28	B
37	of	B
38	43	B
39	(	B
40	65	B
41	%)	B
42	were	B
43	in	B
44	regimen	B
45	C	B
46	met	B
47	the	B
48	treatment	B
49	success	B
50	criterion	B
51	.	B

1	One	B
2	maternal	B
3	death	B
4	,	B
5	reduced	B
6	body	B
7	weight	B
8	,	B
9	and	B
10	reduced	B
11	weight	B
12	gain	B
13	were	B
14	noted	B
15	at	B
16	the	B
17	high	B
18	dose	B
19	;	B
20	confirmed	B
21	pregnancy	B
22	rates	B
23	were	B
24	84	B
25	to	B
26	100	B
27	%	B
28	for	B
29	each	B
30	group	B
31	.	B

1	Karger	B
2	AG	B
3	,	B
4	Basel	B

1	In	B
2	regards	B
3	to	B
4	the	B
5	latter	B
6	activity	B
7	,	B
8	it	B
9	has	B
10	been	B
11	shown	B
12	that	B
13	S3	B
14	contains	B
15	vigorous	B
16	N	B
17	-	B
18	glycosylase	B
19	activity	B
20	for	B
21	the	B
22	removal	B
23	of	B
24	8	B
25	-	B
26	oxoguanine	B
27	residues	B
28	in	B
29	DNA	B
30	that	B
31	leaves	B
32	baseless	B
33	sites	B
34	in	B
35	their	B
36	places	B
37	.	B

1	We	B
2	describe	B
3	a	B
4	total	B
5	of	B
6	39	B
7	DEAH	B
8	helicases	B
9	in	B
10	these	B
11	four	B
12	species	B
13	.	B

1	A	B
2	prospective	B
3	trial	B
4	was	B
5	undertaken	B
6	to	B
7	determine	B
8	(	B
9	1	B
10	)	B
11	clinical	B
12	characteristics	B
13	of	B
14	patients	B
15	with	B
16	chest	B
17	pain	B
18	;	B
19	(	B
20	2	B
21	)	B
22	value	B
23	of	B
24	cardiac	B
25	markers	B
26	troponin	B
27	T	B
28	,	B
29	myoglobin	B
30	and	B
31	CK	B
32	-	B
33	MB	B
34	mass	B
35	in	B
36	differentiating	B
37	cardiac	B
38	and	B
39	noncardiac	B
40	chest	B
41	pain	B
42	;	B
43	(	B
44	3	B
45	)	B
46	the	B
47	proportion	B
48	of	B
49	patients	B
50	with	B
51	ACS	B
52	in	B
53	whom	B
54	these	B
55	markers	B
56	provided	B
57	helpful	B
58	additional	B
59	information	B
60	on	B
61	admission	B
62	and	B
63	afterwards	B
64	.	B

1	Inactivity	B
2	of	B
3	the	B
4	human	B
5	cytomegalovirus	B
6	(	B
7	HCMV	B
8	)	B
9	major	B
10	immediate	B
11	-	B
12	early	B
13	regulatory	B
14	region	B
15	(	B
16	MIERR	B
17	),	B
18	which	B
19	is	B
20	composed	B
21	of	B
22	promoter	B
23	,	B
24	enhancer	B
25	,	B
26	unique	B
27	region	B
28	,	B
29	and	B
30	modulator	B
31	,	B
32	is	B
33	linked	B
34	to	B
35	lack	B
36	of	B
37	HCMV	B
38	replication	B
39	in	B
40	latently	B
41	infected	B
42	cells	B
43	and	B
44	in	B
45	other	B
46	nonpermissive	B
47	cell	B
48	types	B
49	,	B
50	including	B
51	human	B
52	embryonal	B
53	NTera2	B
54	carcinoma	B
55	(	B
56	NT2	B
57	)	B
58	cells	B
59	.	B

1	The	B
2	observed	B
3	triplexes	B
4	depend	B
5	on	B
6	the	B
7	length	B
8	of	B
9	the	B
10	repeat	B
11	.	B

1	Statistical	B
2	Analysis	B
3	included	B
4	ANOVA	B
5	,	B
6	the	B
7	Pearson	B
8	Product	B
9	Moment	B
10	Correlation	B
11	Coefficient	B
12	,	B
13	Principal	B
14	Components	B
15	Analysis	B
16	and	B
17	Discriminant	B
18	Function	B
19	Analysis	B
20	and	B
21	the	B
22	calculation	B
23	of	B
24	Cronbach	B
25	'	B
26	s	B
27	alpha	B
28	(	B
29	alpha	B
30	)	B
31	RESULTS	B
32	:	B
33	Both	B
34	Sensitivity	B
35	and	B
36	specificity	B
37	exceed	B
38	90	B
39	.	B
40	00	B
41	at	B
42	23	B
43	/	B
44	24	B
45	,	B
46	Chronbach	B
47	'	B
48	s	B
49	alpha	B
50	for	B
51	the	B
52	total	B
53	scale	B
54	was	B
55	equal	B
56	to	B
57	0	B
58	.	B
59	95	B
60	.	B

1	BACKGROUND	B
2	:	B
3	Previous	B
4	studies	B
5	have	B
6	indicated	B
7	that	B
8	the	B
9	60	B
10	-,	B
11	30	B
12	-,	B
13	28	B
14	-	B
15	and	B
16	12	B
17	-	B
18	item	B
19	versions	B
20	of	B
21	the	B
22	General	B
23	Health	B
24	Questionnaire	B
25	(	B
26	GHQ	B
27	)	B
28	are	B
29	liable	B
30	to	B
31	retest	B
32	effects	B
33	,	B
34	especially	B
35	when	B
36	administered	B
37	multiple	B
38	times	B
39	with	B
40	short	B
41	intervals	B
42	.	B

1	Cross	B
2	-	B
3	linking	B
4	FcalphaR	B
5	on	B
6	wt	B
7	-	B
8	ITAM	B
9	or	B
10	IIA	B
11	-	B
12	ITAM	B
13	cells	B
14	triggered	B
15	equivalent	B
16	PI	B
17	3	B
18	-	B
19	kinase	B
20	-	B
21	dependent	B
22	activation	B
23	of	B
24	PKBalpha	B
25	.	B

1	An	B
2	F222W	B
3	:	B
4	W21F	B
5	rGST	B
6	A1	B
7	-	B
8	1	B
9	double	B
10	mutant	B
11	provides	B
12	a	B
13	direct	B
14	fluorescence	B
15	probe	B
16	of	B
17	changes	B
18	in	B
19	the	B
20	environment	B
21	of	B
22	the	B
23	C	B
24	-	B
25	terminal	B
26	residue	B
27	.	B

1	Binding	B
2	of	B
3	serum	B
4	response	B
5	factor	B
6	to	B
7	CArG	B
8	box	B
9	sequences	B
10	is	B
11	necessary	B
12	but	B
13	not	B
14	sufficient	B
15	to	B
16	restrict	B
17	gene	B
18	expression	B
19	to	B
20	arterial	B
21	smooth	B
22	muscle	B
23	cells	B
24	.	B

1	They	B
2	consist	B
3	of	B
4	at	B
5	least	B
6	two	B
7	separable	B
8	components	B
9	,	B
10	one	B
11	heat	B
12	stable	B
13	and	B
14	the	B
15	other	B
16	heat	B
17	labile	B
18	.	B

1	No	B
2	preferential	B
3	VH	B
4	/	B
5	VL	B
6	-	B
7	chains	B
8	correlated	B
9	with	B
10	any	B
11	of	B
12	the	B
13	12	B
14	different	B
15	antigen	B
16	reactivities	B
17	,	B
18	even	B
19	for	B
20	mAbs	B
21	with	B
22	nearly	B
23	identical	B
24	cross	B
25	-	B
26	reactivities	B
27	.	B

1	These	B
2	results	B
3	were	B
4	compared	B
5	with	B
6	the	B
7	estimates	B
8	of	B
9	penetration	B
10	from	B
11	steady	B
12	-	B
13	state	B
14	calculations	B
15	,	B
16	square	B
17	root	B
18	of	B
19	time	B
20	calculations	B
21	,	B
22	and	B
23	a	B
24	biologically	B
25	based	B
26	mathematical	B
27	model	B
28	.	B

1	Based	B
2	on	B
3	this	B
4	analysis	B
5	,	B
6	we	B
7	propose	B
8	that	B
9	the	B
10	interactions	B
11	of	B
12	Sos	B
13	with	B
14	the	B
15	switch	B
16	1	B
17	and	B
18	switch	B
19	2	B
20	regions	B
21	of	B
22	Ras	B
23	have	B
24	distinct	B
25	functional	B
26	consequences	B
27	:	B
28	the	B
29	interaction	B
30	with	B
31	switch	B
32	2	B
33	mediates	B
34	the	B
35	anchoring	B
36	of	B
37	Ras	B
38	to	B
39	Sos	B
40	,	B
41	whereas	B
42	the	B
43	interaction	B
44	with	B
45	switch	B
46	1	B
47	leads	B
48	to	B
49	disruption	B
50	of	B
51	the	B
52	nucleotide	B
53	-	B
54	binding	B
55	site	B
56	and	B
57	GDP	B
58	dissociation	B
59	.	B

1	Thus	B
2	,	B
3	the	B
4	interaction	B
5	of	B
6	Tat	B
7	with	B
8	the	B
9	components	B
10	of	B
11	this	B
12	rel	B
13	/	B
14	AP1	B
15	cooperative	B
16	complex	B
17	seems	B
18	to	B
19	induce	B
20	quantitative	B
21	and	B
22	qualitative	B
23	alterations	B
24	of	B
25	this	B
26	complex	B
27	as	B
28	activation	B
29	progresses	B
30	,	B
31	resulting	B
32	in	B
33	a	B
34	decrease	B
35	of	B
36	IL	B
37	-	B
38	2	B
39	gene	B
40	transcription	B
41	.	B

1	SIT	B
2	(	B
3	SHP2	B
4	-	B
5	interacting	B
6	transmembrane	B
7	adaptor	B
8	protein	B
9	)	B
10	is	B
11	a	B
12	recently	B
13	identified	B
14	transmembrane	B
15	adaptor	B
16	protein	B
17	,	B
18	which	B
19	is	B
20	expressed	B
21	in	B
22	lymphocytes	B
23	.	B

1	In	B
2	this	B
3	manuscript	B
4	we	B
5	demonstrate	B
6	that	B
7	two	B
8	tandem	B
9	Ets	B
10	sites	B
11	in	B
12	the	B
13	mouse	B
14	GL	B
15	alpha	B
16	promoter	B
17	bind	B
18	the	B
19	transcription	B
20	factors	B
21	Elf	B
22	-	B
23	1	B
24	and	B
25	PU	B
26	.	B
27	1	B
28	,	B
29	and	B
30	that	B
31	the	B
32	3	B
33	'	B
34	site	B
35	is	B
36	essential	B
37	for	B
38	expression	B
39	of	B
40	a	B
41	luciferase	B
42	reporter	B
43	gene	B
44	driven	B
45	by	B
46	the	B
47	GL	B
48	alpha	B
49	promoter	B
50	.	B

1	ICA	B
2	in	B
3	the	B
4	reference	B
5	solution	B
6	was	B
7	characterised	B
8	by	B
9	LC	B
10	and	B
11	time	B
12	-	B
13	of	B
14	-	B
15	flight	B
16	(	B
17	TOF	B
18	)	B
19	MS	B
20	and	B
21	quantified	B
22	by	B
23	LC	B
24	chemiluminescent	B
25	nitrogen	B
26	detection	B
27	(	B
28	LC	B
29	-	B
30	CLND	B
31	).	B

1	These	B
2	disorders	B
3	include	B
4	low	B
5	-	B
6	back	B
7	pain	B
8	,	B
9	saddle	B
10	anesthesia	B
11	,	B
12	bilateral	B
13	sciatica	B
14	,	B
15	then	B
16	motor	B
17	weakness	B
18	of	B
19	the	B
20	lower	B
21	extremities	B
22	or	B
23	chronic	B
24	paraplegia	B
25	and	B
26	,	B
27	bladder	B
28	dysfunction	B
29	.	B

1	C	B
2	.	B
3	elegans	B
4	embryogenesis	B
5	begins	B
6	with	B
7	a	B
8	stereotyped	B
9	sequence	B
10	of	B
11	asymmetric	B
12	cell	B
13	divisions	B
14	that	B
15	are	B
16	largely	B
17	responsible	B
18	for	B
19	establishing	B
20	the	B
21	nematode	B
22	body	B
23	plan	B
24	.	B

1	Additionally	B
2	,	B
3	a	B
4	CaCO3	B
5	-	B
6	CO2	B
7	/	B
8	N2	B
9	buffered	B
10	solution	B
11	was	B
12	necessary	B
13	to	B
14	maintain	B
15	a	B
16	pH	B
17	of	B
18	8	B
19	.	B

1	Mss4	B
2	also	B
3	acts	B
4	as	B
5	a	B
6	relatively	B
7	inefficient	B
8	guanine	B
9	nucleotide	B
10	exchange	B
11	factor	B
12	(	B
13	GEF	B
14	).	B

1	Effects	B
2	of	B
3	3	B
4	'	B
5	terminus	B
6	modifications	B
7	on	B
8	mRNA	B
9	functional	B
10	decay	B
11	during	B
12	in	B
13	vitro	B
14	protein	B
15	synthesis	B
16	.	B

1	Disciplinary	B
2	action	B
3	for	B
4	DNA	B
5	violation	B
6	.	B

1	This	B
2	is	B
3	necessary	B
4	if	B
5	psychiatric	B
6	diagnoses	B
7	are	B
8	ultimately	B
9	going	B
10	to	B
11	be	B
12	refined	B
13	and	B
14	validated	B
15	against	B
16	biological	B
17	criteria	B
18	.	B

1	We	B
2	also	B
3	demonstrate	B
4	that	B
5	the	B
6	spo20	B
7	(+)	B
8	gene	B
9	product	B
10	is	B
11	structurally	B
12	homologous	B
13	to	B
14	Saccharomyces	B
15	cerevisiae	B
16	Sec14	B
17	,	B
18	the	B
19	major	B
20	phosphatidylinositol	B
21	transfer	B
22	protein	B
23	of	B
24	budding	B
25	yeast	B
26	.	B

1	In	B
2	addition	B
3	,	B
4	another	B
5	derivative	B
6	of	B
7	pCMVJS21	B
8	(	B
9	pCMVJS21DeltaGP	B
10	)	B
11	in	B
12	which	B
13	the	B
14	gag	B
15	,	B
16	pol	B
17	(	B
18	and	B
19	orf	B
20	-	B
21	x	B
22	)	B
23	coding	B
24	sequences	B
25	were	B
26	deleted	B
27	also	B
28	gave	B
29	transformed	B
30	foci	B
31	.	B

1	It	B
2	is	B
3	shown	B
4	that	B
5	,	B
6	for	B
7	any	B
8	periodic	B
9	input	B
10	,	B
11	the	B
12	map	B
13	representing	B
14	the	B
15	relation	B
16	between	B
17	input	B
18	phases	B
19	at	B
20	consecutive	B
21	discharge	B
22	times	B
23	can	B
24	be	B
25	restricted	B
26	to	B
27	a	B
28	piecewise	B
29	continuous	B
30	,	B
31	orientation	B
32	preserving	B
33	circle	B
34	map	B
35	.	B

1	Decreased	B
2	serum	B
3	ceruloplasmin	B
4	and	B
5	copper	B
6	levels	B
7	in	B
8	cervical	B
9	dystonia	B
10	.	B

1	Northern	B
2	blot	B
3	analysis	B
4	of	B
5	RNAs	B
6	from	B
7	a	B
8	number	B
9	of	B
10	mouse	B
11	tissues	B
12	reveals	B
13	that	B
14	Atp6i	B
15	is	B
16	expressed	B
17	predominantly	B
18	in	B
19	osteoclasts	B
20	,	B
21	and	B
22	this	B
23	predominant	B
24	expression	B
25	was	B
26	confirmed	B
27	by	B
28	reverse	B
29	-	B
30	transcription	B
31	polymerase	B
32	chain	B
33	reaction	B
34	(	B
35	RT	B
36	-	B
37	PCR	B
38	)	B
39	assay	B
40	and	B
41	immunohistochemical	B
42	analysis	B
43	.	B

1	Behavioural	B
2	tests	B
3	with	B
4	192	B
5	specimen	B
6	of	B
7	the	B
8	roman	B
9	garden	B
10	snail	B
11	Helix	B
12	pomatia	B
13	L	B
14	.	B
15	were	B
16	performed	B
17	in	B
18	order	B
19	to	B
20	clarify	B
21	whether	B
22	the	B
23	thermopreferendum	B
24	of	B
25	this	B
26	pulmonate	B
27	is	B
28	influenced	B
29	not	B
30	only	B
31	by	B
32	the	B
33	temperature	B
34	of	B
35	the	B
36	substratum	B
37	but	B
38	also	B
39	by	B
40	air	B
41	temperature	B
42	.	B

1	As	B
2	well	B
3	,	B
4	IFN	B
5	-	B
6	gamma	B
7	-	B
8	induced	B
9	expression	B
10	of	B
11	IRF	B
12	-	B
13	1	B
14	and	B
15	its	B
16	binding	B
17	to	B
18	the	B
19	IRF	B
20	element	B
21	is	B
22	inhibited	B
23	.	B

1	Baseline	B
2	BMD	B
3	values	B
4	were	B
5	significantly	B
6	lower	B
7	in	B
8	the	B
9	oligo	B
10	-	B
11	amenorrheic	B
12	group	B
13	than	B
14	in	B
15	the	B
16	two	B
17	others	B
18	at	B
19	the	B
20	level	B
21	of	B
22	lumbar	B
23	spine	B
24	(	B
25	anteroposterior	B
26	view	B
27	:	B
28	0	B
29	.	B
30	941	B
31	+/-	B
32	0	B
33	.	B
34	039	B
35	in	B
36	oligo	B
37	-	B
38	amenorrheic	B
39	vs	B
40	1	B
41	.	B
42	077	B
43	+/-	B
44	0	B
45	.	B
46	029	B
47	or	B
48	1	B
49	.	B
50	051	B
51	+/-	B
52	0	B
53	.	B
54	017	B
55	g	B
56	x	B
57	cm	B
58	(-	B
59	2	B
60	),	B
61	P	B
62	<	B
63	0	B
64	.	B
65	005	B
66	,	B
67	in	B
68	the	B
69	eumenorrheic	B
70	and	B
71	contraceptive	B
72	user	B
73	groups	B
74	,	B
75	respectively	B
76	)	B
77	but	B
78	not	B
79	in	B
80	weight	B
81	-	B
82	bearing	B
83	bone	B
84	such	B
85	as	B
86	proximal	B
87	and	B
88	midshaft	B
89	femur	B
90	.	B

1	The	B
2	glucose	B
3	/	B
4	insulin	B
5	stimulation	B
6	was	B
7	inhibited	B
8	by	B
9	the	B
10	addition	B
11	of	B
12	polyunsaturated	B
13	fatty	B
14	acids	B
15	.	B

1	We	B
2	report	B
3	the	B
4	results	B
5	of	B
6	a	B
7	detailed	B
8	policy	B
9	analysis	B
10	comparing	B
11	2	B
12	CJD	B
13	-	B
14	related	B
15	decisions	B
16	:	B
17	a	B
18	1995	B
19	recall	B
20	of	B
21	blood	B
22	from	B
23	a	B
24	donor	B
25	with	B
26	classic	B
27	CJD	B
28	and	B
29	the	B
30	1999	B
31	decision	B
32	to	B
33	defer	B
34	donations	B
35	from	B
36	individuals	B
37	with	B
38	a	B
39	6	B
40	-	B
41	month	B
42	travel	B
43	history	B
44	to	B
45	the	B
46	UK	B
47	between	B
48	1980	B
49	and	B
50	1996	B
51	due	B
52	to	B
53	concerns	B
54	related	B
55	to	B
56	variant	B
57	CJD	B
58	.	B

1	The	B
2	5	B
3	'	B
4	flanking	B
5	sequence	B
6	of	B
7	the	B
8	3B	B
9	gene	B
10	is	B
11	extremely	B
12	A	B
13	+	B
14	T	B
15	rich	B
16	but	B
17	contains	B
18	five	B
19	G	B
20	/	B
21	C	B
22	rich	B
23	stretches	B
24	,	B
25	each	B
26	approximately	B
27	7bp	B
28	long	B
29	,	B
30	which	B
31	have	B
32	strong	B
33	sequence	B
34	similarity	B
35	to	B
36	the	B
37	G	B
38	boxes	B
39	found	B
40	upstream	B
41	of	B
42	other	B
43	developmentally	B
44	regulated	B
45	Dictyostelium	B
46	genes	B
47	.	B

1	PACAP	B
2	mRNA	B
3	was	B
4	widely	B
5	expressed	B
6	in	B
7	most	B
8	human	B
9	tissues	B
10	;	B
11	in	B
12	transfected	B
13	cells	B
14	,	B
15	PACAP	B
16	was	B
17	diffusely	B
18	expressed	B
19	in	B
20	the	B
21	cytoplasm	B
22	.	B

1	The	B
2	proportion	B
3	of	B
4	the	B
5	biopsies	B
6	found	B
7	to	B
8	be	B
9	seropositive	B
10	for	B
11	HBs	B
12	antigen	B
13	was	B
14	27	B
15	.	B
16	9	B
17	%,	B
18	and	B
19	these	B
20	showed	B
21	either	B
22	MGN	B
23	or	B
24	MPGN	B
25	pattern	B
26	.	B

1	In	B
2	the	B
3	present	B
4	study	B
5	,	B
6	we	B
7	have	B
8	determined	B
9	the	B
10	ICBP90	B
11	gene	B
12	structure	B
13	by	B
14	screening	B
15	of	B
16	a	B
17	human	B
18	placenta	B
19	genomic	B
20	library	B
21	and	B
22	PCR	B
23	analysis	B
24	.	B

1	In	B
2	the	B
3	stable	B
4	transfectants	B
5	(	B
6	BM3	B
7	cells	B
8	)	B
9	expressing	B
10	a	B
11	mutant	B
12	bacterial	B
13	P450	B
14	AA	B
15	epoxygenase	B
16	,	B
17	F87V	B
18	BM3	B
19	,	B
20	which	B
21	was	B
22	genetically	B
23	engineered	B
24	to	B
25	metabolize	B
26	arachidonic	B
27	acid	B
28	only	B
29	to	B
30	14	B
31	,	B
32	15	B
33	-	B
34	EET	B
35	,	B
36	AA	B
37	did	B
38	not	B
39	induce	B
40	apoptosis	B
41	and	B
42	protected	B
43	against	B
44	agonist	B
45	-	B
46	induced	B
47	apoptosis	B
48	.	B

1	The	B
2	revitalization	B
3	of	B
4	surgery	B
5	for	B
6	Parkinson	B
7	'	B
8	s	B
9	disease	B
10	(	B
11	PD	B
12	)	B
13	has	B
14	fueled	B
15	discussion	B
16	about	B
17	the	B
18	best	B
19	methodology	B
20	to	B
21	define	B
22	the	B
23	target	B
24	.	B

1	Foreigners	B
2	return	B
3	.	B

1	She	B
2	drank	B
3	alcohol	B
4	once	B
5	or	B
6	twice	B
7	a	B
8	week	B
9	and	B
10	regularly	B
11	took	B
12	an	B
13	analgesic	B
14	preparation	B
15	,	B
16	containing	B
17	aspirin	B
18	and	B
19	acetaminophen	B
20	,	B
21	for	B
22	alleviation	B
23	of	B
24	headaches	B
25	.	B

1	The	B
2	authors	B
3	did	B
4	not	B
5	detect	B
6	any	B
7	significant	B
8	correlations	B
9	between	B
10	parameters	B
11	of	B
12	the	B
13	lipids	B
14	of	B
15	bone	B
16	marrow	B
17	and	B
18	leptin	B
19	levels	B
20	in	B
21	serum	B
22	and	B
23	bone	B
24	marrow	B
25	.	B

1	When	B
2	the	B
3	blood	B
4	clot	B
5	is	B
6	formed	B
7	in	B
8	the	B
9	vitreous	B
10	cavity	B
11	,	B
12	intravitreal	B
13	injection	B
14	of	B
15	t	B
16	-	B
17	PA	B
18	can	B
19	convert	B
20	plasminogen	B
21	to	B
22	plasmin	B
23	and	B
24	remove	B
25	the	B
26	clot	B
27	.	B

1	When	B
2	this	B
3	CCAAT	B
4	box	B
5	was	B
6	inserted	B
7	into	B
8	a	B
9	heterologous	B
10	promoter	B
11	construct	B
12	,	B
13	OA	B
14	induction	B
15	was	B
16	dependent	B
17	on	B
18	an	B
19	intact	B
20	CCAAT	B
21	box	B
22	.	B

1	Encouraged	B
2	by	B
3	a	B
4	Dutch	B
5	study	B
6	using	B
7	etidronate	B
8	/	B
9	fluoride	B
10	in	B
11	corticoid	B
12	-	B
13	induced	B
14	osteoporosis	B
15	,	B
16	we	B
17	performed	B
18	a	B
19	pilot	B
20	study	B
21	in	B
22	33	B
23	men	B
24	with	B
25	severe	B
26	established	B
27	primary	B
28	osteoporosis	B
29	giving	B
30	cyclically	B
31	etidronate	B
32	for	B
33	14	B
34	days	B
35	followed	B
36	by	B
37	fluoride	B
38	plus	B
39	calcium	B
40	/	B
41	vitamin	B
42	D	B
43	for	B
44	76	B
45	days	B
46	.	B

1	Far	B
2	Western	B
3	blot	B
4	analysis	B
5	suggested	B
6	that	B
7	the	B
8	tandem	B
9	SH2	B
10	domains	B
11	of	B
12	SHP2	B
13	bind	B
14	to	B
15	Gab1	B
16	in	B
17	a	B
18	specific	B
19	orientation	B
20	,	B
21	in	B
22	which	B
23	the	B
24	N	B
25	-	B
26	SH2	B
27	domain	B
28	binds	B
29	to	B
30	phosphotyrosine	B
31	(	B
32	Tyr	B
33	(	B
34	P	B
35	))-	B
36	627	B
37	and	B
38	the	B
39	C	B
40	-	B
41	SH2	B
42	domain	B
43	binds	B
44	to	B
45	Tyr	B
46	(	B
47	P	B
48	)-	B
49	659	B
50	.	B

1	Electrophoretic	B
2	mobility	B
3	shift	B
4	assays	B
5	and	B
6	coimmunoprecipitation	B
7	studies	B
8	suggest	B
9	that	B
10	homo	B
11	-	B
12	and	B
13	heterodimerization	B
14	occurs	B
15	between	B
16	cKrox	B
17	family	B
18	members	B
19	.	B

1	Expression	B
2	of	B
3	human	B
4	RACK1	B
5	efficiently	B
6	relieves	B
7	E1A	B
8	-	B
9	mediated	B
10	growth	B
11	inhibition	B
12	in	B
13	HF7c	B
14	and	B
15	protects	B
16	human	B
17	tumor	B
18	cells	B
19	from	B
20	E1A	B
21	-	B
22	induced	B
23	apoptosis	B
24	.	B

1	By	B
2	using	B
3	space	B
4	-	B
5	discrete	B
6	/	B
7	continuous	B
8	metapopulation	B
9	dynamic	B
10	models	B
11	and	B
12	computer	B
13	simulations	B
14	,	B
15	we	B
16	show	B
17	that	B
18	there	B
19	can	B
20	be	B
21	two	B
22	principally	B
23	different	B
24	regimes	B
25	of	B
26	metapopulation	B
27	dynamics	B
28	.	B

1	Arterial	B
2	blood	B
3	gas	B
4	tensions	B
5	were	B
6	similar	B
7	across	B
8	all	B
9	ventilation	B
10	modes	B
11	.	B

1	Four	B
2	casein	B
3	kinase	B
4	I	B
5	isoforms	B
6	are	B
7	differentially	B
8	partitioned	B
9	between	B
10	nucleus	B
11	and	B
12	cytoplasm	B
13	.	B

1	CONCLUSION	B
2	:	B
3	Extrusion	B
4	cooking	B
5	is	B
6	effective	B
7	for	B
8	the	B
9	inactivation	B
10	of	B
11	DON	B
12	but	B
13	is	B
14	of	B
15	limited	B
16	value	B
17	for	B
18	AFB1	B
19	,	B
20	even	B
21	if	B
22	metabisulphite	B
23	is	B
24	added	B
25	.	B

1	Also	B
2	,	B
3	the	B
4	EWS	B
5	protein	B
6	stimulates	B
7	transcription	B
8	mediated	B
9	by	B
10	the	B
11	COOH	B
12	-	B
13	terminal	B
14	transactivation	B
15	domain	B
16	of	B
17	the	B
18	cofactor	B
19	CREB	B
20	-	B
21	binding	B
22	protein	B
23	(	B
24	CBP	B
25	).	B

1	HSF	B
2	binds	B
3	DNA	B
4	as	B
5	a	B
6	trimer	B
7	,	B
8	and	B
9	additional	B
10	trimers	B
11	can	B
12	bind	B
13	DNA	B
14	co	B
15	-	B
16	operatively	B
17	.	B

1	Two	B
2	cases	B
3	with	B
4	marked	B
5	chronic	B
6	arm	B
7	lymphoedema	B
8	reported	B
9	major	B
10	and	B
11	persistent	B
12	improvements	B
13	in	B
14	arm	B
15	volume	B
16	for	B
17	at	B
18	least	B
19	12	B
20	months	B
21	after	B
22	treatment	B
23	with	B
24	HBO2	B
25	.	B

1	Growth	B
2	hormone	B
3	and	B
4	insulin	B
5	-	B
6	like	B
7	growth	B
8	factor	B
9	I	B
10	receptors	B
11	in	B
12	the	B
13	temporomandibular	B
14	joint	B
15	of	B
16	the	B
17	rat	B
18	.	B

1	Folate	B
2	metabolism	B
3	in	B
4	the	B
5	human	B
6	malaria	B
7	parasite	B
8	Plasmodium	B
9	falciparum	B
10	is	B
11	an	B
12	essential	B
13	activity	B
14	for	B
15	cell	B
16	growth	B
17	and	B
18	replication	B
19	,	B
20	and	B
21	the	B
22	target	B
23	of	B
24	an	B
25	important	B
26	class	B
27	of	B
28	therapeutic	B
29	agents	B
30	in	B
31	widespread	B
32	use	B
33	.	B

1	These	B
2	results	B
3	indicate	B
4	that	B
5	BACM	B
6	has	B
7	antiplaque	B
8	and	B
9	stronger	B
10	antidegradation	B
11	effects	B
12	than	B
13	GLCM	B
14	.	B

1	A	B
2	mutation	B
3	in	B
4	the	B
5	C	B
6	domain	B
7	of	B
8	Rb	B
9	,	B
10	L901Q	B
11	,	B
12	has	B
13	been	B
14	identified	B
15	that	B
16	completely	B
17	abolishes	B
18	cdk4	B
19	/	B
20	D1	B
21	phosphorylation	B
22	of	B
23	the	B
24	isolated	B
25	C	B
26	domain	B
27	.	B

1	Homo	B
2	-	B
3	oligomerisation	B
4	and	B
5	nuclear	B
6	localisation	B
7	of	B
8	mouse	B
9	histone	B
10	deacetylase	B
11	1	B
12	.	B

1	Energy	B
2	expenditure	B
3	was	B
4	obtained	B
5	using	B
6	a	B
7	primed	B
8	,	B
9	3	B
10	-	B
11	hour	B
12	infusion	B
13	of	B
14	NaH	B
15	(	B
16	13	B
17	)	B
18	CO	B
19	(	B
20	3	B
21	'),	B
22	breath	B
23	(	B
24	13	B
25	)	B
26	CO	B
27	(	B
28	2	B
29	)	B
30	enrichment	B
31	determination	B
32	by	B
33	isotope	B
34	ratio	B
35	mass	B
36	spectroscopy	B
37	,	B
38	and	B
39	the	B
40	application	B
41	of	B
42	a	B
43	standard	B
44	regression	B
45	equation	B
46	.	B

1	Fasting	B
2	gastrin	B
3	levels	B
4	(	B
5	normal	B
6	range	B
7	:	B
8	25	B
9	-	B
10	110	B
11	mU	B
12	/	B
13	L	B
14	)	B
15	varied	B
16	from	B
17	48	B
18	.	B
19	78	B
20	mU	B
21	/	B
22	L	B
23	-	B
24	168	B
25	.	B
26	20	B
27	(	B
28	mean	B
29	:	B
30	85	B
31	.	B
32	23	B
33	mU	B
34	/	B
35	L	B
36	).	B

1	Identification	B
2	of	B
3	pulmonary	B
4	vein	B
5	stenosis	B
6	after	B
7	radiofrequency	B
8	ablation	B
9	for	B
10	atrial	B
11	fibrillation	B
12	using	B
13	MRI	B
14	.	B

1	The	B
2	continuing	B
3	development	B
4	of	B
5	ligands	B
6	that	B
7	function	B
8	as	B
9	selective	B
10	estrogens	B
11	or	B
12	antiestrogens	B
13	for	B
14	ERalpha	B
15	or	B
16	ERbeta	B
17	should	B
18	allow	B
19	optimized	B
20	tissue	B
21	selectivity	B
22	of	B
23	these	B
24	agents	B
25	for	B
26	menopausal	B
27	hormone	B
28	replacement	B
29	therapy	B
30	and	B
31	the	B
32	treatment	B
33	and	B
34	prevention	B
35	of	B
36	breast	B
37	cancer	B
38	.	B

1	Baseline	B
2	variables	B
3	associated	B
4	with	B
5	CD	B
6	included	B
7	a	B
8	less	B
9	frequent	B
10	use	B
11	of	B
12	prestroke	B
13	aspirin	B
14	and	B
15	a	B
16	higher	B
17	incidence	B
18	of	B
19	early	B
20	CT	B
21	changes	B
22	of	B
23	edema	B
24	or	B
25	mass	B
26	effect	B
27	or	B
28	dense	B
29	middle	B
30	cerebral	B
31	artery	B
32	sign	B
33	.	B

1	A	B
2	peculiar	B
3	people	B
4	:	B
5	"	B
6	the	B
7	physiological	B
8	aspects	B
9	of	B
10	Mormonism	B
11	1850	B
12	-	B
13	1975	B
14	."	B

1	SH2D1A	B
2	protein	B
3	levels	B
4	are	B
5	up	B
6	-	B
7	regulated	B
8	by	B
9	CD40	B
10	cross	B
11	-	B
12	linking	B
13	and	B
14	down	B
15	-	B
16	regulated	B
17	by	B
18	B	B
19	cell	B
20	receptor	B
21	ligation	B
22	.	B

1	The	B
2	Genescan	B
3	program	B
4	predicted	B
5	an	B
6	open	B
7	reading	B
8	frame	B
9	of	B
10	a	B
11	novel	B
12	,	B
13	intron	B
14	-	B
15	less	B
16	gene	B
17	adjacent	B
18	to	B
19	the	B
20	B236	B
21	spot	B
22	that	B
23	encodes	B
24	a	B
25	putative	B
26	493	B
27	-	B
28	amino	B
29	acid	B
30	protein	B
31	containing	B
32	the	B
33	SNAG	B
34	repressor	B
35	motif	B
36	in	B
37	the	B
38	NH2	B
39	-	B
40	terminal	B
41	region	B
42	and	B
43	five	B
44	C2H2	B
45	-	B
46	type	B
47	zinc	B
48	finger	B
49	motifs	B
50	in	B
51	the	B
52	COOH	B
53	-	B
54	terminal	B
55	half	B
56	.	B

1	Under	B
2	our	B
3	conditions	B
4	,	B
5	the	B
6	combination	B
7	O3	B
8	/	B
9	UV	B
10	did	B
11	not	B
12	improve	B
13	the	B
14	degradation	B
15	rate	B
16	obtained	B
17	by	B
18	ozonation	B
19	.	B

1	The	B
2	metabolic	B
3	events	B
4	occurring	B
5	at	B
6	or	B
7	near	B
8	that	B
9	structure	B
10	and	B
11	involving	B
12	cyclin	B
13	D3	B
14	cause	B
15	the	B
16	translocation	B
17	of	B
18	ICP0	B
19	to	B
20	the	B
21	cytoplasm	B
22	.	B

1	In	B
2	the	B
3	single	B
4	case	B
5	the	B
6	restoration	B
7	of	B
8	a	B
9	structured	B
10	daily	B
11	routine	B
12	represents	B
13	the	B
14	presupposition	B
15	for	B
16	a	B
17	cognitive	B
18	therapy	B
19	.	B

1	Immunofluorescence	B
2	studies	B
3	in	B
4	C2C12	B
5	myotubes	B
6	show	B
7	that	B
8	Smad2	B
9	and	B
10	MEF2A	B
11	co	B
12	-	B
13	localise	B
14	in	B
15	the	B
16	nucleus	B
17	of	B
18	multinuclear	B
19	myotubes	B
20	during	B
21	differentiation	B
22	.	B

1	In	B
2	35	B
3	of	B
4	those	B
5	patients	B
6	DD	B
7	was	B
8	measured	B
9	also	B
10	with	B
11	microlatex	B
12	tests	B
13	--	B
14	Tinaquant	B
15	and	B
16	BC	B
17	d	B
18	-	B
19	dimer	B
20	.	B

1	Simulating	B
2	the	B
3	impact	B
4	during	B
5	human	B
6	jumping	B
7	by	B
8	means	B
9	of	B
10	a	B
11	4	B
12	-	B
13	degrees	B
14	-	B
15	of	B
16	-	B
17	freedom	B
18	model	B
19	with	B
20	time	B
21	-	B
22	dependent	B
23	properties	B
24	.	B

1	A	B
2	novel	B
3	approach	B
4	was	B
5	developed	B
6	for	B
7	identifying	B
8	transcription	B
9	factor	B
10	activities	B
11	associated	B
12	with	B
13	NGF	B
14	-	B
15	activated	B
16	,	B
17	but	B
18	not	B
19	EGF	B
20	-	B
21	activated	B
22	,	B
23	signaling	B
24	,	B
25	using	B
26	random	B
27	oligonucleotide	B
28	clones	B
29	from	B
30	a	B
31	DNA	B
32	recognition	B
33	library	B
34	to	B
35	isolate	B
36	specific	B
37	DNA	B
38	binding	B
39	proteins	B
40	from	B
41	PC12	B
42	nuclear	B
43	extracts	B
44	.	B

1	Atheroma	B
2	appears	B
3	as	B
4	a	B
5	very	B
6	low	B
7	signal	B
8	intensity	B
9	area	B
10	on	B
11	2	B
12	-	B
13	dimensional	B
14	time	B
15	-	B
16	of	B
17	-	B
18	flight	B
19	(	B
20	TOF	B
21	)	B
22	magnetic	B
23	resonance	B
24	(	B
25	MR	B
26	)	B
27	images	B
28	,	B
29	and	B
30	its	B
31	components	B
32	have	B
33	various	B
34	signal	B
35	intensities	B
36	on	B
37	spin	B
38	-	B
39	echo	B
40	(	B
41	SE	B
42	)	B
43	images	B
44	.	B

1	Finally	B
2	a	B
3	10	B
4	-	B
5	nucleotide	B
6	region	B
7	flanking	B
8	the	B
9	exon	B
10	4	B
11	protein	B
12	-	B
13	binding	B
14	site	B
15	is	B
16	homologous	B
17	to	B
18	instability	B
19	elements	B
20	within	B
21	five	B
22	other	B
23	transcripts	B
24	,	B
25	suggesting	B
26	that	B
27	a	B
28	common	B
29	coding	B
30	region	B
31	determinant	B
32	may	B
33	exist	B
34	.	B

1	Chronic	B
2	nutritional	B
3	diseases	B
4	of	B
5	infectious	B
6	origin	B
7	:	B
8	an	B
9	assessment	B
10	of	B
11	a	B
12	nascent	B
13	field	B
14	.	B

1	The	B
2	cut	B
3	-	B
4	off	B
5	percentage	B
6	positivity	B
7	value	B
8	was	B
9	established	B
10	using	B
11	500	B
12	brucellosis	B
13	-	B
14	positive	B
15	and	B
16	500	B
17	brucellosis	B
18	-	B
19	negative	B
20	serum	B
21	samples	B
22	,	B
23	confirmed	B
24	with	B
25	reference	B
26	to	B
27	the	B
28	sample	B
29	data	B
30	using	B
31	the	B
32	indirect	B
33	ELISA	B
34	kit	B
35	.	B

1	PROCEDURE	B
2	:	B
3	Cannulas	B
4	were	B
5	surgically	B
6	positioned	B
7	in	B
8	the	B
9	abomasal	B
10	body	B
11	and	B
12	pyloric	B
13	antrum	B
14	of	B
15	each	B
16	calf	B
17	.	B

1	The	B
2	utilities	B
3	measured	B
4	in	B
5	our	B
6	study	B
7	can	B
8	be	B
9	applied	B
10	directly	B
11	to	B
12	quality	B
13	-	B
14	of	B
15	-	B
16	life	B
17	determinations	B
18	in	B
19	clinical	B
20	trials	B
21	of	B
22	adjuvant	B
23	IFN	B
24	alpha	B
25	-	B
26	2b	B
27	to	B
28	measure	B
29	the	B
30	net	B
31	benefit	B
32	of	B
33	therapy	B
34	.	B

1	Cells	B
2	lacking	B
3	p116	B
4	exhibit	B
5	a	B
6	striking	B
7	defect	B
8	in	B
9	the	B
10	formation	B
11	of	B
12	these	B
13	macropinocytic	B
14	structures	B
15	,	B
16	a	B
17	concomitant	B
18	reduction	B
19	in	B
20	the	B
21	rate	B
22	of	B
23	fluid	B
24	phase	B
25	pinocytosis	B
26	,	B
27	a	B
28	significant	B
29	decrease	B
30	in	B
31	the	B
32	efficiency	B
33	of	B
34	chemotactic	B
35	aggregation	B
36	,	B
37	and	B
38	a	B
39	decrease	B
40	in	B
41	cellular	B
42	F	B
43	-	B
44	actin	B
45	content	B
46	.	B

1	Ectopic	B
2	expression	B
3	of	B
4	the	B
5	dominant	B
6	mutant	B
7	Lg3	B
8	allele	B
9	is	B
10	believed	B
11	to	B
12	cause	B
13	the	B
14	phenotype	B
15	.	B

1	Specimen	B
2	mass	B
3	reduction	B
4	increased	B
5	with	B
6	irradiance	B
7	from	B
8	19	B
9	to	B
10	72	B
11	%	B
12	of	B
13	the	B
14	initial	B
15	mass	B
16	for	B
17	9	B
18	--	B
19	31	B
20	W	B
21	/	B
22	cm	B
23	(	B
24	2	B
25	),	B
26	respectively	B
27	.	B

1	Analysis	B
2	of	B
3	the	B
4	genome	B
5	sequence	B
6	revealed	B
7	26	B
8	,	B
9	588	B
10	protein	B
11	-	B
12	encoding	B
13	transcripts	B
14	for	B
15	which	B
16	there	B
17	was	B
18	strong	B
19	corroborating	B
20	evidence	B
21	and	B
22	an	B
23	additional	B
24	approximately	B
25	12	B
26	,	B
27	000	B
28	computationally	B
29	derived	B
30	genes	B
31	with	B
32	mouse	B
33	matches	B
34	or	B
35	other	B
36	weak	B
37	supporting	B
38	evidence	B
39	.	B

1	The	B
2	other	B
3	inhibitor	B
4	was	B
5	a	B
6	single	B
7	TAR	B
8	decoy	B
9	,	B
10	driven	B
11	by	B
12	the	B
13	U6	B
14	small	B
15	nuclear	B
16	RNA	B
17	promoter	B
18	(	B
19	U6	B
20	-	B
21	P	B
22	).	B

1	By	B
2	comparison	B
3	,	B
4	in	B
5	nontumorigenic	B
6	Ad5	B
7	cells	B
8	,	B
9	class	B
10	I	B
11	expression	B
12	is	B
13	high	B
14	due	B
15	to	B
16	negligible	B
17	binding	B
18	of	B
19	COUP	B
20	-	B
21	TF	B
22	and	B
23	strong	B
24	binding	B
25	of	B
26	NF	B
27	-	B
28	kappaB	B
29	.	B

1	Moreover	B
2	,	B
3	a	B
4	complex	B
5	containing	B
6	PTP	B
7	phi	B
8	,	B
9	paxillin	B
10	,	B
11	and	B
12	a	B
13	paxillin	B
14	-	B
15	associated	B
16	tyrosine	B
17	kinase	B
18	,	B
19	Pyk2	B
20	,	B
21	can	B
22	be	B
23	immunoprecipitated	B
24	from	B
25	macrophage	B
26	lysates	B
27	,	B
28	and	B
29	the	B
30	catalytic	B
31	domain	B
32	of	B
33	PTP	B
34	phi	B
35	selectively	B
36	binds	B
37	paxillin	B
38	and	B
39	Pyk2	B
40	in	B
41	vitro	B
42	.	B

1	Our	B
2	previous	B
3	studies	B
4	have	B
5	shown	B
6	that	B
7	SHP	B
8	-	B
9	1	B
10	,	B
11	a	B
12	SH2	B
13	domain	B
14	-	B
15	containing	B
16	protein	B
17	-	B
18	tyrosine	B
19	phosphatase	B
20	,	B
21	is	B
22	expressed	B
23	not	B
24	only	B
25	in	B
26	cells	B
27	of	B
28	hematopoietic	B
29	lineages	B
30	,	B
31	but	B
32	also	B
33	in	B
34	many	B
35	non	B
36	-	B
37	hematopoietic	B
38	cells	B
39	under	B
40	the	B
41	control	B
42	of	B
43	an	B
44	alternative	B
45	tissue	B
46	-	B
47	specific	B
48	promoter	B
49	,	B
50	P1	B
51	.	B

1	Whereas	B
2	Smad2	B
3	was	B
4	rapidly	B
5	phosphorylated	B
6	by	B
7	TGF	B
8	-	B
9	beta	B
10	and	B
11	involved	B
12	in	B
13	the	B
14	initial	B
15	activation	B
16	of	B
17	Agc	B
18	expression	B
19	in	B
20	confluent	B
21	cells	B
22	,	B
23	Smad2	B
24	activation	B
25	was	B
26	not	B
27	required	B
28	for	B
29	maintaining	B
30	the	B
31	high	B
32	level	B
33	of	B
34	Agc	B
35	expression	B
36	.	B

1	The	B
2	astronaut	B
3	crew	B
4	operates	B
5	the	B
6	payload	B
7	and	B
8	documents	B
9	its	B
10	operation	B
11	.	B

1	This	B
2	molecule	B
3	,	B
4	wH22xeGFP	B
5	,	B
6	consists	B
7	of	B
8	the	B
9	entire	B
10	humanized	B
11	anti	B
12	-	B
13	FcgammaRI	B
14	mAb	B
15	H22	B
16	with	B
17	eGFP	B
18	genetically	B
19	fused	B
20	to	B
21	the	B
22	C	B
23	-	B
24	terminal	B
25	end	B
26	of	B
27	each	B
28	CH3	B
29	domain	B
30	.	B
31	wH22xeGFP	B
32	binds	B
33	within	B
34	the	B
35	ligand	B
36	-	B
37	binding	B
38	region	B
39	by	B
40	its	B
41	Fc	B
42	end	B
43	,	B
44	as	B
45	well	B
46	as	B
47	outside	B
48	the	B
49	ligand	B
50	-	B
51	binding	B
52	region	B
53	by	B
54	its	B
55	Fab	B
56	ends	B
57	,	B
58	thereby	B
59	cross	B
60	-	B
61	linking	B
62	FcgammaRI	B
63	.	B

1	On	B
2	the	B
3	other	B
4	hand	B
5	,	B
6	hepatic	B
7	arterial	B
8	infusion	B
9	therapy	B
10	prolongs	B
11	the	B
12	survival	B
13	of	B
14	H3	B
15	patients	B
16	only	B
17	.	B

1	Hepatitis	B
2	B	B
3	and	B
4	C	B
5	seroprevalence	B
6	rates	B
7	among	B
8	high	B
9	-	B
10	risk	B
11	adolescents	B
12	are	B
13	lower	B
14	in	B
15	El	B
16	Paso	B
17	than	B
18	in	B
19	other	B
20	similar	B
21	US	B
22	populations	B
23	,	B
24	presenting	B
25	an	B
26	ideal	B
27	climate	B
28	for	B
29	prevention	B
30	programs	B
31	.	B

1	We	B
2	found	B
3	that	B
4	the	B
5	SOCS	B
6	box	B
7	interacted	B
8	with	B
9	Cullin	B
10	-	B
11	2	B
12	and	B
13	promoted	B
14	ubiquitination	B
15	of	B
16	TEL	B
17	-	B
18	JAK2	B
19	.	B

1	A	B
2	patient	B
3	is	B
4	described	B
5	with	B
6	skin	B
7	lesions	B
8	resembling	B
9	Kaposi	B
10	'	B
11	s	B
12	sarcoma	B
13	(	B
14	KS	B
15	).	B

1	Special	B
2	issues	B
3	devoted	B
4	to	B
5	the	B
6	biosynthesis	B
7	of	B
8	woody	B
9	plant	B
10	biopolymers	B
11	and	B
12	related	B
13	substances	B
14	.	B

1	These	B
2	data	B
3	suggest	B
4	that	B
5	ADAM	B
6	-	B
7	TS12	B
8	may	B
9	play	B
10	roles	B
11	in	B
12	pulmonary	B
13	cells	B
14	during	B
15	fetal	B
16	development	B
17	or	B
18	in	B
19	tumor	B
20	processes	B
21	through	B
22	its	B
23	proteolytic	B
24	activity	B
25	or	B
26	as	B
27	a	B
28	molecule	B
29	potentially	B
30	involved	B
31	in	B
32	regulation	B
33	of	B
34	cell	B
35	adhesion	B
36	.	B

1	Progressive	B
2	study	B
3	and	B
4	robustness	B
5	test	B
6	of	B
7	QSAR	B
8	model	B
9	based	B
10	on	B
11	quantum	B
12	chemical	B
13	parameters	B
14	for	B
15	predicting	B
16	BCF	B
17	of	B
18	selected	B
19	polychlorinated	B
20	organic	B
21	compounds	B
22	(	B
23	PCOCs	B
24	).	B

1	Additional	B
2	deletion	B
3	mutations	B
4	revealed	B
5	a	B
6	new	B
7	,	B
8	67	B
9	-	B
10	amino	B
11	-	B
12	acid	B
13	functional	B
14	domain	B
15	within	B
16	the	B
17	proline	B
18	-	B
19	rich	B
20	region	B
21	of	B
22	SLP	B
23	-	B
24	76	B
25	,	B
26	which	B
27	we	B
28	have	B
29	termed	B
30	the	B
31	P	B
32	-	B
33	1	B
34	domain	B
35	.	B

1	Patients	B
2	with	B
3	type	B
4	III	B
5	SOD	B
6	may	B
7	have	B
8	visceral	B
9	hyperalgesia	B
10	;	B
11	a	B
12	trial	B
13	of	B
14	antidepressants	B
15	or	B
16	a	B
17	therapeutic	B
18	trial	B
19	with	B
20	botulinum	B
21	toxin	B
22	injection	B
23	into	B
24	the	B
25	ampulla	B
26	should	B
27	be	B
28	considered	B
29	prior	B
30	to	B
31	more	B
32	invasive	B
33	endoscopic	B
34	therapy	B
35	.	B

1	We	B
2	have	B
3	now	B
4	tested	B
5	all	B
6	known	B
7	mammalian	B
8	Groucho	B
9	family	B
10	members	B
11	for	B
12	their	B
13	ability	B
14	to	B
15	interact	B
16	specifically	B
17	with	B
18	individual	B
19	Tcf	B
20	/	B
21	Lef	B
22	family	B
23	members	B
24	.	B

1	Body	B
2	weight	B
3	reduction	B
4	increases	B
5	insulin	B
6	sensitivity	B
7	and	B
8	improves	B
9	both	B
10	blood	B
11	glucose	B
12	and	B
13	blood	B
14	pressure	B
15	control	B
16	.	B

1	Sequence	B
2	analysis	B
3	indicates	B
4	that	B
5	RBP21	B
6	shares	B
7	homology	B
8	with	B
9	other	B
10	retinoblastoma	B
11	-	B
12	binding	B
13	proteins	B
14	in	B
15	the	B
16	pRb	B
17	-	B
18	binding	B
19	motif	B
20	LxCxE	B
21	at	B
22	the	B
23	C	B
24	-	B
25	terminal	B
26	region	B
27	.	B

1	Tolerance	B
2	in	B
3	renal	B
4	transplantation	B
5	after	B
6	allogeneic	B
7	bone	B
8	marrow	B
9	transplantation	B
10	-	B
11	6	B
12	-	B
13	year	B
14	follow	B
15	-	B
16	up	B
17	.	B

1	By	B
2	analyzing	B
3	5	B
4	'-	B
5	deletion	B
6	insulin	B
7	promoter	B
8	-	B
9	reporter	B
10	constructs	B
11	in	B
12	transient	B
13	transfections	B
14	of	B
15	clonal	B
16	INS	B
17	-	B
18	1	B
19	beta	B
20	-	B
21	cells	B
22	,	B
23	we	B
24	located	B
25	activating	B
26	Hh	B
27	-	B
28	responsive	B
29	regions	B
30	within	B
31	the	B
32	rat	B
33	insulin	B
34	I	B
35	promoter	B
36	that	B
37	include	B
38	the	B
39	glucose	B
40	-	B
41	response	B
42	elements	B
43	Far	B
44	(	B
45	E2	B
46	)	B
47	and	B
48	Flat	B
49	(	B
50	A2	B
51	/	B
52	A3	B
53	).	B

1	However	B
2	,	B
3	when	B
4	directed	B
5	to	B
6	the	B
7	nucleosome	B
8	by	B
9	fusion	B
10	to	B
11	core	B
12	histone	B
13	H2A	B
14	or	B
15	H2B	B
16	,	B
17	the	B
18	non	B
19	-	B
20	histone	B
21	tail	B
22	forms	B
23	an	B
24	MCB	B
25	that	B
26	appears	B
27	identical	B
28	to	B
29	that	B
30	of	B
31	the	B
32	endogenous	B
33	protein	B
34	.	B

1	Data	B
2	were	B
3	obtained	B
4	from	B
5	2	B
6	undergraduate	B
7	student	B
8	samples	B
9	,	B
10	a	B
11	self	B
12	-	B
13	report	B
14	group	B
15	(	B
16	n	B
17	=	B
18	132	B
19	)	B
20	who	B
21	provided	B
22	NEO	B
23	-	B
24	PI	B
25	-	B
26	R	B
27	self	B
28	-	B
29	ratings	B
30	on	B
31	2	B
32	occasions	B
33	separated	B
34	by	B
35	a	B
36	7	B
37	-	B
38	to	B
39	14	B
40	-	B
41	day	B
42	interval	B
43	and	B
44	an	B
45	informant	B
46	group	B
47	(	B
48	n	B
49	=	B
50	109	B
51	)	B
52	who	B
53	provided	B
54	ratings	B
55	of	B
56	well	B
57	-	B
58	known	B
59	friends	B
60	or	B
61	relatives	B
62	on	B
63	2	B
64	occasions	B
65	separated	B
66	by	B
67	a	B
68	6	B
69	month	B
70	interval	B
71	.	B

1	Pulmonary	B
2	embolectomy	B
3	and	B
4	lung	B
5	transplantation	B
6	are	B
7	the	B
8	main	B
9	indications	B
10	for	B
11	the	B
12	use	B
13	of	B
14	heart	B
15	-	B
16	lung	B
17	-	B
18	machine	B
19	.	B

1	Comparison	B
2	of	B
3	German	B
4	language	B
5	versions	B
6	of	B
7	the	B
8	QWB	B
9	-	B
10	SA	B
11	and	B
12	SF	B
13	-	B
14	36	B
15	evaluating	B
16	outcomes	B
17	for	B
18	patients	B
19	with	B
20	prostate	B
21	disease	B
22	.	B

1	The	B
2	median	B
3	preoperative	B
4	best	B
5	-	B
6	corrected	B
7	visual	B
8	acuity	B
9	of	B
10	0	B
11	.	B
12	08	B
13	(	B
14	range	B
15	hand	B
16	motions	B
17	/	B
18	0	B
19	.	B
20	003	B
21	to	B
22	0	B
23	.	B
24	4	B
25	),	B
26	improved	B
27	by	B
28	5	B
29	lines	B
30	to	B
31	a	B
32	median	B
33	final	B
34	postoperative	B
35	best	B
36	-	B
37	corrected	B
38	visual	B
39	acuity	B
40	of	B
41	0	B
42	.	B
43	25	B
44	(	B
45	range	B
46	0	B
47	.	B
48	025	B
49	-	B
50	0	B
51	.	B
52	5	B
53	)	B
54	(	B
55	P	B
56	=	B
57	0	B
58	.	B
59	001	B
60	).	B

1	Angina	B
2	(	B
3	Q	B
4	)	B
5	persistence	B
6	showed	B
7	marked	B
8	associations	B
9	with	B
10	previous	B
11	myocardial	B
12	infarction	B
13	,	B
14	diagnosed	B
15	angina	B
16	,	B
17	electrocardiogram	B
18	ischemia	B
19	,	B
20	and	B
21	subsequent	B
22	major	B
23	ischemic	B
24	heart	B
25	disease	B
26	events	B
27	from	B
28	Q5	B
29	onward	B
30	.	B

1	Site	B
2	-	B
3	directed	B
4	mutagenesis	B
5	of	B
6	CAR	B
7	revealed	B
8	that	B
9	CAR	B
10	residues	B
11	Leu73	B
12	and	B
13	Lys121	B
14	and	B
15	/	B
16	or	B
17	Lys123	B
18	are	B
19	critical	B
20	contact	B
21	residues	B
22	,	B
23	with	B
24	Tyr80	B
25	and	B
26	Tyr83	B
27	being	B
28	peripherally	B
29	involved	B
30	in	B
31	the	B
32	binding	B
33	interaction	B
34	with	B
35	the	B
36	Ad5	B
37	,	B
38	Ad9	B
39	,	B
40	Ad12	B
41	,	B
42	and	B
43	Ad41L	B
44	fiber	B
45	knobs	B
46	.	B

1	Transforming	B
2	growth	B
3	factor	B
4	-	B
5	beta	B
6	(	B
7	TGF	B
8	-	B
9	beta	B
10	)	B
11	induced	B
12	growth	B
13	arrest	B
14	of	B
15	cells	B
16	involves	B
17	regulation	B
18	of	B
19	the	B
20	activities	B
21	of	B
22	both	B
23	D	B
24	-	B
25	and	B
26	E	B
27	-	B
28	type	B
29	cyclin	B
30	kinase	B
31	complexes	B
32	thought	B
33	to	B
34	be	B
35	mediated	B
36	primarily	B
37	by	B
38	the	B
39	regulation	B
40	of	B
41	p15	B
42	(	B
43	Ink4b	B
44	)	B
45	and	B
46	p27	B
47	(	B
48	Kip1	B
49	)	B
50	cyclin	B
51	kinase	B
52	inhibitors	B
53	.	B

1	These	B
2	data	B
3	indicate	B
4	that	B
5	the	B
6	SmSmad2	B
7	responds	B
8	to	B
9	the	B
10	TGF	B
11	-	B
12	beta	B
13	signals	B
14	by	B
15	interaction	B
16	with	B
17	receptor	B
18	I	B
19	,	B
20	which	B
21	phosphorylates	B
22	it	B
23	,	B
24	whereupon	B
25	it	B
26	translocates	B
27	into	B
28	the	B
29	nucleus	B
30	presumably	B
31	to	B
32	regulate	B
33	target	B
34	gene	B
35	transcription	B
36	and	B
37	consequently	B
38	elicit	B
39	a	B
40	specific	B
41	TGF	B
42	-	B
43	beta	B
44	effect	B
45	.	B

1	We	B
2	propose	B
3	that	B
4	TFOs	B
5	represent	B
6	a	B
7	therapeutic	B
8	potential	B
9	to	B
10	specifically	B
11	diminish	B
12	the	B
13	expression	B
14	of	B
15	c	B
16	-	B
17	sis	B
18	/	B
19	PDGF	B
20	-	B
21	B	B
22	proto	B
23	-	B
24	oncogene	B
25	in	B
26	various	B
27	pathologic	B
28	settings	B
29	where	B
30	constitutive	B
31	expression	B
32	of	B
33	this	B
34	gene	B
35	has	B
36	been	B
37	observed	B
38	.	B

1	The	B
2	increased	B
3	clearance	B
4	observed	B
5	in	B
6	young	B
7	infants	B
8	is	B
9	in	B
10	contrast	B
11	to	B
12	other	B
13	opioids	B
14	.	B

1	Peripheral	B
2	metabolism	B
3	of	B
4	androgens	B
5	takes	B
6	place	B
7	in	B
8	various	B
9	areas	B
10	within	B
11	the	B
12	pilosebaceous	B
13	unit	B
14	,	B
15	as	B
16	indicated	B
17	by	B
18	local	B
19	differences	B
20	in	B
21	the	B
22	activities	B
23	of	B
24	aromatase	B
25	,	B
26	5alpha	B
27	-	B
28	reductase	B
29	as	B
30	well	B
31	as	B
32	of	B
33	the	B
34	presence	B
35	of	B
36	the	B
37	androgen	B
38	receptors	B
39	.	B

1	This	B
2	unique	B
3	location	B
4	of	B
5	cavernous	B
6	malformation	B
7	is	B
8	associated	B
9	with	B
10	a	B
11	risk	B
12	of	B
13	permanent	B
14	loss	B
15	of	B
16	the	B
17	vision	B
18	.	B

1	The	B
2	JHRLSS	B
3	has	B
4	been	B
5	used	B
6	in	B
7	prior	B
8	studies	B
9	to	B
10	assess	B
11	RLS	B
12	severity	B
13	,	B
14	but	B
15	has	B
16	not	B
17	previously	B
18	been	B
19	validated	B
20	in	B
21	relation	B
22	to	B
23	direct	B
24	measures	B
25	of	B
26	the	B
27	morbidity	B
28	associated	B
29	with	B
30	RLS	B
31	.	B

1	Consistent	B
2	effects	B
3	on	B
4	pVHL	B
5	function	B
6	were	B
7	observed	B
8	for	B
9	all	B
10	mutations	B
11	within	B
12	each	B
13	subclass	B
14	.	B

1	Interestingly	B
2	,	B
3	the	B
4	CYP71D20	B
5	-	B
6	encoded	B
7	enzyme	B
8	activity	B
9	was	B
10	capable	B
11	of	B
12	converting	B
13	both	B
14	5	B
15	-	B
16	epi	B
17	-	B
18	aristolochene	B
19	and	B
20	1	B
21	-	B
22	deoxycapsidiol	B
23	to	B
24	capsidiol	B
25	in	B
26	vitro	B
27	,	B
28	consistent	B
29	with	B
30	the	B
31	notion	B
32	that	B
33	this	B
34	P450	B
35	enzyme	B
36	catalyzes	B
37	both	B
38	hydroxylations	B
39	of	B
40	its	B
41	hydrocarbon	B
42	substrate	B
43	.	B

1	A	B
2	new	B
3	species	B
4	of	B
5	Euspondylus	B
6	is	B
7	described	B
8	based	B
9	on	B
10	a	B
11	female	B
12	(	B
13	taken	B
14	within	B
15	a	B
16	bromeliad	B
17	)	B
18	from	B
19	Cerro	B
20	El	B
21	Humo	B
22	,	B
23	Sucre	B
24	,	B
25	northeastern	B
26	Venezuela	B
27	.	B

1	The	B
2	most	B
3	important	B
4	finding	B
5	,	B
6	however	B
7	,	B
8	was	B
9	that	B
10	IMT	B
11	values	B
12	were	B
13	related	B
14	with	B
15	24	B
16	h	B
17	SBP	B
18	or	B
19	PP	B
20	standard	B
21	deviation	B
22	(	B
23	P	B
24	<	B
25	0	B
26	.	B
27	001	B
28	),	B
29	a	B
30	measure	B
31	of	B
32	overall	B
33	SBP	B
34	or	B
35	PP	B
36	variability	B
37	.	B

1	In	B
2	addition	B
3	,	B
4	severe	B
5	vision	B
6	loss	B
7	can	B
8	be	B
9	seen	B
10	with	B
11	interferon	B
12	alfa	B
13	-	B
14	2b	B
15	-	B
16	associated	B
17	retinopathy	B
18	.	B

1	FLP	B
2	and	B
3	Cre	B
4	recombinase	B
5	function	B
6	in	B
7	Xenopus	B
8	embryos	B
9	.	B

1	Keratoconjunctivitis	B
2	sicca	B
3	appears	B
4	to	B
5	be	B
6	a	B
7	common	B
8	ocular	B
9	complication	B
10	and	B
11	all	B
12	children	B
13	with	B
14	JRA	B
15	should	B
16	be	B
17	screened	B
18	for	B
19	it	B
20	with	B
21	a	B
22	comprehensive	B
23	battery	B
24	of	B
25	tests	B
26	.	B

1	Moreover	B
2	,	B
3	PTax	B
4	expressed	B
5	higher	B
6	background	B
7	activities	B
8	than	B
9	PTF	B
10	,	B
11	indicating	B
12	that	B
13	the	B
14	sequence	B
15	of	B
16	the	B
17	synthetic	B
18	regulatory	B
19	region	B
20	can	B
21	influence	B
22	background	B
23	levels	B
24	.	B

1	After	B
2	allowing	B
3	time	B
4	for	B
5	absorption	B
6	,	B
7	participants	B
8	completed	B
9	a	B
10	bridge	B
11	simulator	B
12	task	B
13	.	B

1	The	B
2	cleavage	B
3	site	B
4	between	B
5	VPg	B
6	and	B
7	RNA	B
8	dependent	B
9	RNA	B
10	polymerase	B
11	was	B
12	predicted	B
13	to	B
14	be	B
15	E445	B
16	-	B
17	T446	B
18	based	B
19	on	B
20	the	B
21	amino	B
22	acid	B
23	sequence	B
24	analysis	B
25	of	B
26	the	B
27	polyprotein	B
28	from	B
29	different	B
30	sobemoviruses	B
31	.	B

1	Conformational	B
2	changes	B
3	of	B
4	the	B
5	ferric	B
6	uptake	B
7	regulation	B
8	protein	B
9	upon	B
10	metal	B
11	activation	B
12	and	B
13	DNA	B
14	binding	B
15	;	B
16	first	B
17	evidence	B
18	of	B
19	structural	B
20	homologies	B
21	with	B
22	the	B
23	diphtheria	B
24	toxin	B
25	repressor	B
26	.	B

1	At	B
2	visit	B
3	5	B
4	,	B
5	the	B
6	isokinetic	B
7	test	B
8	showed	B
9	impaired	B
10	muscle	B
11	function	B
12	recovery	B
13	from	B
14	23	B
15	%	B
16	to	B
17	32	B
18	%,	B
19	while	B
20	the	B
21	manual	B
22	test	B
23	showed	B
24	almost	B
25	full	B
26	recovery	B
27	.	B

1	Constitutive	B
2	phosphorylation	B
3	and	B
4	nuclear	B
5	localization	B
6	of	B
7	Smad3	B
8	are	B
9	correlated	B
10	with	B
11	increased	B
12	collagen	B
13	gene	B
14	transcription	B
15	in	B
16	activated	B
17	hepatic	B
18	stellate	B
19	cells	B
20	.	B

1	Cholesteryl	B
2	ester	B
3	transfer	B
4	protein	B
5	and	B
6	atherosclerosis	B
7	in	B
8	Japanese	B
9	subjects	B
10	:	B
11	a	B
12	study	B
13	based	B
14	on	B
15	coronary	B
16	angiography	B
17	.	B

1	And	B
2	,	B
3	most	B
4	importantly	B
5	,	B
6	reconstitution	B
7	of	B
8	a	B
9	consensus	B
10	CRE	B
11	,	B
12	within	B
13	the	B
14	21	B
15	-	B
16	bp	B
17	enhancers	B
18	increases	B
19	binding	B
20	of	B
21	CREB	B
22	/	B
23	ATF	B
24	proteins	B
25	but	B
26	abrogates	B
27	basal	B
28	repression	B
29	of	B
30	LTR	B
31	-	B
32	directed	B
33	transcription	B
34	in	B
35	vitro	B
36	.	B

1	Stable	B
2	transfection	B
3	of	B
4	human	B
5	CHOP	B
6	cDNA	B
7	into	B
8	mammary	B
9	carcinoma	B
10	cells	B
11	demonstrated	B
12	that	B
13	CHOP	B
14	functioned	B
15	not	B
16	as	B
17	a	B
18	mediator	B
19	of	B
20	hGH	B
21	-	B
22	stimulated	B
23	mitogenesis	B
24	but	B
25	rather	B
26	enhanced	B
27	the	B
28	protection	B
29	from	B
30	apoptosis	B
31	afforded	B
32	by	B
33	hGH	B
34	in	B
35	a	B
36	p38	B
37	MAPK	B
38	-	B
39	dependent	B
40	manner	B
41	.	B

1	The	B
2	combination	B
3	of	B
4	ifosfamide	B
5	,	B
6	epirubicin	B
7	and	B
8	etoposide	B
9	(	B
10	IEV	B
11	)	B
12	is	B
13	an	B
14	effective	B
15	salvage	B
16	regimen	B
17	for	B
18	lymphoproliferative	B
19	disease	B
20	.	B

1	Interestingly	B
2	,	B
3	the	B
4	activity	B
5	of	B
6	IkappaB	B
7	kinase	B
8	(	B
9	IKK	B
10	-	B
11	beta	B
12	),	B
13	which	B
14	plays	B
15	an	B
16	essential	B
17	role	B
18	in	B
19	NF	B
20	-	B
21	kappaB	B
22	activation	B
23	through	B
24	IkappaB	B
25	phosphorylation	B
26	,	B
27	was	B
28	largely	B
29	enhanced	B
30	in	B
31	paclitaxel	B
32	-	B
33	treated	B
34	cells	B
35	,	B
36	detected	B
37	as	B
38	IkappaBalpha	B
39	phosphorylation	B
40	.	B

1	The	B
2	recessive	B
3	hos1	B
4	mutation	B
5	causes	B
6	enhanced	B
7	induction	B
8	of	B
9	the	B
10	CBF	B
11	transcription	B
12	factors	B
13	by	B
14	low	B
15	temperature	B
16	as	B
17	well	B
18	as	B
19	of	B
20	their	B
21	downstream	B
22	cold	B
23	-	B
24	responsive	B
25	genes	B
26	.	B

1	Apart	B
2	from	B
3	antimicrobial	B
4	properties	B
5	,	B
6	recent	B
7	data	B
8	indicate	B
9	that	B
10	PMN	B
11	also	B
12	exert	B
13	anti	B
14	-	B
15	inflammatory	B
16	effects	B
17	by	B
18	stimulation	B
19	and	B
20	release	B
21	of	B
22	cytokine	B
23	antagonists	B
24	such	B
25	as	B
26	interleukin	B
27	-	B
28	1	B
29	receptor	B
30	antagonist	B
31	(	B
32	IL	B
33	-	B
34	1ra	B
35	).	B

1	Early	B
2	indicators	B
3	of	B
4	the	B
5	effect	B
6	of	B
7	a	B
8	breast	B
9	cancer	B
10	screening	B
11	program	B
12	for	B
13	low	B
14	-	B
15	income	B
16	women	B
17	.	B

1	An	B
2	association	B
3	was	B
4	demonstrated	B
5	between	B
6	the	B
7	expression	B
8	of	B
9	aberrantly	B
10	and	B
11	/	B
12	or	B
13	alternatively	B
14	spliced	B
15	mdm2	B
16	mRNAs	B
17	and	B
18	a	B
19	lack	B
20	of	B
21	progesterone	B
22	receptor	B
23	.	B

1	BACKGROUND	B
2	:	B
3	Dermoscopy	B
4	is	B
5	a	B
6	noninvasive	B
7	technique	B
8	that	B
9	increases	B
10	the	B
11	diagnostic	B
12	accuracy	B
13	of	B
14	pigmented	B
15	skin	B
16	lesions	B
17	,	B
18	particularly	B
19	improving	B
20	the	B
21	diagnosis	B
22	of	B
23	patients	B
24	with	B
25	cutaneous	B
26	melanoma	B
27	in	B
28	situ	B
29	(	B
30	CMIS	B
31	)	B
32	and	B
33	early	B
34	invasive	B
35	melanoma	B
36	.	B

1	Increased	B
2	erythropoietin	B
3	synthesis	B
4	in	B
5	patients	B
6	with	B
7	COLD	B
8	or	B
9	left	B
10	heart	B
11	failure	B
12	is	B
13	related	B
14	to	B
15	alterations	B
16	in	B
17	renal	B
18	haemodynamics	B
19	.	B

1	The	B
2	(	B
3	two	B
4	-	B
5	motif	B
6	)	B
7	domain	B
8	fold	B
9	contains	B
10	a	B
11	pair	B
12	of	B
13	calcium	B
14	binding	B
15	sites	B
16	very	B
17	similar	B
18	to	B
19	those	B
20	found	B
21	in	B
22	a	B
23	two	B
24	-	B
25	domain	B
26	prokaryotic	B
27	betagamma	B
28	-	B
29	crystallin	B
30	fold	B
31	family	B
32	member	B
33	,	B
34	Protein	B
35	S	B
36	.	B

1	Twenty	B
2	-	B
3	five	B
4	patients	B
5	also	B
6	received	B
7	PET	B
8	examinations	B
9	during	B
10	the	B
11	staging	B
12	procedures	B
13	.	B

1	In	B
2	the	B
3	last	B
4	case	B
5	,	B
6	both	B
7	hydroxychloroquine	B
8	,	B
9	carbamazepine	B
10	and	B
11	fluvoxamine	B
12	had	B
13	a	B
14	common	B
15	imputability	B
16	which	B
17	was	B
18	plausible	B
19	.	B

1	In	B
2	all	B
3	of	B
4	these	B
5	cases	B
6	,	B
7	expression	B
8	of	B
9	the	B
10	implicated	B
11	genes	B
12	was	B
13	absent	B
14	.	B

1	A	B
2	subset	B
3	of	B
4	patients	B
5	(	B
6	n	B
7	=	B
8	30	B
9	)	B
10	underwent	B
11	multichannel	B
12	pressure	B
13	flow	B
14	studies	B
15	,	B
16	which	B
17	demonstrated	B
18	that	B
19	transrectal	B
20	HIFU	B
21	reduces	B
22	bladder	B
23	outflow	B
24	obstruction	B
25	.	B

1	Biochemical	B
2	experiments	B
3	have	B
4	shown	B
5	that	B
6	CopG	B
7	co	B
8	-	B
9	operatively	B
10	associates	B
11	to	B
12	its	B
13	target	B
14	DNA	B
15	at	B
16	low	B
17	protein	B
18	:	B
19	DNA	B
20	ratios	B
21	,	B
22	completely	B
23	protecting	B
24	four	B
25	helical	B
26	turns	B
27	on	B
28	the	B
29	same	B
30	face	B
31	of	B
32	the	B
33	double	B
34	helix	B
35	in	B
36	both	B
37	directions	B
38	from	B
39	the	B
40	inverted	B
41	repeat	B
42	that	B
43	constitutes	B
44	the	B
45	CopG	B
46	primary	B
47	target	B
48	.	B

1	The	B
2	mechanism	B
3	of	B
4	ligand	B
5	-	B
6	activated	B
7	estrogen	B
8	receptor	B
9	alpha	B
10	(	B
11	ERalpha	B
12	)-	B
13	dependent	B
14	activation	B
15	of	B
16	gene	B
17	expression	B
18	through	B
19	the	B
20	SRE	B
21	was	B
22	determined	B
23	by	B
24	mutational	B
25	analysis	B
26	of	B
27	the	B
28	promoter	B
29	,	B
30	analysis	B
31	of	B
32	mitogen	B
33	-	B
34	activated	B
35	protein	B
36	kinase	B
37	(	B
38	MAPK	B
39	)	B
40	pathway	B
41	activation	B
42	by	B
43	E2	B
44	,	B
45	and	B
46	transforming	B
47	growth	B
48	factor	B
49	alpha	B
50	(	B
51	TGF	B
52	-	B
53	alpha	B
54	)	B
55	as	B
56	a	B
57	positive	B
58	control	B
59	.	B

1	This	B
2	study	B
3	investigated	B
4	whether	B
5	boron	B
6	would	B
7	enhance	B
8	the	B
9	ability	B
10	of	B
11	17beta	B
12	-	B
13	estradiol	B
14	(	B
15	E2	B
16	)	B
17	or	B
18	parathyroid	B
19	hormone	B
20	(	B
21	PTH	B
22	)	B
23	to	B
24	improve	B
25	bone	B
26	quality	B
27	in	B
28	ovariectomized	B
29	OVX	B
30	rats	B
31	.	B

1	2001	B
2	.	B

1	The	B
2	Gap69C	B
3	is	B
4	a	B
5	single	B
6	-	B
7	copy	B
8	gene	B
9	producing	B
10	a	B
11	major	B
12	2	B
13	.	B
14	1	B
15	-	B
16	kb	B
17	mRNA	B
18	throughout	B
19	development	B
20	,	B
21	but	B
22	its	B
23	amount	B
24	is	B
25	decreased	B
26	in	B
27	larvae	B
28	.	B

1	In	B
2	the	B
3	long	B
4	term	B
5	,	B
6	questions	B
7	still	B
8	remain	B
9	about	B
10	whether	B
11	pre	B
12	-	B
13	dialysis	B
14	rHu	B
15	EPO	B
16	either	B
17	speeds	B
18	up	B
19	or	B
20	delays	B
21	the	B
22	onset	B
23	of	B
24	dialysis	B
25	.	B

1	The	B
2	validity	B
3	of	B
4	the	B
5	FPS	B
6	-	B
7	R	B
8	was	B
9	further	B
10	supported	B
11	by	B
12	strong	B
13	positive	B
14	correlations	B
15	with	B
16	the	B
17	VAS	B
18	(	B
19	r	B
20	=	B
21	0	B
22	.	B
23	92	B
24	,	B
25	N	B
26	=	B
27	45	B
28	)	B
29	and	B
30	the	B
31	CAS	B
32	(	B
33	r	B
34	=	B
35	0	B
36	.	B
37	84	B
38	,	B
39	N	B
40	=	B
41	45	B
42	)	B
43	in	B
44	this	B
45	clinical	B
46	sample	B
47	.	B

1	The	B
2	BFA	B
3	System	B
4	reads	B
5	a	B
6	text	B
7	file	B
8	with	B
9	flows	B
10	,	B
11	measured	B
12	with	B
13	fluorescent	B
14	microsphere	B
15	technique	B
16	,	B
17	and	B
18	constructs	B
19	the	B
20	lung	B
21	anatomy	B
22	with	B
23	volumetric	B
24	pixels	B
25	showing	B
26	the	B
27	flows	B
28	with	B
29	a	B
30	color	B
31	schema	B
32	.	B

1	Therefore	B
2	,	B
3	to	B
4	understand	B
5	how	B
6	ErbB1	B
7	/	B
8	ErbB2	B
9	signaling	B
10	contributes	B
11	to	B
12	this	B
13	process	B
14	,	B
15	we	B
16	used	B
17	the	B
18	ErbB	B
19	kinase	B
20	inhibitor	B
21	AG1478in	B
22	ErbB2	B
23	-	B
24	dependent	B
25	BT	B
26	-	B
27	474	B
28	and	B
29	SKBR	B
30	-	B
31	3	B
32	human	B
33	breast	B
34	cancer	B
35	cells	B
36	.	B

1	Deletion	B
2	analyses	B
3	implicate	B
4	the	B
5	N	B
6	-	B
7	terminal	B
8	110	B
9	amino	B
10	acids	B
11	of	B
12	Grb14	B
13	and	B
14	ankyrin	B
15	repeats	B
16	10	B
17	-	B
18	19	B
19	of	B
20	tankyrase	B
21	2	B
22	in	B
23	mediating	B
24	this	B
25	interaction	B
26	.	B

1	Hormonal	B
2	regulation	B
3	of	B
4	multiple	B
5	promoters	B
6	of	B
7	the	B
8	rat	B
9	mitochondrial	B
10	glycerol	B
11	-	B
12	3	B
13	-	B
14	phosphate	B
15	dehydrogenase	B
16	gene	B
17	:	B
18	identification	B
19	of	B
20	a	B
21	complex	B
22	hormone	B
23	-	B
24	response	B
25	element	B
26	in	B
27	the	B
28	ubiquitous	B
29	promoter	B
30	B	B
31	.	B

1	SAMPLE	B
2	POPULATION	B
3	:	B
4	MCB	B
5	from	B
6	7	B
7	racing	B
8	Greyhounds	B
9	euthanatized	B
10	for	B
11	reasons	B
12	unrelated	B
13	to	B
14	MCB	B
15	abnormalities	B
16	.	B

1	Structural	B
2	studies	B
3	have	B
4	shown	B
5	that	B
6	class	B
7	I	B
8	major	B
9	histocompatibility	B
10	complex	B
11	(	B
12	MHC	B
13	)-	B
14	restricted	B
15	peptide	B
16	-	B
17	specific	B
18	T	B
19	cell	B
20	receptor	B
21	(	B
22	TCR	B
23	)-	B
24	alpha	B
25	/	B
26	betas	B
27	make	B
28	multiple	B
29	contacts	B
30	with	B
31	the	B
32	alpha1	B
33	and	B
34	alpha2	B
35	helices	B
36	of	B
37	the	B
38	MHC	B
39	,	B
40	but	B
41	it	B
42	is	B
43	unclear	B
44	which	B
45	or	B
46	how	B
47	many	B
48	of	B
49	these	B
50	interactions	B
51	contribute	B
52	to	B
53	functional	B
54	binding	B
55	.	B

1	Fans	B
2	in	B
3	tunnels	B
4	and	B
5	open	B
6	windows	B
7	at	B
8	aboveground	B
9	locations	B
10	appeared	B
11	to	B
12	greatly	B
13	reduce	B
14	the	B
15	likelihood	B
16	of	B
17	high	B
18	PH3	B
19	concentrations	B
20	in	B
21	enclosed	B
22	areas	B
23	.	B

1	In	B
2	DNA	B
3	strand	B
4	exchange	B
5	reactions	B
6	using	B
7	oligonucleotides	B
8	,	B
9	we	B
10	found	B
11	that	B
12	Rec2	B
13	exhibited	B
14	a	B
15	pairing	B
16	bias	B
17	that	B
18	is	B
19	opposite	B
20	that	B
21	of	B
22	RecA	B
23	.	B

1	A	B
2	major	B
3	mechanism	B
4	by	B
5	which	B
6	estrogens	B
7	prevent	B
8	osteoporosis	B
9	seems	B
10	to	B
11	be	B
12	repression	B
13	of	B
14	transcription	B
15	of	B
16	NF	B
17	-	B
18	kappa	B
19	B	B
20	target	B
21	genes	B
22	,	B
23	such	B
24	as	B
25	the	B
26	osteoclast	B
27	-	B
28	activating	B
29	cytokines	B
30	interleukin	B
31	-	B
32	6	B
33	and	B
34	interleukin	B
35	-	B
36	1	B
37	.	B

1	Linear	B
2	eight	B
3	-	B
4	or	B
5	nine	B
6	-	B
7	residue	B
8	D	B
9	-	B
10	peptides	B
11	derived	B
12	from	B
13	the	B
14	pocket	B
15	-	B
16	binding	B
17	domain	B
18	of	B
19	the	B
20	cyclic	B
21	molecules	B
22	also	B
23	bind	B
24	specifically	B
25	.	B

1	As	B
2	expected	B
3	,	B
4	homologous	B
5	loxP	B
6	sequences	B
7	efficiently	B
8	underwent	B
9	Cre	B
10	-	B
11	mediated	B
12	recombination	B
13	.	B

1	Multistage	B
2	models	B
3	and	B
4	the	B
5	A	B
6	-	B
7	bomb	B
8	survivor	B
9	data	B
10	:	B
11	implications	B
12	for	B
13	carcinogenic	B
14	mechanisms	B
15	?	B

1	The	B
2	results	B
3	indicate	B
4	that	B
5	a	B
6	more	B
7	differentiated	B
8	diagnosis	B
9	of	B
10	the	B
11	molar	B
12	relationship	B
13	will	B
14	allow	B
15	for	B
16	a	B
17	more	B
18	causally	B
19	directed	B
20	correction	B
21	of	B
22	Class	B
23	II	B
24	molar	B
25	relationship	B
26	.	B

1	It	B
2	is	B
3	surprising	B
4	that	B
5	dnaE173	B
6	,	B
7	a	B
8	potent	B
9	mutator	B
10	mutation	B
11	specific	B
12	for	B
13	sequence	B
14	substitution	B
15	as	B
16	well	B
17	as	B
18	single	B
19	-	B
20	base	B
21	frameshift	B
22	,	B
23	did	B
24	not	B
25	enhance	B
26	the	B
27	frequency	B
28	of	B
29	the	B
30	hot	B
31	-	B
32	spot	B
33	frameshift	B
34	mutation	B
35	.	B

1	Hypercalcemia	B
2	associated	B
3	with	B
4	elevated	B
5	serum	B
6	PTH	B
7	concentration	B
8	indicating	B
9	primary	B
10	hyperparathyroidism	B
11	was	B
12	found	B
13	in	B
14	7	B
15	BC	B
16	patients	B
17	(	B
18	7	B
19	%)	B
20	and	B
21	in	B
22	none	B
23	of	B
24	healthy	B
25	women	B
26	or	B
27	patients	B
28	with	B
29	thyroid	B
30	cancer	B
31	.	B

1	[	B
2	figure	B
3	:	B
4	see	B
5	text	B
6	]	B
7	The	B
8	Stille	B
9	coupling	B
10	reaction	B
11	has	B
12	been	B
13	performed	B
14	in	B
15	1	B
16	-	B
17	butyl	B
18	-	B
19	3	B
20	-	B
21	methylimidazolium	B
22	tetrafluoroborate	B
23	(	B
24	BMIM	B
25	BF4	B
26	),	B
27	a	B
28	room	B
29	-	B
30	temperature	B
31	ionic	B
32	liquid	B
33	(	B
34	RTIL	B
35	).	B

1	Examination	B
2	of	B
3	various	B
4	promoter	B
5	deletion	B
6	mutants	B
7	indicated	B
8	that	B
9	SF	B
10	-	B
11	1	B
12	acts	B
13	through	B
14	the	B
15	proximal	B
16	promoter	B
17	region	B
18	and	B
19	upstream	B
20	promoter	B
21	sequences	B
22	.	B

1	ORF1	B
2	(	B
3	1029	B
4	bp	B
5	;	B
6	EMBL	B
7	databank	B
8	,	B
9	Accession	B
10	No	B
11	.	B

1	Vector	B
2	stocks	B
3	containing	B
4	envelope	B
5	proteins	B
6	from	B
7	three	B
8	different	B
9	SIVmac	B
10	clones	B
11	,	B
12	namely	B
13	,	B
14	SIVmac239	B
15	(	B
16	T	B
17	-	B
18	lymphocyte	B
19	tropic	B
20	[	B
21	T	B
22	-	B
23	tropic	B
24	]),	B
25	SIVmac316	B
26	(	B
27	macrophage	B
28	tropic	B
29	[	B
30	M	B
31	-	B
32	tropic	B
33	]),	B
34	and	B
35	SIVmac1A11	B
36	(	B
37	dualtropic	B
38	),	B
39	were	B
40	tested	B
41	.	B

1	ISS	B
2	and	B
3	the	B
4	acute	B
5	physiology	B
6	and	B
7	chronic	B
8	health	B
9	evaluation	B
10	(	B
11	APACHE	B
12	II	B
13	)	B
14	calculated	B
15	on	B
16	admission	B
17	.	B

1	Ga	B
2	-	B
3	67	B
4	and	B
5	Tl	B
6	-	B
7	201	B
8	scintigraphy	B
9	in	B
10	extramedullary	B
11	plasmacytoma	B
12	:	B
13	a	B
14	case	B
15	report	B
16	.	B

1	Finally	B
2	,	B
3	there	B
4	are	B
5	a	B
6	growing	B
7	number	B
8	of	B
9	arguments	B
10	favouring	B
11	the	B
12	use	B
13	of	B
14	ACE	B
15	inhibitors	B
16	very	B
17	early	B
18	in	B
19	patients	B
20	with	B
21	diabetes	B
22	mellitus	B
23	.	B

1	This	B
2	paper	B
3	describes	B
4	the	B
5	results	B
6	of	B
7	an	B
8	initial	B
9	study	B
10	on	B
11	the	B
12	application	B
13	of	B
14	linear	B
15	solvation	B
16	energy	B
17	relationships	B
18	(	B
19	LSERs	B
20	)	B
21	to	B
22	the	B
23	prediction	B
24	of	B
25	internal	B
26	standard	B
27	compounds	B
28	in	B
29	reversed	B
30	-	B
31	phase	B
32	liquid	B
33	chromatographic	B
34	(	B
35	RPLC	B
36	)	B
37	method	B
38	development	B
39	.	B

1	A	B
2	38	B
3	-	B
4	year	B
5	-	B
6	old	B
7	woman	B
8	with	B
9	ulcerative	B
10	colitis	B
11	subsequently	B
12	developed	B
13	sarcoidosis	B
14	.	B

1	Blood	B
2	from	B
3	dams	B
4	was	B
5	collected	B
6	prior	B
7	to	B
8	inoculation	B
9	and	B
10	at	B
11	time	B
12	of	B
13	necropsy	B
14	for	B
15	measurement	B
16	of	B
17	IgM	B
18	and	B
19	IgG	B
20	antibodies	B
21	to	B
22	M	B
23	.	B
24	pulmonis	B
25	.	B

1	She	B
2	has	B
3	since	B
4	developed	B
5	a	B
6	positive	B
7	anti	B
8	-	B
9	cardiolipin	B
10	antibody	B
11	but	B
12	does	B
13	not	B
14	meet	B
15	diagnostic	B
16	criteria	B
17	for	B
18	systemic	B
19	lupus	B
20	erythematosis	B
21	.	B
22	CONCLUSION	B
23	:	B
24	The	B
25	presence	B
26	of	B
27	known	B
28	autoimmune	B
29	disease	B
30	in	B
31	a	B
32	woman	B
33	with	B
34	POF	B
35	should	B
36	not	B
37	dissuade	B
38	the	B
39	clinician	B
40	from	B
41	evaluating	B
42	for	B
43	a	B
44	potential	B
45	genetic	B
46	cause	B
47	.	B

1	The	B
2	mutation	B
3	experiments	B
4	showed	B
5	that	B
6	the	B
7	most	B
8	critical	B
9	sequence	B
10	for	B
11	the	B
12	repression	B
13	of	B
14	PTH	B
15	was	B
16	5	B
17	'-	B
18	GGGGGAGGGGAG	B
19	-	B
20	3	B
21	'	B
22	(+	B
23	1	B
24	to	B
25	+	B
26	12	B
27	)	B
28	of	B
29	PTHSR	B
30	.	B

1	Thus	B
2	,	B
3	while	B
4	the	B
5	folds	B
6	of	B
7	all	B
8	Myb	B
9	domains	B
10	resemble	B
11	each	B
12	other	B
13	closely	B
14	,	B
15	the	B
16	function	B
17	of	B
18	each	B
19	Myb	B
20	domain	B
21	depends	B
22	on	B
23	the	B
24	amino	B
25	acid	B
26	residues	B
27	that	B
28	are	B
29	located	B
30	on	B
31	the	B
32	surface	B
33	of	B
34	each	B
35	protein	B
36	.	B

1	A	B
2	cDNA	B
3	clone	B
4	encoding	B
5	C2H2	B
6	-	B
7	type	B
8	zinc	B
9	finger	B
10	protein	B
11	,	B
12	SCOF	B
13	-	B
14	1	B
15	,	B
16	was	B
17	isolated	B
18	from	B
19	soybean	B
20	.	B

1	The	B
2	purpose	B
3	of	B
4	this	B
5	study	B
6	was	B
7	to	B
8	evaluate	B
9	simplified	B
10	methods	B
11	for	B
12	estimation	B
13	of	B
14	Technetium	B
15	Tc	B
16	99m	B
17	(	B
18	99mTc	B
19	)-	B
20	pentetate	B
21	and	B
22	orthoiodohippurate	B
23	I	B
24	131	B
25	(	B
26	131I	B
27	-	B
28	OIH	B
29	)	B
30	plasma	B
31	clearance	B
32	in	B
33	dogs	B
34	and	B
35	cats	B
36	with	B
37	1	B
38	and	B
39	2	B
40	blood	B
41	samples	B
42	.	B

1	Sevelamer	B
2	hydrochloride	B
3	(	B
4	Renagel	B
5	)	B
6	is	B
7	a	B
8	nonabsorbed	B
9	phosphate	B
10	-	B
11	binding	B
12	polymer	B
13	marketed	B
14	for	B
15	the	B
16	treatment	B
17	of	B
18	hyperphosphatemia	B
19	in	B
20	adult	B
21	patients	B
22	receiving	B
23	hemodialysis	B
24	.	B

1	Using	B
2	a	B
3	novel	B
4	method	B
5	combining	B
6	chromatin	B
7	immunoprecipitation	B
8	and	B
9	genomic	B
10	array	B
11	hybridization	B
12	,	B
13	we	B
14	have	B
15	identified	B
16	a	B
17	460	B
18	-	B
19	kb	B
20	CENP	B
21	-	B
22	A	B
23	-	B
24	binding	B
25	DNA	B
26	domain	B
27	of	B
28	a	B
29	neocentromere	B
30	derived	B
31	from	B
32	the	B
33	20p12	B
34	region	B
35	of	B
36	an	B
37	invdup	B
38	(	B
39	20p	B
40	)	B
41	human	B
42	marker	B
43	chromosome	B
44	.	B

1	Cases	B
2	of	B
3	lung	B
4	cancer	B
5	with	B
6	intramedullary	B
7	metastasis	B
8	are	B
9	rare	B
10	,	B
11	especially	B
12	those	B
13	diagnosed	B
14	before	B
15	death	B
16	.	B

1	Direct	B
2	current	B
3	polarography	B
4	and	B
5	differential	B
6	pulse	B
7	polarographic	B
8	methods	B
9	have	B
10	been	B
11	developed	B
12	for	B
13	the	B
14	qualitative	B
15	as	B
16	well	B
17	as	B
18	quantitative	B
19	analysis	B
20	of	B
21	vitamin	B
22	B1	B
23	,	B
24	B2	B
25	and	B
26	B6	B
27	.	B

1	Fluorimetric	B
2	determination	B
3	of	B
4	methylmercury	B
5	as	B
6	an	B
7	ion	B
8	-	B
9	association	B
10	complex	B
11	with	B
12	rhodamine	B
13	B	B
14	in	B
15	the	B
16	presence	B
17	of	B
18	iodide	B
19	.	B

1	The	B
2	corresponding	B
3	genotype	B
4	was	B
5	determined	B
6	with	B
7	a	B
8	restriction	B
9	enzyme	B
10	-	B
11	based	B
12	assay	B
13	.	B

1	Patients	B
2	were	B
3	divided	B
4	into	B
5	two	B
6	group	B
7	;	B
8	Control	B
9	group	B
10	A	B
11	in	B
12	which	B
13	a	B
14	hot	B
15	-	B
16	water	B
17	circulating	B
18	system	B
19	was	B
20	used	B
21	and	B
22	group	B
23	B	B
24	in	B
25	which	B
26	a	B
27	transtracheal	B
28	heating	B
29	and	B
30	humidification	B
31	system	B
32	by	B
33	ANAMED	B
34	HUMITUBE	B
35	was	B
36	used	B
37	,	B
38	during	B
39	gastric	B
40	cancer	B
41	operation	B
42	.	B

1	Mental	B
2	rotation	B
3	of	B
4	paired	B
5	figures	B
6	engendered	B
7	activation	B
8	in	B
9	the	B
10	left	B
11	superior	B
12	parietal	B
13	lobule	B
14	and	B
15	the	B
16	right	B
17	frontal	B
18	medial	B
19	gyrus	B
20	.	B

1	Here	B
2	we	B
3	demonstrate	B
4	that	B
5	the	B
6	Ras	B
7	-	B
8	activated	B
9	Raf	B
10	-	B
11	MEK	B
12	-	B
13	extracellular	B
14	signal	B
15	-	B
16	regulated	B
17	kinase	B
18	(	B
19	ERK	B
20	)	B
21	signaling	B
22	pathway	B
23	can	B
24	specifically	B
25	control	B
26	the	B
27	expression	B
28	of	B
29	individual	B
30	integrin	B
31	subunits	B
32	in	B
33	a	B
34	variety	B
35	of	B
36	human	B
37	and	B
38	mouse	B
39	cell	B
40	lines	B
41	.	B

1	These	B
2	TxRE	B
3	contain	B
4	cyclic	B
5	AMP	B
6	-	B
7	responsive	B
8	elements	B
9	(	B
10	CRE	B
11	),	B
12	but	B
13	,	B
14	remarkably	B
15	,	B
16	the	B
17	"	B
18	TGACGTCA	B
19	"	B
20	consensus	B
21	is	B
22	never	B
23	strictly	B
24	conserved	B
25	in	B
26	any	B
27	viral	B
28	strain	B
29	(	B
30	e	B
31	.	B
32	g	B
33	.,	B
34	AGACGTCA	B
35	,	B
36	TGACGGCA	B
37	,	B
38	TGACCTCA	B
39	).	B

1	The	B
2	hatcher	B
3	incubators	B
4	of	B
5	both	B
6	companies	B
7	were	B
8	also	B
9	persistently	B
10	contaminated	B
11	with	B
12	Salmonella	B
13	livingstone	B
14	and	B
15	Salmonella	B
16	thomasville	B
17	in	B
18	company	B
19	A	B
20	and	B
21	with	B
22	Salmonella	B
23	senftenberg	B
24	in	B
25	company	B
26	B	B
27	.	B

1	Binding	B
2	of	B
3	cell	B
4	type	B
5	-	B
6	specific	B
7	nuclear	B
8	proteins	B
9	to	B
10	the	B
11	5	B
12	'-	B
13	flanking	B
14	region	B
15	of	B
16	maize	B
17	C4	B
18	phosphoenolpyruvate	B
19	carboxylase	B
20	gene	B
21	confers	B
22	its	B
23	differential	B
24	transcription	B
25	in	B
26	mesophyll	B
27	cells	B
28	.	B

1	Susceptibility	B
2	to	B
3	ischemia	B
4	-	B
5	induced	B
6	arrhythmias	B
7	was	B
8	lower	B
9	in	B
10	1	B
11	-	B
12	week	B
13	diabetics	B
14	:	B
15	only	B
16	42	B
17	%	B
18	of	B
19	diabetic	B
20	hearts	B
21	exhibited	B
22	ventricular	B
23	tachycardia	B
24	(	B
25	VT	B
26	)	B
27	and	B
28	16	B
29	%	B
30	had	B
31	short	B
32	episodes	B
33	of	B
34	ventricular	B
35	fibrillation	B
36	(	B
37	VF	B
38	)	B
39	as	B
40	compared	B
41	to	B
42	VT	B
43	100	B
44	%	B
45	and	B
46	VF	B
47	70	B
48	%	B
49	(	B
50	including	B
51	sustained	B
52	VF	B
53	36	B
54	%)	B
55	in	B
56	the	B
57	non	B
58	-	B
59	diabetics	B
60	(	B
61	P	B
62	<	B
63	0	B
64	.	B
65	05	B
66	).	B

1	CONCLUSIONS	B
2	:	B
3	The	B
4	methodology	B
5	of	B
6	LHR	B
7	measurement	B
8	significantly	B
9	influences	B
10	the	B
11	clinical	B
12	contribution	B
13	of	B
14	Tl	B
15	-	B
16	201	B
17	lung	B
18	uptake	B
19	evaluation	B
20	.	B

1	The	B
2	authors	B
3	made	B
4	an	B
5	analysis	B
6	of	B
7	social	B
8	-	B
9	economical	B
10	conditions	B
11	limiting	B
12	the	B
13	possibilities	B
14	of	B
15	rendering	B
16	cardiosurgical	B
17	care	B
18	to	B
19	children	B
20	.	B

1	METHODS	B
2	:	B
3	Experiments	B
4	testing	B
5	the	B
6	new	B
7	catheter	B
8	and	B
9	comparing	B
10	it	B
11	to	B
12	the	B
13	existing	B
14	catheter	B
15	included	B
16	:	B
17	(	B
18	1	B
19	)	B
20	measurement	B
21	of	B
22	the	B
23	laser	B
24	output	B
25	beam	B
26	sizes	B
27	and	B
28	divergences	B
29	;	B
30	(	B
31	2	B
32	)	B
33	evaluation	B
34	of	B
35	particulate	B
36	matter	B
37	generation	B
38	during	B
39	ablation	B
40	of	B
41	atherosclerotic	B
42	tissue	B
43	;	B
44	(	B
45	3	B
46	)	B
47	measurement	B
48	of	B
49	ablation	B
50	hole	B
51	sizes	B
52	and	B
53	tissue	B
54	penetration	B
55	rates	B
56	;	B
57	(	B
58	4	B
59	)	B
60	histopathologic	B
61	examination	B
62	of	B
63	laser	B
64	-	B
65	induced	B
66	in	B
67	vivo	B
68	vessel	B
69	wall	B
70	injury	B
71	.	B

1	The	B
2	reproductive	B
3	effects	B
4	of	B
5	the	B
6	administration	B
7	of	B
8	4	B
9	-	B
10	chloro	B
11	-	B
12	2	B
13	-	B
14	methylphenoxyacetic	B
15	acid	B
16	(	B
17	MCPA	B
18	)	B
19	to	B
20	rats	B
21	were	B
22	evaluated	B
23	through	B
24	two	B
25	generations	B
26	,	B
27	from	B
28	prior	B
29	to	B
30	mating	B
31	,	B
32	throughout	B
33	mating	B
34	,	B
35	to	B
36	gestation	B
37	and	B
38	lactation	B
39	.	B

1	Here	B
2	we	B
3	suggest	B
4	that	B
5	uvrA	B
6	and	B
7	the	B
8	nucleotide	B
9	excision	B
10	repair	B
11	pathway	B
12	are	B
13	involved	B
14	in	B
15	the	B
16	repair	B
17	of	B
18	acid	B
19	-	B
20	induced	B
21	DNA	B
22	damage	B
23	and	B
24	are	B
25	associated	B
26	with	B
27	successful	B
28	adaptation	B
29	of	B
30	S	B
31	.	B
32	mutans	B
33	to	B
34	low	B
35	pH	B
36	.	B

1	The	B
2	improved	B
3	CSF	B
4	outflow	B
5	conductance	B
6	may	B
7	increase	B
8	the	B
9	intracranial	B
10	compliance	B
11	and	B
12	thereby	B
13	dampen	B
14	a	B
15	pathological	B
16	ICP	B
17	waveform	B
18	.	B

1	These	B
2	studies	B
3	demonstrate	B
4	that	B
5	site	B
6	-	B
7	specific	B
8	recognition	B
9	of	B
10	the	B
11	bxd	B
12	PRE	B
13	by	B
14	d	B
15	(	B
16	GA	B
17	)(	B
18	n	B
19	)	B
20	repeat	B
21	binding	B
22	activities	B
23	mediates	B
24	PcG	B
25	-	B
26	dependent	B
27	silencing	B
28	.	B

1	The	B
2	gonadotrope	B
3	-	B
4	specific	B
5	and	B
6	regulated	B
7	expression	B
8	of	B
9	the	B
10	GnRH	B
11	receptor	B
12	(	B
13	GnRH	B
14	-	B
15	R	B
16	)	B
17	gene	B
18	is	B
19	dependent	B
20	on	B
21	multiple	B
22	transcription	B
23	factors	B
24	that	B
25	interact	B
26	with	B
27	the	B
28	noncanonical	B
29	GnRH	B
30	-	B
31	R	B
32	activating	B
33	sequence	B
34	(	B
35	GRAS	B
36	),	B
37	the	B
38	activator	B
39	protein	B
40	-	B
41	1	B
42	(	B
43	AP	B
44	-	B
45	1	B
46	)	B
47	element	B
48	,	B
49	and	B
50	the	B
51	steroidogenic	B
52	factor	B
53	-	B
54	1	B
55	(	B
56	SF	B
57	-	B
58	1	B
59	)	B
60	binding	B
61	site	B
62	.	B

1	Before	B
2	PO3	B
3	administration	B
4	,	B
5	more	B
6	than	B
7	half	B
8	(	B
9	57	B
10	.	B
11	4	B
12	%)	B
13	of	B
14	the	B
15	patients	B
16	received	B
17	only	B
18	1	B
19	or	B
20	2	B
21	antituberculous	B
22	drugs	B
23	(	B
24	ethambutole	B
25	and	B
26	ethionamide	B
27	or	B
28	ethambutole	B
29	and	B
30	oprofloxacin	B
31	).	B

1	Using	B
2	the	B
3	presented	B
4	categorical	B
5	structure	B
6	as	B
7	domain	B
8	model	B
9	a	B
10	prototype	B
11	DSS	B
12	for	B
13	dipslide	B
14	urine	B
15	cultures	B
16	has	B
17	been	B
18	developed	B
19	.	B

1	Conclusion	B
2	:	B
3	The	B
4	Lp	B
5	(	B
6	a	B
7	)	B
8	levels	B
9	in	B
10	these	B
11	children	B
12	were	B
13	the	B
14	lower	B
15	ever	B
16	reported	B
17	.	B

1	Foxp1	B
2	and	B
3	Foxp2	B
4	are	B
5	expressed	B
6	at	B
7	high	B
8	levels	B
9	in	B
10	the	B
11	lung	B
12	as	B
13	early	B
14	as	B
15	E12	B
16	.	B
17	5	B
18	of	B
19	mouse	B
20	development	B
21	with	B
22	Foxp2	B
23	expression	B
24	restricted	B
25	to	B
26	the	B
27	airway	B
28	epithelium	B
29	.	B

1	Audiological	B
2	findings	B
3	in	B
4	pregnancy	B
5	.	B

1	Children	B
2	who	B
3	developed	B
4	lower	B
5	respiratory	B
6	tract	B
7	infections	B
8	or	B
9	PCP	B
10	had	B
11	increased	B
12	rates	B
13	of	B
14	decline	B
15	of	B
16	CD4	B
17	cell	B
18	counts	B
19	during	B
20	the	B
21	first	B
22	6	B
23	months	B
24	of	B
25	life	B
26	.	B

1	A	B
2	randomized	B
3	mix	B
4	of	B
5	180	B
6	sections	B
7	(	B
8	10	B
9	samples	B
10	x	B
11	3	B
12	tissues	B
13	x	B
14	3	B
15	stains	B
16	x	B
17	2	B
18	)	B
19	gave	B
20	90	B
21	matched	B
22	pairs	B
23	.	B

1	Sural	B
2	nerve	B
3	biopsy	B
4	showed	B
5	mild	B
6	thickening	B
7	of	B
8	the	B
9	perineurium	B
10	,	B
11	vascular	B
12	alterations	B
13	with	B
14	inflammatory	B
15	cell	B
16	infiltration	B
17	in	B
18	the	B
19	perineurium	B
20	,	B
21	and	B
22	remarkable	B
23	loss	B
24	of	B
25	large	B
26	and	B
27	small	B
28	myelinated	B
29	fibers	B
30	.	B

1	OBJECTIVES	B
2	:	B
3	The	B
4	objective	B
5	of	B
6	this	B
7	review	B
8	was	B
9	to	B
10	assess	B
11	the	B
12	effects	B
13	of	B
14	prophylactic	B
15	prostaglandin	B
16	use	B
17	in	B
18	the	B
19	third	B
20	stage	B
21	of	B
22	labour	B
23	.	B

1	Testing	B
2	was	B
3	associated	B
4	with	B
5	a	B
6	history	B
7	of	B
8	nonsexual	B
9	risk	B
10	behavior	B
11	,	B
12	increased	B
13	knowledge	B
14	of	B
15	the	B
16	hepatitis	B
17	C	B
18	virus	B
19	,	B
20	and	B
21	healthcare	B
22	provider	B
23	communication	B
24	.	B

1	Cytomegalovirus	B
2	,	B
3	Chlamydia	B
4	pneumoniae	B
5	,	B
6	and	B
7	Helicobacter	B
8	pylori	B
9	IgG	B
10	antibodies	B
11	and	B
12	restenosis	B
13	after	B
14	stent	B
15	implantation	B
16	:	B
17	an	B
18	angiographic	B
19	and	B
20	intravascular	B
21	ultrasound	B
22	study	B
23	.	B

1	A	B
2	5	B
3	-	B
4	month	B
5	-	B
6	old	B
7	infant	B
8	with	B
9	persistent	B
10	congenital	B
11	stridor	B
12	and	B
13	acute	B
14	respiratory	B
15	distress	B
16	is	B
17	presented	B
18	.	B

1	OBJECTIVE	B
2	:	B
3	To	B
4	determine	B
5	whether	B
6	RSTD	B
7	predicts	B
8	coronary	B
9	anatomy	B
10	during	B
11	acute	B
12	coronary	B
13	occlusion	B
14	.	B

1	Even	B
2	if	B
3	the	B
4	electrocardiographic	B
5	signs	B
6	are	B
7	subdued	B
8	,	B
9	the	B
10	underlying	B
11	blockade	B
12	of	B
13	I	B
14	(	B
15	Kr	B
16	)	B
17	current	B
18	may	B
19	precipitate	B
20	the	B
21	occurrence	B
22	of	B
23	arrhythmia	B
24	.	B

1	Acetoin	B
2	can	B
3	be	B
4	reused	B
5	by	B
6	the	B
7	bacteria	B
8	during	B
9	stationary	B
10	phase	B
11	when	B
12	other	B
13	carbon	B
14	sources	B
15	have	B
16	been	B
17	depleted	B
18	.	B

1	Analysis	B
2	of	B
3	the	B
4	promoter	B
5	sequence	B
6	revealed	B
7	the	B
8	presence	B
9	of	B
10	a	B
11	major	B
12	transcriptional	B
13	start	B
14	site	B
15	,	B
16	a	B
17	canonical	B
18	TATA	B
19	box	B
20	and	B
21	putative	B
22	cis	B
23	regulatory	B
24	elements	B
25	for	B
26	pituitary	B
27	specific	B
28	expression	B
29	as	B
30	well	B
31	as	B
32	an	B
33	E	B
34	-	B
35	responsive	B
36	element	B
37	.	B

1	IL	B
2	-	B
3	1beta	B
4	was	B
5	significantly	B
6	higher	B
7	in	B
8	endometrioma	B
9	than	B
10	in	B
11	lesions	B
12	of	B
13	other	B
14	localizations	B
15	.	B

1	An	B
2	economic	B
3	analysis	B
4	using	B
5	West	B
6	of	B
7	Scotland	B
8	Coronary	B
9	Prevention	B
10	Study	B
11	(	B
12	WOSCOPS	B
13	)	B
14	findings	B
15	indicates	B
16	that	B
17	statin	B
18	treatment	B
19	would	B
20	have	B
21	prevented	B
22	318	B
23	events	B
24	per	B
25	10	B
26	,	B
27	000	B
28	patients	B
29	in	B
30	a	B
31	population	B
32	similar	B
33	to	B
34	that	B
35	in	B
36	WOSCOPS	B
37	(	B
38	average	B
39	1	B
40	.	B
41	5	B
42	%	B
43	annual	B
44	risk	B
45	of	B
46	a	B
47	cardiovascular	B
48	event	B
49	)	B
50	at	B
51	a	B
52	discounted	B
53	cost	B
54	per	B
55	life	B
56	-	B
57	year	B
58	gained	B
59	of	B
60	20	B
61	,	B
62	375	B
63	pounds	B
64	($	B
65	31	B
66	,	B
67	818	B
68	).	B

1	Hydrogels	B
2	for	B
3	tissue	B
4	engineering	B
5	.	B

1	No	B
2	mutation	B
3	of	B
4	the	B
5	NRL	B
6	gene	B
7	was	B
8	found	B
9	in	B
10	any	B
11	of	B
12	the	B
13	two	B
14	families	B
15	.	B

1	However	B
2	,	B
3	most	B
4	produced	B
5	significant	B
6	alteration	B
7	of	B
8	small	B
9	intestinal	B
10	permeability	B
11	.	B

1	Our	B
2	results	B
3	show	B
4	that	B
5	CVN	B
6	specifically	B
7	recognizes	B
8	with	B
9	nanomolar	B
10	affinity	B
11	Man	B
12	(	B
13	9	B
14	)	B
15	GlcNAc	B
16	(	B
17	2	B
18	)	B
19	and	B
20	the	B
21	D1D3	B
22	isomer	B
23	of	B
24	Man	B
25	(	B
26	8	B
27	)	B
28	GlcNAc	B
29	(	B
30	2	B
31	).	B

1	Saccharomyces	B
2	cerevisiae	B
3	activates	B
4	a	B
5	regulatory	B
6	network	B
7	called	B
8	"	B
9	general	B
10	control	B
11	"	B
12	that	B
13	provides	B
14	the	B
15	cell	B
16	with	B
17	sufficient	B
18	amounts	B
19	of	B
20	protein	B
21	precursors	B
22	during	B
23	amino	B
24	acid	B
25	starvation	B
26	.	B

1	In	B
2	Saccharomyces	B
3	cerevisiae	B
4	,	B
5	entry	B
6	into	B
7	mitosis	B
8	requires	B
9	activation	B
10	of	B
11	the	B
12	cyclin	B
13	-	B
14	dependent	B
15	kinase	B
16	Cdc28	B
17	in	B
18	its	B
19	cyclin	B
20	B	B
21	(	B
22	Clb	B
23	)-	B
24	associated	B
25	form	B
26	.	B

1	Data	B
2	from	B
3	in	B
4	vitro	B
5	splicing	B
6	assays	B
7	,	B
8	UV	B
9	crosslinking	B
10	and	B
11	RNA	B
12	-	B
13	binding	B
14	competition	B
15	experiments	B
16	indicates	B
17	a	B
18	strong	B
19	correlation	B
20	between	B
21	the	B
22	binding	B
23	affinities	B
24	of	B
25	PSI	B
26	for	B
27	the	B
28	SELEX	B
29	sequences	B
30	and	B
31	their	B
32	ability	B
33	to	B
34	modulate	B
35	splicing	B
36	of	B
37	P	B
38	element	B
39	IVS3	B
40	in	B
41	vitro	B
42	.	B

1	The	B
2	sensitivity	B
3	of	B
4	human	B
5	neuroblastoma	B
6	cells	B
7	SK	B
8	-	B
9	N	B
10	-	B
11	SH	B
12	to	B
13	undergo	B
14	apoptosis	B
15	induced	B
16	by	B
17	thapsigargin	B
18	was	B
19	examined	B
20	.	B

1	A	B
2	.,	B
3	Slatkin	B
4	,	B
5	D	B
6	.	B

1	Multiparous	B
2	women	B
3	presented	B
4	higher	B
5	BMI	B
6	(	B
7	P	B
8	=	B
9	0	B
10	.	B
11	01	B
12	)	B
13	and	B
14	PBF	B
15	(	B
16	P	B
17	=	B
18	0	B
19	.	B
20	03	B
21	)	B
22	compared	B
23	with	B
24	primi	B
25	-	B
26	and	B
27	nulliparous	B
28	groups	B
29	.	B

1	CONCLUSIONS	B
2	AND	B
3	CLINICAL	B
4	RELEVANCE	B
5	:	B
6	Increased	B
7	cortical	B
8	thickness	B
9	and	B
10	geometric	B
11	properties	B
12	of	B
13	left	B
14	MCB	B
15	-	B
16	IV	B
17	and	B
18	-	B
19	V	B
20	of	B
21	Greyhounds	B
22	,	B
23	together	B
24	with	B
25	altered	B
26	turnover	B
27	and	B
28	orientation	B
29	of	B
30	osteons	B
31	in	B
32	the	B
33	dorsal	B
34	quadrants	B
35	of	B
36	left	B
37	MCB	B
38	,	B
39	are	B
40	site	B
41	-	B
42	specific	B
43	adaptive	B
44	responses	B
45	associated	B
46	with	B
47	asymmetric	B
48	cyclic	B
49	loading	B
50	as	B
51	a	B
52	result	B
53	of	B
54	racing	B
55	on	B
56	circular	B
57	tracks	B
58	.	B

1	To	B
2	examine	B
3	transcriptional	B
4	regulation	B
5	of	B
6	the	B
7	rat	B
8	eIF4E	B
9	gene	B
10	,	B
11	2	B
12	.	B
13	1	B
14	kB	B
15	of	B
16	the	B
17	rat	B
18	eIF4E	B
19	promoter	B
20	region	B
21	was	B
22	cloned	B
23	and	B
24	the	B
25	contribution	B
26	of	B
27	specific	B
28	elements	B
29	in	B
30	regulating	B
31	transcription	B
32	was	B
33	determined	B
34	in	B
35	primary	B
36	cultures	B
37	of	B
38	rat	B
39	cardiocytes	B
40	and	B
41	in	B
42	a	B
43	murine	B
44	C	B
45	(	B
46	2	B
47	)	B
48	C	B
49	(	B
50	12	B
51	)	B
52	myoblast	B
53	cell	B
54	line	B
55	.	B

1	The	B
2	prevalence	B
3	of	B
4	tobacco	B
5	dependence	B
6	diagnosed	B
7	according	B
8	to	B
9	the	B
10	ICD	B
11	-	B
12	10	B
13	criteria	B
14	was	B
15	higher	B
16	in	B
17	alcohol	B
18	-	B
19	dependent	B
20	individuals	B
21	(	B
22	58	B
23	.	B
24	1	B
25	%)	B
26	than	B
27	in	B
28	nondrinkers	B
29	or	B
30	social	B
31	drinkers	B
32	(	B
33	12	B
34	.	B
35	8	B
36	%).	B

1	Management	B
2	of	B
3	postvitrectomy	B
4	diabetic	B
5	vitreous	B
6	hemorrhage	B
7	with	B
8	tissue	B
9	plasminogen	B
10	activator	B
11	(	B
12	t	B
13	-	B
14	PA	B
15	)	B
16	and	B
17	volume	B
18	homeostatic	B
19	fluid	B
20	-	B
21	fluid	B
22	exchanger	B
23	.	B

1	Transactivation	B
2	of	B
3	oIFNtau	B
4	enhancer	B
5	-	B
6	reporter	B
7	constructs	B
8	was	B
9	primarily	B
10	regulated	B
11	by	B
12	three	B
13	regions	B
14	containing	B
15	AP	B
16	-	B
17	1	B
18	site	B
19	,	B
20	GATA	B
21	like	B
22	sequence	B
23	and	B
24	site	B
25	(	B
26	s	B
27	)	B
28	unidentified	B
29	.	B

1	SELECTION	B
2	CRITERIA	B
3	:	B
4	Randomised	B
5	controlled	B
6	trials	B
7	of	B
8	cabergoline	B
9	versus	B
10	placebo	B
11	in	B
12	patients	B
13	with	B
14	a	B
15	clinical	B
16	diagnosis	B
17	of	B
18	idiopathic	B
19	Parkinson	B
20	'	B
21	s	B
22	disease	B
23	and	B
24	long	B
25	-	B
26	term	B
27	complications	B
28	of	B
29	levodopa	B
30	therapy	B
31	.	B

1	0	B
2	%)	B
3	and	B
4	IL	B
5	-	B
6	12	B
7	(	B
8	42	B
9	.	B
10	6	B
11	%	B
12	vs	B
13	.	B

1	Copyright	B
2	2000	B
3	John	B
4	Wiley	B
5	&	B
6	Sons	B
7	,	B
8	Ltd	B
9	.	B

1	Here	B
2	we	B
3	demonstrate	B
4	that	B
5	native	B
6	MRCK	B
7	exists	B
8	in	B
9	high	B
10	-	B
11	molecular	B
12	-	B
13	weight	B
14	complexes	B
15	.	B

1	METHODS	B
2	:	B
3	This	B
4	retrospective	B
5	review	B
6	comprised	B
7	2711	B
8	eyes	B
9	that	B
10	had	B
11	LASIK	B
12	between	B
13	September	B
14	1996	B
15	and	B
16	September	B
17	1999	B
18	.	B

1	Sixty	B
2	-	B
3	one	B
4	cases	B
5	of	B
6	cholera	B
7	,	B
8	all	B
9	caused	B
10	by	B
11	V	B
12	.	B
13	cholerae	B
14	O1	B
15	,	B
16	were	B
17	reported	B
18	.	B

1	This	B
2	could	B
3	lead	B
4	to	B
5	subsequent	B
6	outbreaks	B
7	if	B
8	Babesia	B
9	carrier	B
10	animals	B
11	were	B
12	to	B
13	be	B
14	introduced	B
15	into	B
16	the	B
17	herd	B
18	.	B

1	Instead	B
2	,	B
3	TRPS1	B
4	potently	B
5	and	B
6	specifically	B
7	represses	B
8	transcriptional	B
9	activation	B
10	mediated	B
11	by	B
12	other	B
13	GATA	B
14	factors	B
15	.	B

1	Eliminating	B
2	any	B
3	subset	B
4	of	B
5	ASCUS	B
6	reduces	B
7	the	B
8	ASCUS	B
9	/	B
10	SIL	B
11	ratio	B
12	but	B
13	also	B
14	significantly	B
15	diminishes	B
16	the	B
17	sensitivity	B
18	of	B
19	the	B
20	Papanicolaou	B
21	test	B
22	.	B

1	In	B
2	order	B
3	to	B
4	overcome	B
5	the	B
6	false	B
7	positive	B
8	readings	B
9	that	B
10	are	B
11	possible	B
12	in	B
13	sphincter	B
14	manometry	B
15	,	B
16	we	B
17	proposed	B
18	to	B
19	use	B
20	secretin	B
21	stimulated	B
22	endoscopic	B
23	ultrasound	B
24	(	B
25	SSEUS	B
26	)	B
27	to	B
28	measure	B
29	pancreatic	B
30	ductal	B
31	response	B
32	as	B
33	an	B
34	adjunctive	B
35	method	B
36	to	B
37	aid	B
38	and	B
39	supplement	B
40	the	B
41	diagnosis	B
42	.	B

1	Endovascular	B
2	aneurysm	B
3	repair	B
4	with	B
5	the	B
6	AneuRx	B
7	stent	B
8	-	B
9	graft	B
10	is	B
11	safe	B
12	,	B
13	but	B
14	is	B
15	it	B
16	effective	B
17	?	B

1	The	B
2	difference	B
3	of	B
4	hardness	B
5	over	B
6	time	B
7	of	B
8	composite	B
9	specimens	B
10	was	B
11	measured	B
12	using	B
13	Knoop	B
14	hardness	B
15	measurements	B
16	taken	B
17	at	B
18	the	B
19	top	B
20	and	B
21	bottom	B
22	surfaces	B
23	of	B
24	resin	B
25	specimens	B
26	made	B
27	in	B
28	a	B
29	Teflon	B
30	mold	B
31	the	B
32	same	B
33	dimensions	B
34	as	B
35	the	B
36	cavity	B
37	prepared	B
38	in	B
39	dentin	B
40	.	B

1	Implications	B
2	in	B
3	biomonitoring	B
4	of	B
5	the	B
6	observed	B
7	accumulation	B
8	patterns	B
9	,	B
10	especially	B
11	in	B
12	the	B
13	different	B
14	tissues	B
15	of	B
16	Posidonia	B
17	oceanica	B
18	,	B
19	are	B
20	discussed	B
21	.	B

1	Based	B
2	on	B
3	mutational	B
4	data	B
5	and	B
6	possible	B
7	mRNA	B
8	structure	B
9	,	B
10	we	B
11	hypothesized	B
12	about	B
13	the	B
14	effect	B
15	of	B
16	mRNA	B
17	structure	B
18	on	B
19	translation	B
20	of	B
21	the	B
22	two	B
23	major	B
24	C	B
25	/	B
26	EBPepsilon	B
27	isoforms	B
28	:	B
29	p32	B
30	and	B
31	p30	B
32	.	B

1	Retinoids	B
2	participate	B
3	in	B
4	the	B
5	onset	B
6	of	B
7	differentiation	B
8	,	B
9	apoptosis	B
10	and	B
11	the	B
12	inhibition	B
13	of	B
14	growth	B
15	in	B
16	a	B
17	wide	B
18	variety	B
19	of	B
20	normal	B
21	and	B
22	cancerous	B
23	cells	B
24	.	B

1	We	B
2	conclude	B
3	that	B
4	RPMS	B
5	acts	B
6	as	B
7	a	B
8	negative	B
9	regulator	B
10	of	B
11	EBNA2	B
12	and	B
13	Notch	B
14	activity	B
15	through	B
16	its	B
17	interactions	B
18	with	B
19	the	B
20	CBF1	B
21	-	B
22	associated	B
23	corepressor	B
24	complex	B
25	.	B

1	Isolated	B
2	Systolic	B
3	Hypertension	B
4	:	B
5	An	B
6	Update	B
7	.	B

1	Transfection	B
2	of	B
3	EGFP	B
4	-	B
5	tagged	B
6	DENTT	B
7	NLS	B
8	deletion	B
9	constructs	B
10	lacking	B
11	the	B
12	bipartite	B
13	NLS	B
14	-	B
15	1	B
16	were	B
17	excluded	B
18	from	B
19	the	B
20	nucleolus	B
21	.	B

1	VE	B
2	-	B
3	DEF	B
4	animals	B
5	had	B
6	significantly	B
7	higher	B
8	(	B
9	p	B
10	<	B
11	0	B
12	.	B
13	05	B
14	)	B
15	levels	B
16	of	B
17	myocardial	B
18	lipid	B
19	peroxidation	B
20	and	B
21	lower	B
22	(	B
23	p	B
24	<	B
25	0	B
26	.	B
27	05	B
28	)	B
29	protein	B
30	thiols	B
31	following	B
32	I	B
33	-	B
34	R	B
35	compared	B
36	to	B
37	the	B
38	CON	B
39	animals	B
40	.	B

1	The	B
2	position	B
3	of	B
4	the	B
5	analyst	B
6	as	B
7	expert	B
8	:	B
9	yesterday	B
10	and	B
11	today	B
12	.	B

1	Furthermore	B
2	,	B
3	we	B
4	showed	B
5	that	B
6	ERSF	B
7	including	B
8	NF	B
9	-	B
10	Y	B
11	and	B
12	ATF6alpha	B
13	and	B
14	/	B
15	or	B
16	beta	B
17	and	B
18	capable	B
19	of	B
20	binding	B
21	to	B
22	ERSE	B
23	is	B
24	indeed	B
25	formed	B
26	when	B
27	the	B
28	cellular	B
29	UPR	B
30	is	B
31	activated	B
32	.	B

1	We	B
2	performed	B
3	the	B
4	present	B
5	study	B
6	to	B
7	clarify	B
8	the	B
9	relationship	B
10	between	B
11	the	B
12	DOX	B
13	binding	B
14	ability	B
15	(%	B
16	DB	B
17	)	B
18	and	B
19	the	B
20	histologic	B
21	response	B
22	,	B
23	rate	B
24	of	B
25	decrease	B
26	in	B
27	tumor	B
28	volume	B
29	of	B
30	malignant	B
31	soft	B
32	tissue	B
33	tumors	B
34	after	B
35	preoperative	B
36	chemotherapy	B
37	and	B
38	prognosis	B
39	.	B

1	We	B
2	have	B
3	also	B
4	isolated	B
5	and	B
6	analyzed	B
7	the	B
8	5	B
9	'	B
10	flanking	B
11	region	B
12	of	B
13	the	B
14	pea	B
15	33RNP	B
16	gene	B
17	.	B

1	We	B
2	have	B
3	previously	B
4	shown	B
5	that	B
6	the	B
7	adenoviral	B
8	12S	B
9	E1A	B
10	protein	B
11	modulates	B
12	the	B
13	phosphorylation	B
14	status	B
15	of	B
16	p130	B
17	and	B
18	p107	B
19	without	B
20	apparent	B
21	changes	B
22	in	B
23	the	B
24	cell	B
25	cycle	B
26	dependent	B
27	phosphorylation	B
28	of	B
29	the	B
30	retinoblastoma	B
31	protein	B
32	.	B

1	Baseline	B
2	MBF	B
3	in	B
4	females	B
5	was	B
6	significantly	B
7	(	B
8	P	B
9	<	B
10	0	B
11	.	B
12	001	B
13	)	B
14	higher	B
15	than	B
16	in	B
17	males	B
18	.	B

1	Only	B
2	nine	B
3	patients	B
4	were	B
5	offered	B
6	surgery	B
7	(	B
8	six	B
9	were	B
10	resected	B
11	and	B
12	three	B
13	were	B
14	found	B
15	inoperable	B
16	).	B

1	The	B
2	deubiquitinating	B
3	enzyme	B
4	DUB	B
5	-	B
6	2	B
7	is	B
8	induced	B
9	in	B
10	response	B
11	to	B
12	IL	B
13	-	B
14	2	B
15	but	B
16	as	B
17	yet	B
18	its	B
19	function	B
20	has	B
21	not	B
22	been	B
23	determined	B
24	.	B

1	A	B
2	split	B
3	motor	B
4	domain	B
5	in	B
6	a	B
7	cytoplasmic	B
8	dynein	B
9	.	B

1	Immunological	B
2	and	B
3	biochemical	B
4	characterization	B
5	of	B
6	streptococcal	B
7	pyrogenic	B
8	exotoxins	B
9	I	B
10	and	B
11	J	B
12	(	B
13	SPE	B
14	-	B
15	I	B
16	and	B
17	SPE	B
18	-	B
19	J	B
20	)	B
21	from	B
22	Streptococcus	B
23	pyogenes	B
24	.	B

1	Five	B
2	modalities	B
3	of	B
4	nonpharmacologic	B
5	approaches	B
6	are	B
7	recommended	B
8	at	B
9	present	B
10	for	B
11	lifestyle	B
12	modification	B
13	and	B
14	control	B
15	of	B
16	arterial	B
17	blood	B
18	pressure	B
19	elevation	B
20	:	B
21	1	B
22	)	B
23	weight	B
24	reduction	B
25	to	B
26	ideal	B
27	body	B
28	weight	B
29	,	B
30	since	B
31	it	B
32	reduces	B
33	risk	B
34	of	B
35	hypertension	B
36	as	B
37	well	B
38	as	B
39	overall	B
40	cardiovascular	B
41	morbidity	B
42	and	B
43	mortality	B
44	;	B
45	2	B
46	)	B
47	dietary	B
48	sodium	B
49	restriction	B
50	to	B
51	less	B
52	than	B
53	2	B
54	g	B
55	a	B
56	day	B
57	,	B
58	without	B
59	assurance	B
60	that	B
61	it	B
62	will	B
63	normalize	B
64	arterial	B
65	pressure	B
66	although	B
67	it	B
68	may	B
69	help	B
70	reduce	B
71	dosage	B
72	and	B
73	numbers	B
74	of	B
75	prescribed	B
76	antihypertensive	B
77	drugs	B
78	;	B
79	3	B
80	)	B
81	moderation	B
82	of	B
83	alcohol	B
84	consumption	B
85	to	B
86	less	B
87	than	B
88	1	B
89	ounce	B
90	a	B
91	day	B
92	;	B
93	4	B
94	)	B
95	a	B
96	regular	B
97	isotonic	B
98	exercise	B
99	program	B
100	;	B
101	and	B
102	5	B
103	)	B
104	cessation	B
105	of	B
106	tobacco	B
107	consumption	B
108	.	B

1	Descriptions	B
2	of	B
3	this	B
4	locus	B
5	would	B
6	allow	B
7	comparison	B
8	with	B
9	functionally	B
10	relevant	B
11	molecular	B
12	genetic	B
13	features	B
14	of	B
15	other	B
16	species	B
17	'	B
18	homologous	B
19	loci	B
20	including	B
21	the	B
22	single	B
23	-	B
24	copy	B
25	equid	B
26	LH	B
27	/	B
28	CGbeta	B
29	gene	B
30	and	B
31	the	B
32	primate	B
33	LHbeta	B
34	-	B
35	CGbeta	B
36	gene	B
37	cluster	B
38	locus	B
39	.	B

1	METHODS	B
2	:	B
3	One	B
4	hundred	B
5	fourteen	B
6	consecutive	B
7	patients	B
8	(	B
9	mean	B
10	age	B
11	61	B
12	years	B
13	)	B
14	with	B
15	focal	B
16	pancreatic	B
17	masses	B
18	,	B
19	detected	B
20	on	B
21	CT	B
22	,	B
23	underwent	B
24	EUS	B
25	-	B
26	FNA	B
27	by	B
28	using	B
29	a	B
30	linear	B
31	-	B
32	array	B
33	echoendoscope	B
34	and	B
35	22	B
36	-	B
37	gauge	B
38	needles	B
39	.	B

1	The	B
2	effects	B
3	of	B
4	chlordiazepoxide	B
5	(	B
6	2	B
7	.	B
8	5	B
9	-	B
10	15	B
11	.	B
12	0mg	B
13	/	B
14	kg	B
15	),	B
16	a	B
17	full	B
18	benzodiazepine	B
19	receptor	B
20	agonist	B
21	,	B
22	and	B
23	bretazenil	B
24	(	B
25	5	B
26	.	B
27	0	B
28	-	B
29	30	B
30	.	B
31	0mg	B
32	/	B
33	kg	B
34	),	B
35	a	B
36	partial	B
37	benzodiazepine	B
38	receptor	B
39	agonist	B
40	,	B
41	were	B
42	examined	B
43	in	B
44	the	B
45	murine	B
46	elevated	B
47	plus	B
48	-	B
49	maze	B
50	paradigm	B
51	.	B

1	Acute	B
2	effects	B
3	of	B
4	LI	B
5	160	B
6	(	B
7	extract	B
8	of	B
9	Hypericum	B
10	perforatum	B
11	,	B
12	St	B
13	John	B
14	'	B
15	s	B
16	wort	B
17	)	B
18	and	B
19	two	B
20	of	B
21	its	B
22	constituents	B
23	on	B
24	neuroendocrine	B
25	responses	B
26	in	B
27	the	B
28	rat	B
29	.	B

1	Guidelines	B
2	for	B
3	performing	B
4	a	B
5	routine	B
6	spiral	B
7	assay	B
8	are	B
9	presented	B
10	,	B
11	and	B
12	alternative	B
13	test	B
14	methods	B
15	intended	B
16	to	B
17	overcome	B
18	a	B
19	variety	B
20	of	B
21	technical	B
22	difficulties	B
23	(	B
24	such	B
25	as	B
26	restricted	B
27	sample	B
28	availability	B
29	,	B
30	sample	B
31	viscosity	B
32	or	B
33	volatility	B
34	,	B
35	etc	B
36	.)	B
37	are	B
38	recommended	B
39	.	B

1	An	B
2	additional	B
3	9	B
4	patients	B
5	achieved	B
6	normal	B
7	levels	B
8	with	B
9	adjunctive	B
10	drug	B
11	therapy	B
12	.	B

1	Anti	B
2	-	B
3	nucleolin	B
4	mAb	B
5	was	B
6	used	B
7	to	B
8	confirm	B
9	the	B
10	antigenic	B
11	properties	B
12	of	B
13	this	B
14	p95	B
15	component	B
16	.	B

1	Eliminating	B
2	any	B
3	subset	B
4	of	B
5	ASCUS	B
6	reduces	B
7	the	B
8	ASCUS	B
9	/	B
10	SIL	B
11	ratio	B
12	but	B
13	also	B
14	significantly	B
15	diminishes	B
16	the	B
17	sensitivity	B
18	of	B
19	the	B
20	Papanicolaou	B
21	test	B
22	.	B

1	Prrp	B
2	can	B
3	also	B
4	associate	B
5	with	B
6	the	B
7	EVH1	B
8	domain	B
9	of	B
10	Mena	B
11	,	B
12	another	B
13	microfilament	B
14	-	B
15	associated	B
16	protein	B
17	.	B

1	Experience	B
2	with	B
3	xylene	B
4	-	B
5	free	B
6	sections	B
7	since	B
8	1995	B
9	at	B
10	the	B
11	Vrinnevi	B
12	Hospital	B
13	is	B
14	favorable	B
15	.	B

1	Acquired	B
2	antithrombin	B
3	deficiency	B
4	in	B
5	sepsis	B
6	.	B

1	SIP1	B
2	(	B
3	Smad	B
4	interacting	B
5	protein	B
6	1	B
7	)	B
8	and	B
9	deltaEF1	B
10	(	B
11	delta	B
12	-	B
13	crystallin	B
14	enhancer	B
15	binding	B
16	factor	B
17	)	B
18	are	B
19	structurally	B
20	similar	B
21	transcriptional	B
22	repressors	B
23	.	B

1	SERS	B
2	spectra	B
3	were	B
4	obtained	B
5	by	B
6	vacuum	B
7	evaporation	B
8	and	B
9	casting	B
10	of	B
11	p	B
12	-	B
13	NTP	B
14	onto	B
15	silver	B
16	island	B
17	films	B
18	,	B
19	and	B
20	also	B
21	from	B
22	colloidal	B
23	silver	B
24	solutions	B
25	.	B

1	The	B
2	moduli	B
3	of	B
4	elasticity	B
5	of	B
6	the	B
7	gray	B
8	and	B
9	white	B
10	matter	B
11	were	B
12	3	B
13	.	B
14	4	B
15	+/-	B
16	1	B
17	.	B
18	4	B
19	kPa	B
20	(	B
21	mean	B
22	+/-	B
23	standard	B
24	deviation	B
25	)	B
26	and	B
27	3	B
28	.	B
29	4	B
30	+/-	B
31	0	B
32	.	B
33	9	B
34	kPa	B
35	in	B
36	the	B
37	axial	B
38	section	B
39	,	B
40	3	B
41	+/-	B
42	0	B
43	.	B
44	3	B
45	kPa	B
46	and	B
47	3	B
48	.	B
49	5	B
50	+/-	B
51	0	B
52	.	B
53	5	B
54	kPa	B
55	in	B
56	the	B
57	frontal	B
58	section	B
59	,	B
60	and	B
61	3	B
62	.	B
63	5	B
64	+/-	B
65	0	B
66	.	B
67	9	B
68	kPa	B
69	and	B
70	2	B
71	.	B
72	8	B
73	+/-	B
74	0	B
75	.	B
76	4	B
77	kPa	B
78	in	B
79	the	B
80	sagittal	B
81	section	B
82	,	B
83	respectively	B
84	.	B

1	[	B
2	Clinical	B
3	and	B
4	epidemiological	B
5	characteristics	B
6	of	B
7	squamous	B
8	cell	B
9	carcinoma	B
10	of	B
11	the	B
12	oral	B
13	cavity	B
14	in	B
15	women	B
16	]	B
17	BACKGROUND	B
18	:	B
19	Squamous	B
20	cell	B
21	carcinoma	B
22	(	B
23	SCC	B
24	)	B
25	of	B
26	the	B
27	oral	B
28	cavity	B
29	occurs	B
30	mainly	B
31	in	B
32	the	B
33	male	B
34	population	B
35	.	B

1	The	B
2	core	B
3	promoter	B
4	of	B
5	human	B
6	thioredoxin	B
7	reductase	B
8	1	B
9	:	B
10	cloning	B
11	,	B
12	transcriptional	B
13	activity	B
14	,	B
15	and	B
16	Oct	B
17	-	B
18	1	B
19	,	B
20	Sp1	B
21	,	B
22	and	B
23	Sp3	B
24	binding	B
25	reveal	B
26	a	B
27	housekeeping	B
28	-	B
29	type	B
30	promoter	B
31	for	B
32	the	B
33	AU	B
34	-	B
35	rich	B
36	element	B
37	-	B
38	regulated	B
39	gene	B
40	.	B

1	Phase	B
2	II	B
3	trial	B
4	of	B
5	the	B
6	anti	B
7	-	B
8	G	B
9	(	B
10	D2	B
11	)	B
12	monoclonal	B
13	antibody	B
14	3F8	B
15	and	B
16	granulocyte	B
17	-	B
18	macrophage	B
19	colony	B
20	-	B
21	stimulating	B
22	factor	B
23	for	B
24	neuroblastoma	B
25	.	B

1	A	B
2	log	B
3	-	B
4	linear	B
5	dose	B
6	-	B
7	response	B
8	was	B
9	obtained	B
10	for	B
11	the	B
12	average	B
13	increase	B
14	in	B
15	FEV1	B
16	up	B
17	to	B
18	6	B
19	h	B
20	(	B
21	AUC0	B
22	-	B
23	6	B
24	h	B
25	)	B
26	and	B
27	peak	B
28	FEV1	B
29	across	B
30	the	B
31	dose	B
32	range	B
33	administered	B
34	by	B
35	Respimat	B
36	.	B

1	Plasma	B
2	DHE	B
3	concentration	B
4	rose	B
5	promptly	B
6	above	B
7	5	B
8	ng	B
9	/	B
10	ml	B
11	after	B
12	the	B
13	application	B
14	of	B
15	the	B
16	PSA	B
17	tape	B
18	onto	B
19	the	B
20	damaged	B
21	skin	B
22	in	B
23	hairless	B
24	rat	B
25	.	B

1	A	B
2	complete	B
3	drug	B
4	history	B
5	was	B
6	compiled	B
7	,	B
8	specifying	B
9	the	B
10	amount	B
11	and	B
12	duration	B
13	of	B
14	VGB	B
15	medication	B
16	.	B

1	Epithelial	B
2	cytotoxicity	B
3	of	B
4	combined	B
5	antibiotics	B
6	was	B
7	additive	B
8	,	B
9	with	B
10	no	B
11	evidence	B
12	of	B
13	competition	B
14	or	B
15	synergism	B
16	.	B

1	In	B
2	Cd	B
3	-	B
4	spiked	B
5	OECD	B
6	soil	B
7	,	B
8	internal	B
9	Cd	B
10	levels	B
11	were	B
12	linearly	B
13	related	B
14	to	B
15	external	B
16	Cd	B
17	concentrations	B
18	,	B
19	whereas	B
20	the	B
21	springtails	B
22	maintained	B
23	fixed	B
24	internal	B
25	levels	B
26	of	B
27	Cu	B
28	and	B
29	Zn	B
30	regardless	B
31	of	B
32	spiked	B
33	concentrations	B
34	.	B

1	Interestingly	B
2	,	B
3	the	B
4	similarities	B
5	with	B
6	the	B
7	endophilin	B
8	proteins	B
9	cover	B
10	the	B
11	entire	B
12	sequence	B
13	of	B
14	the	B
15	SH3GLB	B
16	family	B
17	,	B
18	suggesting	B
19	a	B
20	common	B
21	fold	B
22	and	B
23	presumably	B
24	a	B
25	common	B
26	mode	B
27	of	B
28	action	B
29	.	B

1	Reovirus	B
2	mRNAs	B
3	are	B
4	efficiently	B
5	translated	B
6	within	B
7	host	B
8	cells	B
9	despite	B
10	the	B
11	absence	B
12	of	B
13	3	B
14	'	B
15	polyadenylated	B
16	tails	B
17	.	B

1	Grippers	B
2	with	B
3	integrated	B
4	piezoresistive	B
5	force	B
6	sensors	B
7	and	B
8	with	B
9	attached	B
10	strain	B
11	gauges	B
12	have	B
13	been	B
14	reported	B
15	.	B

1	Both	B
2	Z	B
3	and	B
4	R	B
5	expression	B
6	resulted	B
7	in	B
8	PML	B
9	dispersion	B
10	in	B
11	EBV	B
12	-	B
13	positive	B
14	cells	B
15	.	B

1	The	B
2	small	B
3	copepod	B
4	Pseudonychocamptus	B
5	proximus	B
6	progressively	B
7	replaced	B
8	the	B
9	large	B
10	Tisbe	B
11	furcata	B
12	in	B
13	sand	B
14	filters	B
15	during	B
16	the	B
17	fall	B
18	of	B
19	1995	B
20	and	B
21	was	B
22	responsible	B
23	for	B
24	the	B
25	large	B
26	increase	B
27	in	B
28	meiofaunal	B
29	biomass	B
30	observed	B
31	after	B
32	spring	B
33	1996	B
34	.	B

1	Evidence	B
2	-	B
3	based	B
4	care	B
5	:	B
6	a	B
7	new	B
8	formula	B
9	for	B
10	an	B
11	old	B
12	problem	B
13	?	B

1	Nrf2	B
2	regulates	B
3	expression	B
4	of	B
5	genes	B
6	encoding	B
7	enzymes	B
8	with	B
9	antioxidant	B
10	(	B
11	e	B
12	.	B
13	g	B
14	.	B
15	heme	B
16	oxygenase	B
17	-	B
18	1	B
19	(	B
20	HO	B
21	-	B
22	1	B
23	))	B
24	or	B
25	xenobiotic	B
26	detoxification	B
27	(	B
28	e	B
29	.	B
30	g	B
31	.	B

1	Workload	B
2	,	B
3	UAPs	B
4	,	B
5	and	B
6	you	B
7	.	B

1	RESULTS	B
2	:	B
3	At	B
4	latest	B
5	examination	B
6	,	B
7	mean	B
8	UPDRS	B
9	II	B
10	and	B
11	III	B
12	scores	B
13	had	B
14	improved	B
15	by	B
16	30	B
17	%	B
18	(	B
19	on	B
20	stimulation	B
21	,	B
22	off	B
23	therapy	B
24	)	B
25	with	B
26	mean	B
27	50	B
28	%	B
29	reduction	B
30	in	B
31	daily	B
32	off	B
33	time	B
34	.	B

1	Perfusion	B
2	technique	B
3	for	B
4	perfusion	B
5	-	B
6	assisted	B
7	direct	B
8	coronary	B
9	artery	B
10	bypass	B
11	(	B
12	PADCAB	B
13	).	B

1	Copyright	B
2	2001	B
3	Academic	B
4	Press	B
5	.	B

1	The	B
2	amount	B
3	of	B
4	drained	B
5	effusion	B
6	was	B
7	measured	B
8	,	B
9	and	B
10	fluid	B
11	was	B
12	sent	B
13	for	B
14	diagnostic	B
15	assessment	B
16	.	B
